KAILI ANIER

The role of DNA methylation
in the development of cocaine-induced
behavioural sensitisation

TARTU ÜLIKOOL · UNIVERSITAS TARTUENSIS · 1632

DISSERTATIONES NEUROSCIENTIAE UNIVERSITATIS TARTUENSIS

19

KAILI ANIER

The role of DNA methylation
in the development of cocaine-induced
behavioural sensitisation

Department of Pharmacology, Institute of Bio- and Translational Medicine, University of Tartu, Estonia

Dissertation was accepted for the commencement of the degree of Doctor of Philosophy (Neurosciences) on October 8, 2013 by the Council of the Commencement of Doctoral Degree in Neuroscience

Supervisors: Anti Kalda, MD, PhD, Senior Research Fellow,
                 Department of Pharmacology, Institute of Bio- and
                 Translational Medicine, University of Tartu

                 Alexander Zharkovsky, MD, PhD, Professor,
                 Department of Pharmacology, Institute of Bio- and
                 Translational Medicine, University of Tartu

Reviewers: Jaanus Harro, MD, PhD, Professor,
                 Department of Psychophysiology, Institute of Psychology,
                 University of Tartu

                 Anton Terasmaa, PhD, Senior Research Fellow,
                 Department of Physiology, Institute of Bio- and
                 Translational Medicine, University of Tartu

Opponent: Markus Mikael Forsberg, PhD, Associate Professor,
                 School of Pharmacy, University of Eastern Finland, Finland

Commencement: December 19, 2013

European Union
Regional Development Fund   Investing in your future

CONTENTS

LIST OF ORIGINAL PUBLICATIONS

This thesis is based on the following original research papers, which are referred to in the text by their Roman numerals.

I **Anier K**, Malinovskaja K, Aonurm-Helm A, Zharkovsky A, Kalda A (2010) DNA methylation regulates cocaine-induced behavioral sensitization in mice. *Neuropsychopharmacology* 35:2450–2461.

II **Anier K**, Zharkovsky A, Kalda A (2013) S-adenosylmethionine modifies cocaine-induced DNA methylation and increases locomotor sensitization in mice. *The International Journal of Neuropsychopharmacology* 16:2053–2066.

III **Anier K**, Malinovskaja K, Pruus K, Aonurm-Helm A, Zharkovsky A, Kalda A (2013) Maternal separation is associated with DNA methylation and behavioural changes in adult rats. *European Neuropsychopharmacology* [Epub ahead of print].

The contribution of the author to the original publications is as follows:

I The author was the primary individual who performed the gene expression, DNA methylation and chromatin immunoprecipitation studies and who analysed the data and participated in the study design and manuscript writing.

II The author was the primary individual who performed the gene expression, DNA methylation and cell culture studies and who analysed the data, participated in the study design, manuscript writing and handled correspondence.

III The author performed all of the molecular biological experiments, with the exception of the Western blotting, and the author also analysed the data, wrote the manuscript and handled the correspondence.

Published papers are reprinted with the permission of the copyright owners.

ABBREVIATIONS

ABC   avidin-biotin complex
AC   acute cocaine treatment
ACTH   adrenocorticotrophic hormone
ADP   adenosine diphosphate
AFR   animal-facility reared
AID   activation-induced cytidine deaminase
AMPA   α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
ANOVA   anaysis of variance
APOBEC   apolipoprotein B mRNA editing enzyme complex
AP-1   activator protein-1
$A_{2A}R$ adenosine A_{2A} receptor
5-aza   5-aza-2'-deoxycytidine
Bdnf   brain-derived neurotrophic factor
bp   base pair
cAMP   cyclic adenosine monophosphate
CBP   CREB-binding protein
Cck   cholecystokinin
Cdk5   cyclin-dependent kinase 5
cDNA   complementary DNA
c-Fos   FBJ murine osteosarcoma viral oncogene
ChIP   chromatin immunoprecipitation
CNS   central nervous system
CpG   cytosine-guanine dinucleotide
CPP   conditioned place preference
CRE   cAMP response element
CREB   cAMP response element binding protein
CRF   corticotrophin-releasing factor
CT   cycle threshold
DARPP-32   cAMP-regulated phosphoprotein 32 kDa
DAVID   database for annotation, visualization and integrated discovery
DNA   deoxyribonucleic acid
DNMT   DNA methyltransferase
ERK   extracellular signal-regulated kinase
FC   fold change
fosB   FBJ osteosarcoma oncogene B
fra-1,2   fos-related antigen 1 and 2
GABA   γ-aminobutyric acid
GADD45   growth arrest and DNA damage-inducible protein 45
Gal   galanin
Gapdh   glyceraldehyde-3-phosphate dehydrogenase
GC   glucocorticoid
GEO   gene expression omnibus

GluR1	glutamate receptor 1
GO	gene ontology
GR	glucocorticoid receptor
G9a	histone H3 lysine K9 methyltransferase
HAT	histone acetyltransferase
HDAC	histone deacetylase
HDM	histone demethylase
5-hmc	5-hydroxymethylcytosine
HMT	histone methyltransferase
HPA	hypothalamic-pituitary-adrenal axis
5-HT	serotonin
i.c.v.	intracerebroventricular
i.p.	intraperitoneal
kb	kilobase
kDa	kilo Dalton, the unified atomic mass unit
LG	licking and grooming
LSD1	lysine specific demethylase 1
MAPK	mitogen activated protein kinase
MBD	methyl-CpG-binding domain protein
5-mC	5-methylcytosine
MeC	methylated cytosine
MeCP2	methyl-CpG-binding protein 2
MeDIP	methylated DNA immunoprecipitation
MET	L-methionine
mRNA	messenger ribonucleic acid
MR	mineralocorticoid receptor
MS	maternal separation
MS15	15 min maternal separation
MS180	180 min maternal separation
MSK1	mitogen- and stress-activated protein kinase 1
MSP qPCR	methylation-specific quantitative polymerase chain reaction
NAc	nucleus accumbens
NH	non-handled
OD	optical density
PBS	phosphate buffered saline
PC12	pheochromocytoma cells
PFC	prefrontal cortex
PKA	protein kinase A
PND	postnatal day
PP1	protein phosphatase 1
PP1c	protein phosphatase 1 catalytic subunit
qPCR	quantitative polymerase chain reaction
Reln	reelin
RC	repeated cocaine treatment

RG-108   non-nucleoside DNA methyltransferase inhibitor
RNA   ribonucleic acid
RST   repeated SAM treatment
SAH   S-adenosylhomocysteine
SAHA   suberoylanilide hydroxamic acid
SAL   saline
SAM   S-adenosylmethionine
SDS   sodium dodecyl sulfate
SEM   standard error of mean
Ser133   serine 133
Slc17a7   solute carrier family 17 member 7
SST   single SAM treatment
TBS   TRIS buffered saline
TET   ten-eleven translocation enzyme
Tris-EDTA   trishydroxymethylaminomethane-Ethylenediaminetetraacetic acid
TSA   trichostatin A
VTA   ventral tegmental area
ZEB   zebularine
ΔcJun   truncated form of cJun, dominant negative of ΔFosB
ΔFosB   truncated form of FosB that is induced by chronic drug use

INTRODUCTION

Drug addiction is a chronic relapsing disorder characterised by a pattern of compulsive drug seeking and taking behaviour despite severe adverse consequences (Kalivas et al., 2005; Hyman et al., 2006; Koob and Kreek, 2007). Prolonged abuse of drugs, such as psychostimulants, may contribute to behavioural abnormalities that can last for months or even years after discontinuing drug consumption. Drug addiction is a multi-factorial and polygenic disorder that does not conform to a simple Mendelian transmission pattern (Goldman, 1993; Enoch and Goldman, 1999; Goldman et al., 2005; Wong et al., 2011). Individuals are differentially vulnerable to substance abuse, and not everyone who uses an addictive substance becomes addicted. Extensive epidemiological studies show that roughly half of an individual's risk for drug addiction is genetic but the specific genes that confer a risk for drug addiction are not well known (Nestler, 2001; Goldman et al., 2005; Hyman et al., 2006), although several possible candidates have been proposed (Wang et al., 2012).

Entrance into the addicted state clearly results from the interplay between an inherited predisposition (e.g., via genetic variants that mediate the personality traits associated with drug-seeking behaviour and dependence) and the environment (e.g., actual exposure to drugs of abuse) (Nestler, 2001; Goldman et al., 2005; Wong et al., 2011). There is evidence that suggests that stressful and traumatic experiences in early life also have a long-lasting impact on the behaviour of an individual. However, the mechanisms that mediate the effects of the early environment on this behaviour are not yet fully understood. Recent findings suggest that the epigenome, which comprises the machinery for programming long-term gene expression profiles and thus defines gene function and phenotype, can be modulated by a variety of environmental factors including nutrients, chemicals and the early-life environment (Weaver et al., 2004; Waterland et al., 2006; Roth et al., 2009; Szyf, 2009). Therefore, the epigenome provides an important interface between genes and the environment and may be viewed as a potential mechanism underlying the rapid form of environmentally driven adaptation (Franklin and Mansuy, 2010).

Repeated administration of psychostimulants (such as cocaine) induces an enhanced behavioural response to subsequent drug exposure, a phenomenon known as psychomotor or behavioural sensitisation (Robinson and Berridge, 1993; Pierce and Kalivas, 1997). Psychostimulant-induced behavioral sensitisation in rodents provides a model of these addictive behaviours (such as those associated with craving and relapse) and the psychotic complications of psychostimulant abuse (Robinson and Becker, 1986). Behavioural sensitisation is remarkably persistent phenomenon. In rodents, it can persist from months to years after drug treatment is discontinued. Persistent behavioural sensitisation indicates that drug-induced short- and long-term changes in gene expression may be involved. Accumulating data suggest that epigenetic mechanisms (such as DNA methylation, histone modifications and microRNAs) contribute to

drug-induced transcriptional and behavioural changes (Kumar et al., 2005; Levine et al., 2005; Renthal et al., 2007; Wang et al., 2010).

The general aim of this study was to investigate the role of DNA methylation in the development of cocaine-induced behavioural sensitisation in mice and rats. The more specific aims were: a) to determine the role of cocaine treatment on the expression of DNA methyltransferases (DNMTs) and selected genes in the nucleus accumbens (NAc) of mice and to assess the effect of the DNMT inhibitor zebularine on the development of behavioural sensitisation in mice; b) to investigate the role of the methyl donor S-adenosylmethionine (SAM) on cocaine-induced gene expression changes and the development of behavioural sensitisation in mice; c) using maternal separation (MS) as an early-life stress model, to evaluate whether MS in rats could alter cocaine-induced behavioural sensitisation in adulthood via aberrant DNA methylation.

REVIEW OF THE LITERATURE

1. Drug addiction and behavioural sensitisation

Drug addiction can be defined as the loss of control of drug use or the compulsive seeking and taking of drugs despite adverse consequences (Nestler, 2001). Once a person becomes addicted to drugs of abuse, only a few effective therapies can be used. Therefore, understanding the neural mechanisms that underlie the transition from recreational drug use to a chronically addicted state, and the mechanisms responsible for the persistence of addictive behaviours even after prolonged drug abstinence would provide clues as to how to block or reverse the addicted state and thereby diminish the rate of relapse (for a review see Renthal and Nestler, 2008).

Psychostimulants, such as cocaine and amphetamine, change neuronal structure and function in specific brain regions, resulting in persistent changes at the molecular, cellular systems and behavioural levels (Paulson et al., 1991; Koob and LeMoal, 2001; Nestler, 2001; McQuown and Wood, 2010). Repeated administration of psychostimulants induces an enhanced behavioural response to subsequent drug exposure, a phenomenon known as psychomotor or behavioural sensitisation, that can persist for months (Robinson and Berridge, 1993; Pierce and Kalivas, 1997). Behavioural sensitisation can be separated into two components – induction and expression of sensitisation. Induction of sensitisation refers to the progressive increase in locomotor activity during the repeated drug treatments. Expression of sensitisation is demonstrated following challenge with a low dose of psychostimulant after a drug-free period (McQuown and Wood, 2010). Psychostimulant-induced behavioural sensitisation in rodents provides a model for addictive behaviours, such as those associated with craving and relapse, and for the psychotic complications of psychostimulant abuse (Koob and Bloom, 1988; Robinson and Berridge, 1993; Chen et al., 2003).

Several neuropharmacological studies have indicated that drugs of abuse activate the brain reward circuitry, which centres on the dopaminergic neurons of the ventral tegmental area (VTA) of the midbrain and their projections to the limbic system – in particular, the NAc and regions of the prefrontal cortex (PFC) (Figure 1) (Kalivas and Volkow, 2005; Koob and LeMoal, 2005; Hyman et al., 2006; Robinson and Nestler, 2011). Under normal conditions, this reward circuitry controls an individual's responses to natural rewards, such as food, sex, play and social interactions. Compared with the natural rewards, drugs of abuse activate this reward circuitry far more strongly and persistently and without an association with productive behavioural outcomes. Chronic exposure to drugs modulates the described brain reward regions in part via homeostatic desensitisation that renders the individual unable to attain sufficient feelings of reward in the absence of drug (for a review see Robinson and Nestler, 2011).

Figure 1. Dopaminergic afferents in the brain that originate in the ventral tegmental area (VTA) and release dopamine in the nucleus accumbens (NAc) and other limbic targets. Thalamus (Thal), prefrontal cortex (PFC; modified from Robinson and Nestler, 2011).

The addictive phenotype may persists for the length of an individual's life with drug craving and relapse occurring after weeks, months or even years of abstinence. This persistence suggests that drugs of abuse induce long-lasting changes in the brain that underlie the addiction behaviours (Robinson and Nestler, 2011). Therefore, it has been hypothesized that persistent alterations in gene expression could be responsible for the long-term behavioural and structural changes (Nestler and Aghajanian, 1997).

The classic mechanism of gene expression regulation involves the actions of transcription factors, which are proteins that, in response to cell signaling pathways, bind specific DNA sequences in promoter regions of target genes and increase or decrease gene expression by promoting or blocking the recruitment of the RNA polymerase-II transcriptional complex (Robinson and Nestler, 2011). It has been proposed that drugs of abuse activate certain transcription factors and thereby cause adaptive changes in neuronal structure and function (Kalivas et al., 2003). Although several different transcription factors exist, two of the most well known and best characterised transcription factors (associated with drug addiction) are cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB) and ΔFosB (Nestler et al., 2001; McClung and Nestler, 2003).

Phosphorylation of CREB by protein kinase A (PKA) at serine133 (Ser133) is an important event in the activation of CREB and cAMP response element (CRE)-dependent gene expression. Furthermore, phosphorylation of CREB at Ser133 allows recruitment of the transcriptional coactivator, CREB-binding protein (CBP), that in turn promotes transcription (Carlezon et al., 2005; Briand and Blendy, 2010; Robinson and Nestler, 2011). Psychostimulants and opiates

upregulate the cAMP pathway and thereby increase CREB activity in multiple brain regions including the NAc and dorsal striatum (Carlezon et al., 2005; Edwards et al., 2007; Briand and Blendy, 2010). Studies involving the inducible overexpression of CREB or a dominant negative mutant in bitransgenic mice or using viral vectors have demonstrated that CREB induction in the NAc decreases the rewarding effects of cocaine and opiates (Carlezon et al., 1998; Barrot et al., 2002; Robinson and Nestler, 2011). Data from Walters and Blendy (2001) demonstrated that mice partially deficient in CREB (CREB$^{\alpha, \Delta}$ mutant mice lack the α and Δ isoforms of CREB) showed an enhanced response to the reinforcing properties of cocaine compared with wild-type controls in both conditioned place preference (CPP) and sensitisation behaviours (Walters and Blendy, 2001). These results suggest that drug-induced CREB activation/ phosphorylation in the NAc comprises a negative feedback mechanism that dampens behavioural sensitivity to subsequent drug exposure (Carlezon et al., 2005; Chen et al., 2009). However, temporally, CREB is induced rapidly after each drug treatment (effects are relatively short-lived) and returns to baseline after a few hours (Nestler, 2008).

The transcription factor ΔFosB (encoded by the *fosB* gene) is a member of the Fos family, which comprises *c-fos*, *fosb*, *fra-1* and *fra-2* genes (Nestler et al., 2001; Nestler, 2008). ΔFosB heterodimerises with Jun family proteins (c-Jun, JunB, JunD) to form activator protein-1 (AP-1; known as transcription factor AP-1) complexes that bind to AP-1 sites in responsive genes to regulate transcription (Curran and Franza, 1988; Jorissen et al., 2007; Nestler, 2008). It has been found that acute exposure to drugs of abuse causes a transient increase in members of the Fos family of transcription factors (including *c-fos*, *fosB*) in the NAc and dorsal striatum (Nestler et al., 2001). During repeated exposures to drug of abuse, the expression of transcription factor ΔFosB increases several fold and often persists long after drug exposure ceases. Thus, ΔFosB extraordinary stability in neurons has led to the theory that it plays an important role in the onset of drug addiction (Bowers et al., 2004; McClung et al., 2004; Kalivas and O'Brien, 2008). Indeed, several previous studies have demonstrated that ΔFosB is directly associated with addiction-related behaviours. It has been found that prolonged ΔFosB expression in the NAc increases the rewarding effects of cocaine. For example, mice overexpressing ΔFosB demonstrated increased CPP, self-administration and incentive motivation for cocaine (Kelz et al., 1999; Nestler, 2001; Colby et al., 2003; Peakman et al., 2003). However, mice that express a dominant-negative form of cJun (ΔcJun), which disrupts normal AP-1 function, demonstrated less preference for cocaine (Nestler, 2008). Thus, to summarize, it appears that gene expression induced by short-term ΔFosB and by CREB reduces the rewarding effects of cocaine whereas prolonged ΔFosB expression increases drug reward. Furthermore, it has been demonstrated that gene expression after a short cocaine exposure was dependent on CREB whereas gene expression after a longer cocaine treatment was ΔFosB dependent (McClung and Nestler, 2003; Nestler, 2008).

Moreover, alterations in expression of *Ags3* (activator of G protein signaling 3) (Bowers et al., 2004) and *Bdnf* (brain-derived neurotrophic factor) (Grimm et al., 2003) has been reported weeks after the last drug experience (Renthal and Nestler, 2008). Manipulation of these genes in rodents regulates drug relapse behaviour (Bowers et al., 2004; Lu et al., 2004; Graham et al., 2007; Renthal and Nestler, 2008). A multitude of microarray studies under different experimental conditions have identified several potential target genes for drugs of abuse in distinct brain reward regions that may promote their long-lasting behavioural effects (Freeman et al., 2001; McClung and Nestler, 2003; Yuferov et al., 2003; Yao et al., 2004; McClung et al., 2005; Winstanley et al., 2007; LaPlant and Nestler, 2011). Several recent reports suggest that epigenetic mechanisms – key cellular processes that transform diverse environmental stimuli into long-lasting changes in gene expression via the regulation of chromatin structure – contribute to drug-induced transcriptional and behavioural changes (Kumar et al., 2005; Levine et al., 2005; Renthal et al., 2007; Renthal and Nestler, 2008; Wang et al., 2010).

2. Epigenetics and epigenetic mechanisms

The sequence of nucleotides comprising an individual's genome is identical, with the exception of a few rare somatic mutations, across all cells in the body. Every cell in our bodies contains the same DNA sequence and each cell has its own unique phenotype characterised by a specific pattern of gene expression that is in a constant state of flux. In the context of determining the phenotype of a cell, it is also important the degree to which specific genes are functionally active at any particular time in development. Therefore, sequencing the genome was only the first step in our quest to understand how genes are expressed and regulated (for a review see Smith and Mill, 2011; Wong et al., 2011).

Accumulating evidence indicates that above the DNA sequence is a second layer of information – the epigenome – that regulates when and where genes are turned on or off. Historically, the term epigenetics (literally meaning "above genetics") was coined by Conrad Hal Waddington in 1942 to describe the examination of causal mechanisms whereby the genes of the genotype bring about phenotypic effects (Haig, 2004; McQuown and Wood, 2010). Currently, epigenetics can be defined as long-lived and reversible modifications to nucleotides or chromosomes that do not change the sequence but can alter gene expression and phenotype (LaSalle et al., 2013). Epigenetic mechanisms are essential for normal cellular development and differentiation and allow the long-term regulation of gene function through non-mutagenic mechanisms (Smith and Mill, 2011). Several data suggest that alterations of epigenetic mechanisms affect the vast majority of nuclear processes (including gene transcription and silencing), DNA replication and repair, cell cycle, telomere and centromere function and structure (Gonzalo, 2010). During the last decade, the field of epigenetics has developed into one of the most influential areas of

scientific research and has become an important topic in several neurobiology fields, such as learning and memory, psychiatric and neurological disorders.

Epigenetics is used to refer to the extremely complex processes of organizing the genome in a manner that allows regulated gene expression in the appropriate cell type upon the appropriate cellular stimuli (LaPlant and Nestler, 2011). The fundamental unit that accomplishes this feat on a molecular level is the chromatin, which is the complex of DNA, histones and non-histone proteins in the cell nucleus. The basic repeating structural unit of the chromatin is the nucleosome (Figure 2), which comprises ~147 base pairs (bp) of DNA wrapped around a core nucleosome (Strahl and Allis, 2000). Nucleosomes are composed of octamers that contain four histone homodimers, one of each of the histones H2A, H2B, H3 and H4, with H1 binding to spans of non-nucleosomal DNA (Robinson and Nestler, 2011). The histone-DNA configuration is maintained by electrostatic bonds between the positively charged histones and the negatively charged DNA (Grunstein, 1997). This highly condensed histone proteins-DNA complex structure means that control over gene expression occurs in part by gating access of transcriptional activators to DNA (Felsenfeld and Groudine, 2003; Li et al., 2007; Renthal and Nestler, 2008).

Figure 2. DNA is wrapped around a cluster of histone proteins to form nucleosomes. During histone modifications, a combination of different molecules can attach to the tails of histones, which consequently change the state of the chromatin around the DNA. When the chromatin open, the transcription of associated genes is activated with the opposite being true when chromatin close. During DNA methylation, methyl marks added to cytosine-guanine dinucleotide (CpG) islands generally repress gene transcription (Wong et al., 2011).

The structure of chromatin and access to the DNA sequence wrapped around it is regulated by posttranslational modifications of histones and the DNA itself (Kouzarides, 2007). Numerous types of posttranslational modifications, such as acetylation, methylation, phosphorylation, ubiquitination and sumoylation of the amino (N)-terminal tails of histones alter chromatin compaction to create more open states (euchromatin, transcriptionally active) versus closed states (heterochromatin, transcriptionally inactive) (Cheung et al., 2000; Berger, 2007; Kouzarides, 2007; Robinson and Nestler, 2011). It has been found that histone modifications that weaken or disrupt histone-DNA contacts, such as histone acetylation, correlate with transcriptionally active states. In contrast, histone modifications that increase histone-DNA contacts, such as histone methylation at certain basic amino acid residues, promote transcriptional repression (Strahl and Allis, 2000; Maze and Nestler, 2011). Combinations of numerous posttranslational modifications on amino (N)-terminal histone tails have been shown to affect chromatin condensation and result in altered levels of gene expression in cells (Jenuwein and Allis, 2001; Maze and Nestler, 2011).

2.1. Histone modifications

Each histone protein comprises a central globular domain and an amino (N)-terminal tail that contains multiple sites for posttranslational modifications including acetylation, phosphorylation, methylation, ubiquitination, and ADP-ribosylation. Most histone posttranslational modifications are dynamic (Allis et al., 2007; Berger, 2007; Kouzarides, 2007) and are regulated by a large number of histone modifying enzymes, such as acetyltransferases, deacetylases, methyltransferases, demethylases and kinases among others (Gibney and Nolan, 2010).

2.1.1. Histone acetylation and deacetylation

The enzymes that regulate histone acetylation levels are histone acetyl-transferases (HATs). The primary function of HATs is to neutralize the charges on histones to relax chromatin structure, which allows greater access of transcription factors to the DNA and thereby increases transcription (Norton et al., 1989; Barrett and Wood, 2008). In contrast, histone deacetylases (HDACs) deacetylate histone tails, and histone deacetylation has been linked to transcriptional repression (Kuo and Allis, 1998; Jenuwein and Allis, 2001; Narlikar et al., 2002). The HDAC family consists of a number of proteins that have a catalytic deacetylase domain and are divided into 4 classes. Class I HDACs (HDAC 1, 2, 3 and 8) are expressed ubiquitously and likely mediate the majority of deacetylase activity within cells. Class II HDACs (HDAC 4–7 and 9–10) are larger proteins containing a deacetylase domain and an N-terminal regulatory domain that enables them to be shuttled in and out of the nucleus in a neural activity-dependent manner, and they enriched in specific tissues, such as

the brain and heart (Chawla et al., 2003; Renthal and Nestler, 2008). Class III HDACs are homologs of silent information regulator 2 (Sir2) and sirtuins, and HDAC11 is a class IV HDAC and shares homology with class I and II enzymes (Yang and Seto, 2008). The balance between the opposing activities of HATs and HDACs determines gene expression levels.

2.1.2. Histone methylation

Another group of important enzymes are histone methyltransferases (HMTs, such as SET, MLL and SUV39 among others), which are methylated at lysine (K) or arginine (R) residues and removed by histone demethylases (HDMs) (Tachibana et al., 2001; Hake et al., 2004; Shi et al., 2004). Histone methylation has been associated with both transcriptional activation and repression depending on the particular residue and the extent of methylation (Su and Tarakhovsky, 2006; Maze and Nestler, 2011). Lysine side chains may be mono-, di- or trimethylated whereas the arginine side chain may be mono- or dimethylated. Currently, there are 24 known methylation sites on histones – 17 are lysine and 7 are arginine residues (Bannister and Kouzarides, 2005). It has been found that trimethylation of histone H3 lysines K4 (H3K4me3) and K36 (H3K36me3) are highly associated with transcriptional initiation and often correlate with increased levels of transcriptional activity whereas di- and trimethylation of the histone H3 lysines K9 (H3K9me2/3) and K27 (H3K27me2/3) is associated with transcriptional repression (Rice and Allis, 2001; Maze and Nestler, 2011). Histone methylation is dynamically regulated by HMTs and HDMs. The first discovered HDM was lysine specific demethylase 1 (LSD1). LSD1 is flavin-dependent monoamine oxidase that demethylates mono- and dimethylated lysines, specifically histone H3 lysines K4 and K9 (H3K4 and H3K9). The Jumonji domain-containing (JmjC) histone demethylases (such as JHDM1 and JHDM2 – JmjC domain-containing histone demethylase 1 and 2, respectively) were discovered because lysines can be mono-, di-, and trimethylated and LSD1 only mediates mono- and dide-methylation. They can demethylate mono-, di-, or trimethylated lysines and enable greater functional control of lysine methylation (Shi and Whetstine, 2007).

2.1.3. Histone phosphorylation

Histone phosphorylation has been shown to be involved in a variety of cellular processes including transcriptional regulation, apoptosis, cell cycle progression, DNA repair and chromosome condensation (Banerjee and Chakravarti, 2011). The most described histone phosphorylation site is serine 10 on histone H3 (H3S10). It has been found that this modification stabilizes a HAT (Gcn5) on gene promoters and antagonizes the methylation of lysine K9 on histone H3 (H3K9) and the recruitment of heterochromatin protein 1 (HP1) (Kouzarides,

2007; Renthal and Nestler, 2008). Phosphorylation of serine or threonine residues on histone tails can be accomplished by nuclear kinases, such as mitogen- and stress-activated protein kinase (MSK-1), and dephosphorylation can be mediated by protein phosphatases (such as protein phosphatase 1, PP1) (Brami-Cherrier et al., 2009; Koshibu et al., 2009; Day and Sweatt, 2011). The exact mechanism by which phosphorylation contributes to transcriptional activation is not well understood but it is hypothesized that the addition of negatively charged phosphate groups to histone tails neutralizes the positive charge of histone tails and reduces their affinity for DNA (Grant, 2001; Tambaro et al., 2010).

2.2. DNA methylation and DNA methyltransferases

DNA methylation represents another important and unique epigenetic mechanism. The methylation of one of the four DNA bases, cytosine, is a relatively stable epigenetic modification that regulate the transcriptional plasticity of mammalian genomes. During DNA methylation, a methyl group is added to the 5′ position on the cytosine pyrimidine ring, occurring primarily where a cytosine (C) is next to guanine (G) in the DNA sequence (C-phosphate link-G or cytosine-guanine dinucleotides, CpG) (Holliday and Pugh, 1975; Klose and Bird, 2006; Wong et al., 2011). The CpG sequences are not evenly dispersed throughout the genome but are clustered in so-called CpG islands – short regions of 0.5 to 4 kb in length with a rich (60–70%) cytosine-guanine content. Over 50–60% of all dinucleotides in these islands are CpG, compared with the rest of the genome where the CpG content is ≤ 20% (Bird, 2002). Approximately 50% of CpG islands are located in promoter regions and around the transcription start sites and are unmethylated in normal cells (Robertson and Wolffe, 2000; Jones and Baylin, 2002).

DNA methylation is generally considered to suppress gene transcription by recruiting co-repressor complexes (e.g., HDACs and HMTs) that can modify nucleosome structure (Robinson and Nestler, 2011). These complexes involve several DNA methyl-CpG-binding domain proteins (MBD; in mammals they are MeCP2, MBD1-4) that are necessary for normal cell growth and development (Robertson and Wolffe, 2000; Chahrour and Zoghbi, 2007; Kim et al., 2009). It should be noted that mechanistically, MeCP2 may act as both an activator and repressor of gene transcription (Chahrour et al., 2008).

The methylation of cytosine is catalysed by DNA methyltransferases (DNMTs). In mammalian genomes, DNMTs are enzymes that have been demonstrated to mediate the transfer of a methyl group from S-adenosylmethionine (SAM or AdoMet) to cytosine (Figure 3) (Eden et al., 2003; Villar-Garea et al., 2003; Goll and Bestor, 2005).

Figure 3. Modification of DNA by methylation at the 5-carbon position of cytosine by DNA methyltransferases (DNMTs) where S-adenosylmethionine (SAM) is the methyl group donor (−CH₃) and which is converted to S-adenosylhomocysteine (SAH; modified from Wong et al., 2011).

There are two main DNMT enzyme groups: DNMT1 and DNMT3 families. DNMT1, the first-identified eukaryotic DNMT, is essential for maintaining DNA methylation patterns in proliferating cells as they copy DNA methylation patterns from the matrix chain to newly synthesized DNA chain. It is also involved in establishing new DNA methylation patterns (*de novo* methylation) (Bestor, 2000; Goll and Bestor, 2005; Siedlecki and Zielenkiewicz, 2006). The DNMT3 family includes two active *de novo* DNMTs – DNMT3A and DNMT3B, which are necessary for establishing new DNA methylation patterns (Okano et al., 1999) – and one regulatory factor, DNMT3-Like protein (DNMT3L) (Bestor, 2000; Goll and Bestor, 2005). DNMT3L has not been shown to possess methyltransferase activity (Bourc'his et al., 2001) but regulates DNMT3A and DNMT3B by stimulating their catalytic activity (Cheng and Blumenthal, 2008). Organisms that contain members of the DNMT1 and DNMT3 families also have DNMT2, which displays weak DNMT activity (Okano et al., 1998; Yoder and Bestor, 1998; Siedlecki and Zielen-kiewicz, 2006).

2.2.1. S-adenosylmethionine and DNA methylation

S-adenosylmethionine (SAM or AdoMet), first discovered in 1952, is formed from the essential amino acid methionine and adenosine triphosphate. SAM is the methyl group donor of multiple methylation reactions in all organisms (Chiang et al., 1996; Lu, 2000; Cheng and Roberts, 2001; Bottiglieri, 2002), whereas S-adenosylhomocysteine (SAH) is the product of transmethylation reactions and a DNMT inhibitor (Chiang, 1998; Detich et al., 2003). Studies have revealed that administration of exogenous SAM increases the intracellular ratio of SAM to SAH (Garcea et al., 1989; Pascale et al., 2002; Detich et al., 2003). An increase in SAH concentration, even without a concomitant reduction in SAM, results in DNMT inhibition and DNA hypomethylation (Caudill et al., 2001). For that reason, the SAM/SAH ratio has been proposed as a

"methylation index" that indicates the likelihood of hyper- or hypomethylation of DNA (Waterland, 2006).

Several studies have suggested that exogenous SAM administration can increase the levels of intracellular SAM and trigger hypermethylation of DNA (Watson et al. 1999; Lu, 2000; Fuso et al. 2001), whereas methyl-deficient diets decrease intracellular SAM concentration, increase SAH concentrations and trigger DNA hypomethylation (Pogribny et al., 1995; Steinmetz et al., 1998; Poirier, 2002). It has been found that dietary supplements, such as SAM, L-methionine (MET) and folic acid, increases DNA methylation thereby altering gene expression (Ross, 2003). SAM has been used as a dietary supplement in Italy (since 1979), Spain (since 1985), Germany (since 1989), in the United States (since 1999) and in several other countries (Bottiglieri, 2002).

2.2.2. DNA demethylation

In contrast to the large amount of information that has accumulated on DNA methylation, DNA demethylation remains a quite controversial and largely unresolved area of research (Kapoor et al., 2005; Wu et al., 2010). DNA demethylation occurs via a series of chemical reactions that modify 5-methylcytosine (5-mC) at two sites, the amino group and the methyl group. An alternative model for DNA demethylation involves the conversion of methylated cytosine (MeC) in DNA to thymine by deamination or loss of the amine group followed by conventional base and nucleotide excision repair processes that resynthesize a nonmethylated cytosine (Figure 4) (Ma et al., 2009a; Day and Sweatt, 2010).

Figure 4. Methylated DNA is deaminated and converted to thymine, and base or nucleotide excision repair processes replace the thymine with unmethylated cytosine. MeC-methylated cytosine (adapted from Day and Sweatt, 2010).

It is assumed that the Growth Arrest and DNA Damage-inducible protein 45 (GADD45) family of proteins (specifically GADD45β) participate in each step of this process and thereby catalyse DNA demethylation (Ma et al., 2009b).

Furthermore, it appears that DNMTs may also participate in the deamination of methylated cytosine in a strand-specific manner (Métivier et al., 2008), giving them a role in both DNA methylation and demethylation processes. Although not clear how this model affects methylation status on the complementary DNA strand, this mechanism enables selective demethylation at specific sites in DNA allowing transient methylation, active demethylation and a route of entry for the nucleoside analog DNMT inhibitors into the DNA of non-dividing cells (Day and Sweatt, 2010). DNMT inhibitors, such as zebularine or 5-aza-2'-deoxycytidine (5-aza), may operate by substituting for cytosine during base excision repair processes; this altered base is resistant to methylation and traps DNMTs, resulting in a decrease in DNMT activity and in the demethylation of the newly repaired strand (Szyf, 2009; Day and Sweatt, 2010).

Another active DNA demethylation mechanism is mediated by the ten-eleven translocation (TET) enzymes TET1-3, which add a hydroxyl group onto the methyl group of 5-methylcytosine (5-mC) to form 5-hydroxymethylcytosine (5-hmC) (Tahiliani et al., 2009; Ito et al., 2010). In mammals, once 5-hmC is formed, 2 separate mechanisms then convert 5-hmC back into cytosine. Initially, iterative oxidation by TET enzymes continue to oxidize 5-hmC to 5-formylcytosine (5-fC) and then to 5-carboxycytosine (5-caC) (Ito et al., 2011). Second, 5-hmC is deaminated by AID/APOBEC (activation-induced cytidine deaminase/apolipoprotein B mRNA editing enzyme complex) to form 5-hydroxymethyl-uracil (5-hmU) (Guo et al., 2011; Moore et al., 2013). These data indicate that 5-hmC may also play a role in the process of active DNA demethylation.

2.3. microRNA

Another level of epigenetic regulation by small non-coding RNAs (termed microRNAs) has been discovered (Bergmann and Lane, 2003). MicroRNAs, which generally are approximately 22 bp long, are posttranslational regulators that bind to complementary sequences on target mRNAs and that regulate gene expression at different levels, i.e., chromatin silencing (affecting histone modifications), mRNA degradation and translation block (Szyf et al., 2008; Taft et al., 2010; Li and van der Vaart, 2011). Thus, as with histone modifications and DNA methylation, microRNAs are also important players in the epigenetic control of gene expression.

2.4. Epigenome

The pattern of epigenetic modifications in the genome, or the epigenome, is the result of a complex interplay between enzymes that modify DNA and histones, proteins that recognize these modifications and microRNAs (Bernstein et al., 2007; Szyf, 2009; Telese et al., 2013). Thus, the epigenome comprises the

machinery that programmes long-term gene expression profiles that define gene function and phenotype and are expressed in behaviour (Szyf, 2009). Unlike the underlying genome, which is largely static within an individual, the epigenome can be dynamically altered by environmental factors, such as nutrients, chemicals and early life environment (Weaver et al., 2004; Waterland et al., 2006; Szyf, 2009). Therefore, the epigenome provides an essential interface between genes and the environment and may be viewed as a potential mechanism underlying the rapid form of environmentally driven adaptation (Franklin and Mansuy, 2010).

2.5. The role of epigenetic mechanisms in drug addiction

2.5.1. Histone modifications in drug addiction

Drugs of abuse (e.g., cocaine, amphetamine, ethanol) induce changes in histone modifications in the brain, and evidence has begun to accumulate that these modifications are associated with some of the functional abnormalities found in addiction models (Kumar et al., 2005; Kim and Shukla, 2006; Kalda et al., 2007; Robinson and Nestler, 2011). For example, it has been found that acute and chronic exposure to cocaine increases global levels of histone H3 and H4 acetylation in the rodent NAc (Kumar et al., 2005). At the gene level, it has been shown that acute cocaine treatment was associated with histone H4 hyperacetylation at the promoters of the immediate early genes, such as *c-fos* and *fosB*, whereas repeated cocaine treatment was associated with histone H3 hyperacetylation at the *Cdk5* and *Bdnf* promoters.

Further studies have demonstrated that modifications in HDAC activity are substantial regulators of the rewarding properties of cocaine. Short-term systemic or intra-NAc administration of non-specific HDAC inhibitors prior to cocaine or morphine exposure enhances behavioural preferences for places associated with drug delivery (so-called CPP) (Kumar et al., 2005; Sanchis-Segura et al., 2009; Robinson and Nestler, 2011). It has been found that overexpression of HDAC4 or HDAC5 reduces behavioural responses to cocaine (Kumar et al., 2005; Renthal et al., 2007), whereas genetic deletion of HDAC5 hypersensitizes mice to the chronic effects (but not to the acute effects) of the drug (Renthal et al., 2007). It has also been demonstrated that mutant mice with decreased expression of CBP (a major HAT in brain), exhibit reduced sensitivity to chronic cocaine exposure (Levine et al., 2005; Robinson and Nestler, 2011). Moreover, chronic cocaine treatment increased expression of two sirtuins, Sirt1 and Sirt2, which are class III HDACs. Upregulation of sirtuin expression is associated with increased H3 acetylation and ΔFosB binding at Sirt1 and Sirt2 promoters, which indicates that sirtuins are downstream targets of ΔFosB (Robinson and Nestler, 2011). Pharmacological inhibition of sirtuins reduces CPP and cocaine self-administration, whereas activation increases rewarding responses to cocaine (Renthal et al., 2009). Despite the fact that a

single cocaine exposure does not itself alter sirtuin activity, upregulation after chronic cocaine exposure may mediate the stable neuroadaptive changes involved in maintaining addiction (McQuown and Wood, 2010).

There is evidence that histone methylation is also directly regulated by drugs of abuse (Robinson and Nestler, 2011). The experiments by Maze and colleagues (2010) have demonstrated that global levels of histone H3 lysine K9 dimethylation (H3K9me2) are decreased in the mouse NAc after chronic cocaine exposure (Maze et al., 2010). Genome-wide studies by Renthal et al. (2009) revealed alterations in H3K9me2 binding on numerous gene-promoter regions in the NAc. The global reduction in H3K9me2 in the NAc was mediated via the repression of G9a (known as HMT), which was regulated by the cocaine-induced transcription factor ΔFosB (Robinson and Nestler, 2011). It has been reported that acute cocaine exposure enhanced G9a binding in the *fosB* promoter region and therefore rapidly suppressed cocaine-induced increases in ΔFosB expression (Maze and Nestler, 2011). Following repeated cocaine exposure, ΔFosB accumulation in the NAc results in G9a repression and decreased global levels of H3K9me2, preventing G9a's ability to maintain normal levels of gene expression and enhancing behavioural responses to the drug (Maze et al., 2010; Maze and Nestler, 2011).

Histone phosphorylation is also an important component of the epigenetic responses to drugs of abuse. Brami-Cherrier and colleagues (2009) reported that cocaine induces a robust phosphorylation of histone H3 within the NAc at the *c-fos* and *c-Jun* promoters (Brami-Cherrier et al., 2009). Histone H3 phosphorylation is positively regulated by the MAPK/extracellular-signal regulated kinase (ERK) cascade, which includes steps to phosphorylate ERK and MSK-1-induced phosphorylation of histone H3 (Brami-Cherrier et al., 2005; Bertran-Gonzalez et al., 2008). Nuclear accumulation of dopamine and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) acts to inhibit PP1, thereby preventing histone dephosphorylation (Stipanovich et al., 2008). Critically, these pathways control behavioural responses to cocaine by inhibiting dopamine D1 receptors, ERK, DARPP-32 and MSK-1, all of which diminish drug-induced locomotor responses or drug CPP (Stipanovich et al., 2008; Brami-Cherrier et al., 2009). Thus, these data confirm that changes in histone modifications may influence the transcription of genes involved in mediating cocaine-induced behaviour.

2.5.2. DNA methylation and drug addiction

Although the majority of studies have focused on histone modifications, DNA methylation is also a critical component of the epigenetic response to drug-related behaviours. Several recent studies have provided crucial evidence of the role of DNA methylation in cocaine-induced neuronal plasticity in the NAc and hippocampus (Im et al., 2010; LaPlant et al., 2010, Paper I). Reports have demonstrated that acute cocaine treatment induces rapid changes in the

expression of *Dnmt3a* and *Dnmt3b* genes in the NAc, suggesting dynamic control of DNA methylation by drugs of abuse. Cocaine treatment also resulted in increased methylation of *protein phosphatase-1 catalytic subunit (PP1c)* promoter region, and binding of MeCP2 at the promoter. These changes were associated with transcriptional downregulation of *PP1c* in the NAc. In contrast, acute and repeated cocaine administrations induced hypomethylation and decreased binding of MeCP2 at the *fosB* promoter, which was associated with transcriptional upregulation of *fosB* in the NAc (Paper I). Im and colleagues (2010) investigated a possible role for MeCP2 in the dorsal striatum in the escalating cocaine intake observed in rats with extended access to the drug and found that MeCP2 knockdown prevented escalation of cocaine self-administration during extended access (Im et al., 2010). It has been shown that NAc-specific manipulations that block DNA methylation potentiated cocaine reward and NAc-specific *Dnmt3a* upregulation attenuated cocaine reward (LaPlant et al., 2010). Recent reports indicate that epigenetic changes in brain regions outside of the striatum are also important regulators of drug memories. It has been found that DNA methylation within the hippocampus and prelimbic cortex is necessary for the establishment and maintenance of cocaine-induced CPP (Han et al., 2010; Day and Sweatt, 2011).

2.5.3. microRNA and drug-related behaviour

Several recent studies have demonstrated that microRNAs are important in addiction-related behaviours. For example, Hollander and colleagues (2010) found that cocaine self-administration upregulated microRNA miR-212 expression in the rat striatum and also that enhanced miR-212 levels in this brain region decreased cocaine reward (Hollander et al., 2010). It appears that the actions of miR-212 depend upon upregulation of CREB, which is known to decrease the rewarding effects of cocaine (Robinson and Nestler, 2011). Im et al. (2010) demonstrated that MeCP2 may interact homeostatically with miR-212 to control *Bdnf* expression and cocaine intake. Therefore, it has been suggested that the CREB-miR212-MeCP2-Bdnf mechanism is partly respon-sible for tolerance to cocaine and the escalation in its intake (Robinson and Nestler, 2011). Moreover, recent studies have demonstrated that overexpression of miR-124 in the NAc of rats reduces cocaine place conditioning, whereas overexpression of miR-181 causes the opposite effect. These data indicate that microRNAs may play an essential role in drug tolerance and escalation of intake (Chandrasekar and Dreyer, 2009; Robinson and Nestler, 2011).

3. The role of early-life stress as a predictor of drug addiction

Data from various clinical and preclinical studies have shown that stressful experiences in early life represent one of the major risk factors for the development of a wide range psychopathologies including drug addiction. Early-life stress can result in permanent hypothalamic-pituitary-adrenal (HPA) axis changes, morphological changes in the brain and gene expression changes in the mesolimbic dopamine reward pathway, which are implicated in the development of drug addiction (for a review see Enoch, 2011).

Stress, which refers to processes involving perception, appraisal and response to harmful, threatening or challenging events or stimuli (Levine, 2005; Sinha, 2008), activates the HPA axis (Figure 5). The magnitude of the HPA response to stress is a function of the neural stimulation of hypothalamic corticotrophin-releasing factor (CRF) release, which stimulates the release of adrenocorticotrophic hormone (ACTH) from the pituitary gland (Smith and Vale, 2006). In turn, ACTH induces the adrenal glands to release glucocorticoids (GCs) (such as cortisol in humans and corticosterone in rodents). It is well established that GCs exert their effects via two ligand-dependent transcription factors: the glucocorticoid receptor (GR) and the mineralocorticoid receptor (MR), which, in turn, regulate patterns of downstream gene expression during development and in adulthood (McEwen and Sapolsky, 1995; Seckl and Meaney, 2004; Akil, 2005; De Kloet et al., 2005). The rate of secretion of GCs is regulated by negative feedback that suppresses CRF and ACTH at the level of hypothalamus and pituitary (Sapolsky, 1996; De Kloet et al., 1998; McEwen, 1998; Shea et al., 2004). The hippocampus is also important for GC negative feedback regulation of the HPA axis. The hippocampus contains a high concentration of both GR and MR receptors, and infusion of GCs into this structure reduces basal and stress induced GC release (Diorio et al., 1993; McEwen, 2000; Smith and Vale, 2006)

The activation of the HPA axis in response to acute stress is essential for survival, whereas chronic activation results in increased risk for several physiological problems, such as anxiety, depression and addiction to drugs (Sapolsky et al., 2000, Ambroggi et al., 2009; Enoch, 2011).

Stress

Hippocampus

Hypothalamus

CRF

Pituitary gland

ACTH

Adrenal gland

Glucocorticoids

Negative feedback

Figure 5. Schematic diagram of the hypothalamic-pituitary-adrenal (HPA) axis. Adrenocorticotrophic hormone (ACTH); corticotrophin-releasing factor (CRF; modified from Shea et al., 2004).

Several preclinical studies have demonstrated that early-life stress leads to heightened responsiveness to stress and alterations to the HPA system throughout the lifespan (Plotsky and Meaney, 1993; Heim and Nemeroff, 2001; Pryce et al., 2005). Disturbances in mother-infant interaction have been demonstrated to be a natural stressor that may lead to maladaptive development (Daniels et al., 2004; Grace et al., 2009). Animal studies indicate that the quality of maternal care (arched back nursing, grooming, licking of pups) during the first two weeks of life influences the development of individual differences in behavioural and HPA responses to stress in offspring (Liu et al. 1997; Caldji et al. 2000; Meaney and Szyf, 2005). For example, it has been found thar poor maternal contact in early life increases plasma ACTH and corticosterone responses to stress in adult rats, decreases hippocampal *GR* mRNA levels and reduces GC feedback sensitivity (Liu et al. 1997; Weaver et al., 2001 and 2004; Weaver, 2009; Enoch, 2011).

Rodent models of early-life stress, such as maternal separation (MS) and neonatal isolation, have been used to investigate the relationship between early life stress and susceptibility to drug addiction. The majority of these studies suggest that early manipulations lead to increased drug-taking behaviour in adulthood; however, the exact mechanism of how MS causes these behavioural changes is not yet understood.

3.1. Maternal separation and drug addiction

MS is an animal model that has been studied to characterize the long-term effects of early-life experience on subsequent behaviour in adulthood (Plotsky and Meaney, 1993; Pryce and Feldon, 2003; Daniels et al., 2009). The MS model involves the daily separation (15 min to 6 h) of litters from the dams during a critical period of development, typically from postnatal day (PND) 2 to 14. These brief separations cause profound neurochemical and behavioural changes in the pups that remain in adulthood (Moffett et al., 2007). Rats that are separated for 15 min per day (MS15) during the first 2 weeks of life (short MS) show less stress reactivity than animals separated for 180 min per day (MS180, long separation). MS15 and MS180 animals have been used in many studies and are typically referred to as "handled" and "maternally separated" animals, respectively. Commonly used control groups are a group reared under standard animal facility conditions (AFR) and a non-handled (NH) group (Meaney et al., 1988; Huot et al., 2002; Moffett et al., 2007).

As models of early life stress, MS and neonatal isolation (a model where pups are separated daily from the dams and also from littermates) have been demonstrated to affect psychostimulant-induced behaviour (Moffett et al., 2007). For example, it has been found that MS alters cocaine-induced locomotor activity in rats and mice (Brake et al., 2004; Kikusui et al., 2005) and behavioural sensitisation to cocaine (Li et al., 2003). Brake and colleagues (2004) have found that MS and NH rats displayed a dose-dependent greater sensitivity to cocaine-induced locomotor activity compared with a handled group (Brake et al., 2004). Studies by Marin and Planeta (2004) demonstrated that male adolescent rats exposed to MS exhibited an enhanced locomotor response to cocaine; however, this response was not observed in adult rats (Marin and Planeta, 2004). Kikusui and colleagues (2005) used mice in MS manipulation procedures and found that repeated MS increased the locomotor response to cocaine regardless of gender (Kikusui et al., 2005). It has also been found that handled rats (exposed to daily 15-min isolation periods as pups) showed an attenuated CPP for amphetamine compared with NH animals (Campbell and Spear, 1999). In addition, several previous studies demonstrated that a daily neonatal isolation of 1 h over PND 2–9 enhanced acquisition and maintenance of cocaine self-administration (Kosten et al., 2000, 2004 and 2005; Zhang et al., 2005; Moffett et al., 2007), and separated rat pups drank more alcohol and self-administered more cocaine compared with the control animals (Matthews et al., 1996; Kosten et al., 2000; Huot et al., 2001; Flagel et al., 2003). Therefore, it is assumed that early life stress leads to profound and lasting changes in the responsiveness of mesocorticolimbic dopamine neurons to stress and psychostimulants (Brake et al., 2004; Enoch, 2011). Studies by Piazza and colleagues demonstrated that the potential for rats to self-administer drugs can be predicted by the response of mesolimbic dopaminergic neurons to stress, i.e., animals that were more sensitive to the dopamine-releasing actions of stress were more likely to display addictive behaviour (Piazza et al., 1991;

Piazza and LeMoal, 1996). Thus, it is highly likely that stress increases the activity of the dopaminergic brain systems that mediate drug-induced rewarding effects (Brady and Sonne, 1999).

Moreover, a growing body of evidence demonstrates that MS results in increased HPA responsivity to stress, leading to increased adrenal GC release during stress, and in turn, GCs appear to regulate mesolimbic DA systems (Meaney et al., 2002). For example, it has been found that stress exposure and increased levels of GC enhance DA release in the NAc, and suppression of GC by adrenalectomy reduces extracellular levels of DA under basal conditions (for a review see Sinha, 2008). Several animal studies have shown that depletion of GC by adrenalectomy reduces drug and alcohol consumption (Fahlke et al., 1994; Marinelli et al., 1997; Marinelli and Piazza, 2002). It has also been found that mice with GR gene deletions show a dose-dependent decrease in motivation to self-administer cocaine (Deroche-Gamonet et al. 2003; Sinha, 2008). Therefore, the activation of the HPA axis and subsequent release of GC may also play an important role in the acquisition of addiction to psychostimulant administration (Piazza and LeMoal, 1996; Mantsch et al., 1998; Goeders, 2002 and 2003; Meaney et al., 2002).

3.2. Maternal separation and epigenetic modifications

There is a growing body of evidence that demonstrates that early-life adversity results in a change in the epigenome. It has been found that epigenetic modifications, such as DNA methylation, alter gene expression programming in the brain that lasts into adulthood. Using rodent models, several studies have demonstrated that the adult offspring of mothers that exhibit increased levels of pup licking/grooming (referred to as high-LG mothers) during the first week of life show increased hippocampal *GR* expression, decreased *CRF* expression and more modest HPA stress responses compared with low-LG mothers (Liu et al., 1997; Francis et al., 1999; Meaney and Szyf, 2005; Weaver et al., 2006; McGowan et al., 2008). Weaver and colleagues (2004) observed that poor maternal care in rats alters DNA methylation at a specific sequence motif upstream of the GR gene (*Nr3c1*) in the hippocampus of the offspring. They found significantly greater methylation of the exon 1_7 *GR* promoter sequence in the offspring of the low-LG mothers (Weaver et al., 2004). These data demonstrate that in low-LG offspring, higher methylation of the *GR* promoter suppresses *GR* expression; therefore, adult offspring of low-LG mothers have lower levels of GR (Liu et al., 1997; Champagne et al., 2003; Weaver et al., 2004). A human postmortem hippocampal study showed that suicide victims exposed to childhood maltreatment had decreased *GR* (*Nr3c1*) mRNA levels and increased cytosine methylation in *Nr3c1* promoter regions (McGowan et al., 2009; Enoch, 2011).

The exact mechanism of how maternal behaviour alters epigenetic programming in the offspring brain is unclear. One hypothesis is that maternal

behaviour increases hippocampal serotonin (5-HT) turnover and activated 5-HT_7 receptors increase cAMP activity in the offspring. Increased cAMP activity results in activation of PKA and CREB, and the subsequent phosphorylated-CREB (pCREB) activity drives expression of the transcription factor NGFI-A (nerve growth factor-inducible protein A) (Figure 6). This transcription factor in turn recruits the histone acetyltransferase CBP and also MBD2 to the *GR* promoter (Weaver et al., 2004; Weaver, 2007). It is assumed that the increased histone acetylation triggered by CBP facilitates the demethylation of the gene by MBD2 and/or other DNA demethylases (Szyf, 2009).

Figure 6. Model of the epigenetic reprogramming of hippocampal glucocorticoid receptor gene expression and stress responses induced by maternal behaviour. (A)-acetylation; (P)-phosphorylation; (LG-ABN)-licking/grooming and arched-back nursing (modified from Bennett, 2011).

However, recent studies have revealed that patterns of epigenetic modification programmed early in life may be reversible using epigenetic modulators. For example, it has been found that injecting the HDAC inhibitor trichostatin A (TSA) into the left lateral ventricle of adult offspring of low-LG mothers reversed the epigenetic programming of the *GR* exon 1_7 promoter and re-established stress responsivity (Cervoni and Szyf, 2001; Cervoni et al., 2002; Weaver et al., 2004). Conversely, it has been found that injecting the amino acid methionine, which is the precursor of SAM, into the ventricle of adult offspring of high-LG mothers resulted in increased DNA methylation and downregulation of *GR* and heightened stress responsivity (Weaver et al., 2004 and 2005; Szyf, 2011).

Early-life stress has been shown to bring about epigenetic changes of other genes. For example, it has been found that early-life stress in mice caused enduring hypersecretion of corticosterone and alterations in passive stress coping. This phenotype was accompanied by a persistent upregulation of arginine-vasopressin (*Avp*) expression and sustained DNA hypomethylation in the hypothalamic paraventricular nucleus (PVN) (Murgatroyd et al., 2009). The experiments by Roth and colleagues (2009) demonstrated that early maltreatment produces persistent changes in methylation of the *Bdnf* gene promoter and decreases *Bdnf* expression in the PFC of adult rats (Roth et al., 2009). Subsequently, Franklin et al. (2010) found that chronic and unpredictable MS alters the profile of DNA methylation in the promoter of several genes, such as *Mecp2*, corticotrophin-releasing factor receptor 2 (*Crhr2*) and cannabinoid receptor-1 (*Cnr1*), in the germline of the separated males, and comparable changes in DNA methylation are present in the brain of the offspring and are associated with altered gene expression (Franklin et al., 2010).

Together, these data suggest that alterations in epigenomic programming impact phenotype, which is expressed as behaviour and that early-life stress leaves its impact on the genome by systematic readjustment of DNA methylation patterns (Szyf, 2009).

AIMS OF THE STUDY

The general aim of this study was to investigate the role of DNA methylation in the development of cocaine-induced behavioural sensitisation in mice and rats.

The more specific aims for this thesis were:

1. To determine: a) the role of cocaine treatment on the expression of DNMTs and selected genes in the NAc of mice; and b) to assess the effect of the DNMT inhibitor zebularine on cocaine-induced gene expression changes and the development of behavioural sensitisation in adult mice.

2. To investigate the role of the methyl donor SAM on cocaine-induced gene expression changes and the development of behavioural sensitisation in adult mice.

3. To evaluate whether the early-life stress alters the expression of DNMTs and selected genes in the NAc of infant and adult rats and whether these changes are associated with the development of cocaine-induced behavioural sensitisation in adulthood.

MATERIALS AND METHODS

1. Animals and housing conditions (Papers I–III)

All experiments were performed in accordance with EU guidelines (directive 86/609/EEC) on the ethical use of animals using the experimental protocol approved by the Ethics committee of the University of Tartu Medical Faculty. Male C57BL/6 mice, 4–5 months old, weight 25–30g were obtained from Scanbur BK, Sweden (Papers I, II) and 20–25 pairs of male and female Wistar rats were obtained from Harlan Laboratories, Netherlands (Paper III). All animals were housed in standard polypropylene cages under temperature and humidity-controlled rooms with 12 h light-dark cycle (light from 7:00 a.m.) and were allowed access to rodent chow and water *ad libitum*. Animals were allowed to acclimate to laboratory conditions and were handled at least 4–7 days before use in behavioural testing. All behavioural experiments were conducted during the light phase in an isolated experimental room.

2. Maternal separation and handling procedures (Paper III)

As the pups were born (total 46, from 3–5 litters), female offspring were removed and male offspring were randomly assigned to one of three groups. During the experiment, every dam had 8 pups. The experimental groups are as follows: (1) AFR where the dams and pups were handled only on PND10 for a cage change and were not separated; (2) handled group (MS15) where pups were handled and separated to a new cage on PND2-15 for 15 min and then returned to the home cage; (3) maternally-separated group (MS180) where pups were removed from the home cage on PND2-15 for 180 min and placed individually into a new cage. At the end of the separation pups were placed back into their home cage with the dam. The manipulation of pups in the MS15 and MS180 groups was initiated at 10:00 a.m., and after the manipulation, we monitored dam and pup behaviour in the home cage for 10 min. We performed seven separation procedures to collect pups from different dams for behavioural and neurochemical tests. We considered AFR as a control group for both handling (MS15) and separation (MS180) groups. A comparison of MS15 and MS180 groups enables collection of "time course" data on MS. Cocaine-induced locomotor activity was evaluated on PND120-140. Animals were allowed to acclimate to laboratory conditions and were handled at least seven days prior to behavioural experiments. All behavioural experiments were conducted during the light phase in an isolated experimental room. For the evaluation of neurochemical changes, rats were euthanised on PND15 and PND120.

3. Drug administration (Papers I–III)

Cocaine hydrochloride (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in sterile saline (0.9% NaCl) and administered intraperitoneally (i.p.) at a dose of 15 mg/kg (Paper I) and 10 mg/kg (i.p.) (Papers II, III) immediately prior to locomotor activity training. Zebularine (Tocris Bioscience, UK) was dissolved in sterile saline and administered intracerebroventricularly (i.c.v.) 300 ng/0.5 μl 20 min before cocaine or saline (0.1 ml/10 g body weight, i.p.) treatment (Paper I). SAM (Sigma-Aldrich Co, St. Louis, MO, USA) was dissolved in sterile saline and administered (i.p.) at a dose of 4520 mg/kg, 10 mmol/kg 20 min before cocaine treatment (Paper II).

3.1. Intracerebroventricular cannula implantation (Paper I)

For i.c.v. injection cannula implantation, mice were anesthetized with Fentanyl/ fluanisone (trade name Hypnorm, VetaPharma, Leeds, UK) and midazolam (trade name Dormicum, Roche, Basel, Switzerland). During surgery, each mouse was implanted with a 26-gauge bilateral stainless steel guide cannula (Plastics One, Roanoke, USA) from which the injector extended 0.5 mm to end in the ventricle. Stereotaxic coordinates were follows: antero-posterior, –0.4 mm from bregma, –1.25 mm lateral from the midline, and –2.0 mm from bregma measured from the tip of the cannula guide (Paxinos and Franklin, 2001). Animals were habituated to dummy cannula removal and given 4 days of recovery and handling before the start of the experimental procedure. At the beginning of the study, target coordinates and proper cannula placement were verified by slowly injecting 1 μl of methylene blue dye into the cannulas of the first four mice, while they were under anesthesia. After waiting 5 min for the dye to circulate through the ventricles, the animals were sacrificed. Brains were removed, sliced at the point of cannula entry and target coordinates were verified.

4. Behavioural experiments

4.1. Locomotor activity measurement (Papers I–III)

Horizontal locomotor activity was monitored in standard polypropylene cages (36 × 20 × 15 cm) that were illuminated uniformly with dim light. A light-sensitive video camera, connected to a computer, was mounted about 1.5 m above the observation cage and locomotor activity of 8 animals at a time was monitored and analysed using VideoMot2 software (TSE Systems, Germany) (Papers I, II). In Paper I, mice (n=11) were randomly assigned to one of the following treatment groups: (1) Saline ("SAL"), mice were treated for 7 days with saline 0.1 ml/10 g body weight (i.p.); (2) Acute cocaine ("AC"), mice were treated for 6 days with saline and on the 7th day with cocaine hydrochloride;

(3) repeated cocaine ("RC"), mice were treated for 7 days with cocaine hydrochloride. On the 1st and 7th treatment days, locomotor activity was recorded for 60 min after the last injection. On the 2nd through to the 6th treatment days, mice were injected and placed in the test cages for 60 min without locomotion recording. To investigate the effect of zebularine, i.c.v. infusions of zebularine (300 ng/0.5 µl, injection speed 0.1 µl/min) or saline (0.5 µl) were performed 20 min before cocaine or saline (0.1 ml/10 g body weight, i.p.) treatment. Mice (n=7–12) were randomly assigned to one of the following treatment groups: (1) saline (i.c.v.) + saline (i.p.) "S+S"; (2) zebularine (i.c.v.) + saline (i.p.) "Z+S"; (3) saline (i.c.v.) + cocaine (i.p.) "S+C" and (4) zebularine (i.c.v.) + cocaine (i.p.) "Z+C". Locomotor activity was recorded for 60 min after i.p. injection daily for 7 days.

In Paper II, mice were treated for 7 days i.p. with sterile saline (0.1 mL/10 g body weight) or SAM (4520 mg/kg, 10 mmol/kg, i.p.) 20 min before cocaine hydrochloride administration (10 mg/kg, i.p.). Animals (n=17–22) were randomly assigned to one of the following treatment groups: (1) Saline + Saline "S+S"; (2) SAM + Saline "M+S"; (3) Saline + Cocaine "S+C" and (4) SAM + Cocaine "M+C". Locomotor activity was recorded for 90 min after the second injection on days 1, 3, 5, and 7. On the days 14 and 28, all groups were tested for locomotor activity for 90 min after cocaine challenge (7 mg/kg, i.p., n=8). On the days 8–13 and 15–27 mice did not receive any treatment. Mice were sacrificed 24 h after the end of the repeated treatment.

In Paper III, cocaine hydrochloride was administered i.p. at a dose of 10 mg/kg immediately prior to locomotor activity training. Locomotor activity was monitored in the standard polypropylene cages (54 × 32 × 20 cm) of 4 animals at a time and analysed. For experiments of acute cocaine treatment, adult male rats (PND120–140) from each of the AFR, MS15 and MS180 groups (n=13; weight 485–520g) were treated for 4 days with saline (2.5 ml/kg, i.p.) and on the 5th day with cocaine hydrochloride (10 mg/kg, i.p.). For experiments assessing the effect of repeated cocaine treatment, all rats received cocaine (10 mg/kg, i.p.) once daily for 5 consecutive days. On the 1st, 3rd and 5th treatment days, locomotor activity was recorded for 60 min after treatment. On the 2nd and 4th treatment days, rats were treated and placed in the test cages for 60 min without recording locomotion.

4.2. Exploration box test (Paper III)

At PND120, adult males from AFR, MS15 and MS180 groups (n = 8 animals in each group) were tested for exploratory behaviour. The test apparatus (modified from Matto et al., 1996 and Mällo et al., 2007) was made of metal and comprised an open area of 50 (width) × 100 (length) × 40 (height) cm with a small compartment (20 × 20 × 20 cm) attached to one of the shorter sides of the open area. The open area was divided into eight squares of equal size (25 × 25 cm) and four objects were situated in specific positions. Three objects

were unfamiliar (a glass jar, a cardboard box, a wooden handle) and one was familiar (food pellet), and the objects remained the same throughout the experiment. The floor of the small compartment was covered with wood shavings and was directly linked to the open area via an opening (size 20 cm × 20 cm). The rat was placed into the small compartment, which was then covered with a lid, and during the 15 min test session, the following measures were taken by the observer: (a) latency to enter the open area with all four paws; (b) entries into the open area; (c) line crossings; (d) rearings; (e) exploration of the three unfamiliar objects in the open area and (f) the time spent exploring the open area. The exploration test box was cleaned after each animal. To provide an index of exploration (considering both the elements of inquisitive and inspective exploration), the scores for line crossings, rearings and object investigations were summed for each animal.

5. Tissue isolation (Papers I–III)

Mice and rats were sacrificed by decapitation. The NAc, hippocampus, cerebellum and PFC were rapidly dissected out on chilled ice-cold plate and frozen immediately in liquid nitrogen and stored at –80 °C until RNA and DNA extracts and protein lysates were prepared. The NAc was dissected out using a round-shape puncher.

6. PC12 cells and DNMT activity measurement (Paper II)

Rat pheochromocytoma cells (PC12) purchased from German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany) were cultured in a humidified 5% CO_2/95% air atmosphere at 37 °C. The PC12 cell line was maintained in RPMI 1640 medium (Gibco CO, USA) supplemented with 10% heat-inactivated horse serum and 5% fetal bovine serum (Gibco CO, USA). Cells were grown on polyethyleneimine (Sigma-Aldrich, St. Louis, MO, USA) coated plastic dishes (Nunc, Thermo Fisher Scientific, MA, USA) at a density of 10^6 cells/ml. The cells from the 4th to 7th passages were treated with 0.5 mM SAM and used for the DNMT activity, gene expression, and DNA methylation experiments. For single SAM treatment, 0.5 mM SAM solution (prepared in RPMI medium) was added to growing cells at time points 0, 2, 6, 12 and 24 h. For repeated SAM experiment, 0.5 mM SAM was added to the cells once a day for 7 days and nuclear extract was prepared 0, 2, 6, 12 and 24 h after last treatment. Control measurements were performed with vehicle (RPMI medium) treated cells. Nuclear extract was isolated from cells using EpiQuik Nuclear Extraction kit (Epigentek Group, Brooklyn, USA). Total DNMT activity was determined using an EpiQuik DNMT activity assay kit (Epigentek Group, Brooklyn, USA). DNMT activity (OD/mg/h) was calculated according to the formula:

$$X = \frac{OD(sample) - OD(blank)}{protein\ amount\ (mg)\ \times\ time\ (hour)} \times 1000$$

Two dishes combined as a sample, 4 samples per group were used. Experiments were repeated twice.

7. Gene expression analyses

7.1. Measuring mRNA levels using qPCR (Papers I–III)

Total RNA was extracted from mouse or rat NAc, hippocampus, cerebellum, PFC and from cells using the RNeasy Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturers' protocol. cDNA was synthesised from 400 ng or 750 ng of total RNA using the First Strand cDNA Synthesis Kit (Fermentas Inc, Burlington, Canada). Quantitative PCR (qPCR) was performed using an ABI PRISM 7000 Sequence Detection System equipped with ABI Prism 7000 SDS Software (Applied Biosystems Inc, USA). Primers for mouse or rat *Dnmt1, Dnmt3a, Dnmt3b, A$_{2A}$R, fosB, Reln* were designed using Primer3 with BLAST sequence verification. Primers were synthesised by TAG Copenhagen AS (Copenhagen, Denmark) and were listed in table 1. Commercial assays were from SABiosciences (Qiagen, Hilden, Germany) for measuring mouse *PP1c* (Cat. No. PPM37272B), *Cck* (Cat. No. PPM24836G), *Gal* (Cat. No. PPM25148F), *Slc17a7* (Cat. No. PPM35361A) and rat *PP1c* (Cat. No. PPR42515B) mRNA expression. PCR amplification was performed in a total reaction volume of 25 µl in three parallels. The reaction mixture consisted of 1 µl First Strand cDNA diluted template, 12.5 µl 2x Master SYBR Green qPCR Master Mix (Applied Biosystems Inc, USA), 10.5 µl H$_2$0 and 1 µl gene-specific 10 µM PCR primer pair stock. The PCR amplification was performed as follows: denaturation step at 95 °C for 10 min, followed by denaturation at 95 °C for 15 s, and annealing and extension at 60 °C for 1 min, repeated for 40 cycles. SYBR Green fluorescence was measured after each extension step and amplification specificity was confirmed by melting curve analyses and gel electrophoresis of the PCR products. Serial dilutions (fivefold) of total RNA from one control sample were analysed for each target gene and used to construct linear standard curves from which the concentrations of the test sample and efficiency of the PCR reaction were calculated. Results were normalised to *β-Actin* or *Gapdh* (Glyceraldehyde-3-phosphate dehydrogenase) using the ΔΔCT method (Livak and Schmittgen, 2001; Schmittgen and Livak, 2008).

7.2. Gene expression profiling (Paper II)

Total RNA was extracted from mouse NAc as described in the section 7.1. Tissues from two animals were combined to a sample, 4 samples per group used. RNA quantity and quality were assessed using the NanoDrop-1000 spectrophotometer and the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, USA). Labeled cRNA was prepared using Illumina TotalPrep RNA amplification Kit according to the manufacturers' instructions using 750 ng of total RNA as a template (Ambion Inc, Austin, TX, USA). The Illumina BeadChip platform (Illumina, San Diego, USA) and the corresponding whole-genome Mouse Ref-8 v2.0 BeadChip (approximately 25,698 transcripts; over 19,100 genes) were used for the gene expression analysis. The raw data was analysed with Illumina BeadStudio Gene Expression Module v3.3.7 (Illumina, San Diego, USA). Further data analysis was performed with R version 2.13.0 (http://www.r-project.org)/Bioconductor software (www.bioconductor.com) using lumi (Du et al., 2008) and limma packages (Smyth, 2005). The 'fdr' method to adjust the p values for multiple testing was used to control the false discovery rate (Benjamini and Hochberg, 1995). With a statistical discrimination p value set at less than 0.05, limma software and B-statistics analyses were used to identify up- and downregulated genes and filtered for 1.5-fold or greater differences in expression in accordance with standards for microarray analysis (Allison et al., 2006). Gene ontology analysis was conducted using DAVID Bioinformatics Resources (Huang et al., 2009).

Microarray data have been deposited in the Gene Expression Omnibus (GEO) repository (Edgar et al., 2002) and are accessible through GEO Series accession number GSE48365

(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48365).

8. DNA methylation assays

8.1. Methylated DNA immunoprecipitation (Papers I–III)

Methylated DNA immunoprecipitation (MeDIP) was performed using the EpiQuik Methylated DNA (Paper III) and Tissue Methylated DNA Immuno-precipitation kit (Epigentek Group Inc, USA) according to the manufacturers' protocol. Genomic DNA was extracted from mouse or rat (PND15 and PND120) NAc, cerebellum, PFC, sonicated into fragments ranging from 200–1000 bp in size and divided into immunoprecipitated (IP) and input (IN) portions. IP DNA was incubated with anti-5-methylcytosine monoclonal antibody to bind methylated DNA. Normal mouse IgG from manufacturers of the EpiQuik MeDIP kit was used as a negative control. Methylated DNA (750 ng) was subjected to qPCR using commercial assays from SABiosciences (Qiagen, Hilden, Germany) for mouse *Dnmt3a* (Cat. No. EPMM102350-1A), *Dnmt3b* (Cat. No. EPMM106719-1A)*, PP1c* (Cat. No. EPMM108835-1A),

fosB (Cat. No. EPMM109802-1A)*, Cck* (Cat. No. EPMM111951-1A), *Gal* (Cat. No. EPMM105518-1A), *Slc17a7* (Cat. No. EPMM110039-1A) (Papers I, II) and for rat *Dnmt3a* (Cat. No. EPRN107117-1A), *PP1c* (Cat. No. EPRN102434-1A), $A_{2A}R$ (Cat. No. EPMM100909-1A) and *Reln* (Cat. No. EPRN105980-1A) (Paper III). To evaluate the relative enrichment of target sequences after MeDIP, the ratios of the signals in the IP DNA vs. IN DNA was calculated. The resulting values were standardised against the unmethylated control sequence *Gapdh* and fold changes were calculated.

8.2. Methylation-specific qPCR analysis (Papers I, III)

DNA was isolated from mouse and rat NAc using QIAmp DNA Mini Kit (QIAGEN, Hilden, Germany) and processed for bisulphite modification using Epitect Bisulfite Kit (QIAGEN, Hilden, Germany). qPCR was used to determine the DNA methylation status of mouse and rat *PP1c* gene. Methylation-specific qPCR primers were designed using Methprimer software (www.urogene.org/methprimer). Methylation-specific and unmethylated PCR primers were designed to target putative CpG islands detected *in silico* in the promoter or non-promoter regions of the *PP1c* gene and were synthesised by TAG Copenhagen AS (Copenhagen, Denmark). Primer sequences are listed in table 1. PCR reactions were performed as described in the section 7.1. The comparative Ct method was used to calculate differences in methylation between samples (Livak and Schmittgen, 2001; Schmittgen and Livak, 2008).

8.3. Primer sequences (Papers I–III)

Table 1. The sequences of all primers (from TAG Copenhagen AS) used in this study.

Target gene	Primer sequences	Species
mRNA qPCR primers		
Dnmt1 Forward:	CCCATGCATAGGTTCACTTCCTTC	Mouse
Dnmt1 Reverse:	TGGCTTCGTCGTAACTCTCTACCT	Mouse
Dnmt3a Forward:	GCCGAATTGTGTCTTGGTGGATGACA	Mouse
Dnmt3a Reverse:	CCTGGTGGAATGCACTGCAGAAGGA	Mouse
Dnmt3b Forward:	TTCAGTGACCAGTCCTCAGACACGAA	Mouse
Dnmt3b Reverse:	TCAGAAGGCTGGAGACCTCCCTCTT	Mouse
fosB Forward:	ACAGATCGACTTCAGGCGGA	Mouse
fosB Reverse:	GTTTGTGGGCCACCAGGAC	Mouse
$A_{2A}R$ Forward:	AACCTGCAGAACGTCAC	Mouse
$A_{2A}R$ Reverse:	GTCACCAAGCCATTGTACCG	Mouse
Gapdh Forward:	GTCATATTTCTCGTGGTTCACACC	Mouse
Gapdh Reverse:	CTGAGTATGTCGTGGAGTCTACTGG	Mouse
β-Actin Forward:	ATGGTGGGAATGGGTCAGAAG	Mouse
β-Actin Reverse:	TCTCCATGTCGTCCCAGTTG	Mouse
Dnmt1 Forward:	AACGGAACACTCTCTCTCACTCA	Rat
Dnmt1 Reverse:	TCACTGTCCGACTTGCTCCTC	Rat
Dnmt3a Forward:	CAGCGTCACACAGAAGCATATCC	Rat
Dnmt3a Reverse:	GGTCCTCACTTTGCTGAACTTGG	Rat
Dnmt3b Forward:	GAATTTGAGCAGCCCAGGTTG	Rat
Dnmt3b Reverse:	TGAAGAAGAGCCTTCCTGTGCC	Rat
$A_{2A}R$ Forward:	AGTCAGAAAGACGGGAAC	Rat
$A_{2A}R$ Reverse:	CAGTAACACGAACGCAA	Rat
Reln Forward:	CTGCTGGACTTCTCTACGGAT	Rat
Reln Reverse:	CAGTAGAGGTGGAAGGATGGG	Rat
Gapdh Forward:	TGCCATCACTGCCACTCAGA	Rat
Gapdh Reverse:	GTCAGATCCACAACGGATACATTG	Rat
β-Actin Forward:	GTAACCCGTTGAACCCCATT	Rat
β-Actin Reverse:	CCATCCAATCGGTAGTAGCG	Rat
Methylation-specific qPCR primers		
PP1c methylated Forward:	TTTTATGGGTTCGTAAAGAAGTTTC	Mouse
PP1c methylated Reverse:	ACGAAAAAAACAAAATAACCGC	Mouse
PP1c unmethylated Forward:	TTTATGGGTTTGTAAAGAAGTTTTG	Mouse
PP1c unmethylated Reverse:	ACCACAAAAAAAACAAAATAACCAC	Mouse
PP1c methylated Forward:	TTTTATGGGTTTGTAAAGAAGTTTC	Rat
PP1c methylated Reverse:	CACGAAAAAAACAAAATAACCG	Rat
PP1c unmethylated Forward:	TTTATGGGTTTGTAAAGAAGTTTTG	Rat
PP1c unmethylated Reverse:	ACCACAAAAAAAACAAAATAACCAC	Rat

9. Global DNA methylation analysis (Paper III)

Total DNA was isolated from rat NAc and PFC using the QIAmp DNA Mini Kit (QIAGEN, Hilden, Germany). Global DNA methylation analysis was performed using a MethylFlash Methylated DNA Quantification kit (Epigentek Group Inc., Farmingdale, NY, USA) according to the manufacturers' instructions. Briefly, sample DNA (100 ng) was bound to high-DNA-affinity strip wells. The methylated fraction of DNA was detected using capture and detection antibodies and then quantified colorimetrically by reading the absorbance at 450 nm using a Tecan Sunrise microplate reader (Tecan Group Ltd., Switzerland). The amount of methylated DNA is proportional to the measured OD intensity. The percentage of methylated DNA (5-mC) in total DNA was quantified according to the manufacturers' protocol and formula.

10. Chromatin immunoprecipitation assay (Paper I)

Chromatin immunoprecipitation (ChIP) of genomic DNA associated with MeCP2 was carried out according to the manufacturer protocol (Millipore Inc, USA). Mouse NAc was minced to small pieces and cross-linked in 1% formaldehyde (10 µl/mg) for 15 min at 37 °C. The minced, fixed tissue was homogenized in SDS lysis buffer, sonicated to produce 200–1000 bp genomic fragments, centrifuged for 15 min at 13,000 x g and the supernatant was used for ChIP assay. Immunoprecipitations were carried out at 4 °C overnight with 5 µg of rabbit polyclonal MeCP2 antibody (AbCam, Cambridge, UK), negative control was anti-Rat IgG (Vector Laboratories Inc, Burlingname, USA) and positive control was anti-RNA Polymerase II from manufacturers ChIP kit. A portion of the sonicated DNA was left untreated to serve as input control. Immune complexes were collected with protein A beads and, according to the manufacturers' protocol, sequentially washed two times with low salt buffer, high salt buffer, LiCl immune complex buffer and TE (Tris-EDTA) buffer. Immunoprecipitated DNA was subjected to qPCR using ChIP commercial assays from SABiosciences for mouse *PP1c* (Cat. No. GPM1037458(–)01A) and *fosB* (Cat. No. GPM1052791(–)01A).

11. Western blotting (Papers I, III)

The NAc was lysed in 10 vol (w/vol) of RIP-A lyses buffer: 50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1% Triton X 100 and protease inhibitors, homogenized, incubated 1 h at 4 °C and centrifuged 13,000 x g for 10 min at 4 °C (Papers I, III). The supernatants were resolved by electrophoresis on 8% SDS-polyacrylamide gel. Proteins were transferred onto Hybond™-P PVDF Transfer Membranes (Amersham Biosciences, UK) in 0.1 M Tris-base, 0.192 M glycine and 20% (w/w) methanol using an electrophoretic transfer system. The

membranes were blocked with 0.1% (w/w) Tween 20/TBS (T-TBS) containing 5% (w/w) non-fat dried milk at room temperature for 1 h. After blocking the membranes were incubated overnight with one of the following antibodies: the anti-PP1γ1 polyclonal antibody (1:1000, Millipore, Temecula, CA, USA) followed by incubation with biotinylated anti-rabbit IgM secondary antibody (1:1000) for 2 h and ABC solution for 30 min (Paper I); chicken anti-Dnmt3a (1:1000; ab14291; AbCam, USA) followed by incubation with secondary antibody anti-chicken HRP conjugate (1:2000; Pierce, USA) (Paper III). The membranes were incubated with ECL detection reagent (ECL, Amersham, UK) for 5 min to visualise proteins, and then exposed to autoradiography X-ray film (Amersham hyperfilm ECL, UK). To normalise immunoreactivity of the proteins, β-actin was measured on the same blot using a mouse monoclonal anti-β-actin antibody (1:10000; Sigma, St. Louis, USA) followed by incubating with an anti-mouse HRP-conjugated secondary antibody (1:2000; Pierce, US). The ratio of proteins of interest to β-actin were calculated and expressed as the mean OD ratio in arbitrary units ± SEM.

12. Statistical analysis (Papers I–III)

Behavioural data of all experiments were analysed using one-way or two-way ANOVAs for repeated measures and followed with Bonferroni's post-hoc tests. Expression levels of genes and proteins, MeDIP and global DNA methylation and ChIP data were analysed using one-way or two-way ANOVAs or t-tests. Differences in methylation-specific qPCR and DNMT activity data were analysed using two-way ANOVAs with Bonferroni's post-hoc tests. GraphPad Prism software (GraphPad, San Diego, CA, USA) was used for statistical analyses, and all data are expressed as the mean ± SEM. Significance levels were set to $p < 0.05$.

RESULTS

1. The effect of DNA methylation on cocaine-induced behavioural sensitisation in mice (Paper I)

1.1. Acute and repeated cocaine treatment increases locomotor activity in mice

The effects of acute (AC) and repeated cocaine (RC) treatment were assessed in adult mice. Our data showed that AC treatment significantly increased the locomotor activity of mice (Figure 7; two-way ANOVA repeated measures, treatment $F_{2,35}=18.9$, $p<0.0001$; days effect $F_{1,35}=28.81$, $p<0.0001$; interaction $F_{2,35}=7.43$, $p=0.002$). We also found that after a daily injection of cocaine for 7 days (RC), all mice displayed significantly enhanced locomotion in response to the same dose of cocaine on day 7 compared with day 1 ($p<0.001$), indicating behavioural sensitisation.


Figure 7. Cocaine-induced behavioural sensitisation in mice. Mice were treated daily for 7 days, and ambulation was recorded for 1 h immediately after treatment. Treatment groups: saline (SAL), mice were treated with saline; acute cocaine (AC), mice were treated with saline for 6 days and with cocaine on the 7th day; repeated cocaine (RC), mice were treated daily for 7 days with cocaine. Two-way ANOVA, Bonferroni post-hoc test, **$p<0.01$ AC treatment 1st vs. 7th day, ***$p<0.001$ RC treatment 1st vs. 7th day, n=11. Error bars indicate SEM.

1.2. The effect of cocaine treatment on DNMT expression in the NAc and hippocampus

Earlier studies by Miller and Sweatt (2007) demonstrated that mRNA levels of *Dnmt3a* and *Dnmt3b* were upregulated in the adult rat hippocampus following contextual fear conditioning. In our study, using qPCR, we found that AC administration caused an increase in *Dnmt3a* mRNA levels at both time points (1.5 h and 24 h), and *Dnmt3b* mRNA levels were increased at 24 h after AC

treatment compared with saline control (Figure 8A-C). However, the RC treatment did not change *Dnmt3a* and *Dnmt3b* mRNA levels significantly compared with saline control. There were also no significant changes in *Dnmt1* mRNA levels after AC and RC treatment.

Figure 8. Acute (AC) and repeated (RC) cocaine treatment effects on (**A**) *Dnmt1*, (**B**) *Dnmt3a* and (**C**) *Dnmt3b* mRNA levels in the NAc at 1.5 and 24 h after treatment. One-way ANOVA, Bonferroni post-hoc test, $*p<0.05$, $**p<0.01$, $***p<0.001$ compared with respective saline (SAL) group, n=11. Error bars indicate SEM.

We also assessed AC and RC treatment effects on *Dnmts* mRNA levels in the hippocampus. Our data showed that AC and RC treatment increased *Dnmt3a* mRNA levels at 1.5 h after treatment and *Dnmt3b* mRNA was enhanced only after AC treatment (Figure 9A-C). There were no changes in *Dnmt3a* and *Dnmt3b* mRNA levels at 24 h after cocaine treatment, and neither AC nor RC treatment altered *Dnmt1* mRNA levels in the hippocampus of adult mice.

Figure 9. Acute cocaine (AC) treatment was associated with an upregulation of *Dnmt3a* and *Dnmt3b* mRNA levels in the hippocampus. (**A–C**) Cocaine effects on *Dnmt1*, *Dnmt3a* and *Dnmt3b* mRNA levels in the hippocampus at 1.5 h and 24 h after treatment. One-way ANOVA, Bonferroni post-hoc test, ***$p<0.001$ compared with respective saline (SAL) group, $n=8$. Error bars indicate SEM.

1.3. Cocaine treatment alters the expression of selected genes in the NAc

Upregulation of *Dnmt3a* and *Dnmt3b* may cause hypermethylation of certain gene promoters and consequently downregulate the expression of these genes. Therefore, a search for genes that show reduced expression following cocaine treatment was conducted. Several genes were tested, such as *Bdnf*, *PP1c*, *fosB*, and *adenosine A_{2A} receptor (A_{2A}R)*, that participate in cocaine-induced neuroadaptations in the NAc and *in silico* analysis revealed that CpG islands were located within their promoter regions. Our qPCR data showed that *PP1c* mRNA levels were not altered at 1.5 h after AC and RC treatments (Figure 10A). However, at 24 h after AC and RC treatment, *PP1c* mRNA levels were significantly decreased compared with saline control. To further confirm

PP1c mRNA downregulation in the NAc, Western blotting was performed. We found that PP1C protein levels were also decreased significantly at 24 h after AC and RC treatments compared with saline control (Figure 10B).

As expected, it was found that AC and RC treatment resulted in upregulation of *fosB* mRNA levels at 1.5 h after treatment (Figure 10C) but there were no significant changes at 24 h after treatment. We also found that both AC and RC treatment decreased $A_{2A}R$ mRNA levels at 1.5 h after treatment (Figure 10D). However, we could not find significant changes in *Bdnf* mRNA levels (data not shown). As our aim was to investigate cocaine-induced long-lasting effects, *PP1c* and *fosB* genes were selected for additional DNA methylation studies.

Figure 10. Altered patterns of expression of *PP1c*, *fosB*, and $A_{2A}R$ genes in the NAc after cocaine treatment. (**A**) The effects of acute (**AC**) and repeated cocaine (**RC**) administration on *PP1c* mRNA levels at 1.5 and 24 h after treatment. (**B**) AC and RC treatment resulted in a decrease in PP1C protein levels in the NAc at 24 h after treatment. (**C**) The effects of AC and RC administration on *fosB* and (**D**) on $A_{2A}R$ mRNA levels. One-way ANOVA, Bonferroni post-hoc test, *$p<0.05$, #$p<0.001$ compared with respective saline (SAL) group, $n=11$. Error bars indicate SEM. OD, optical density.

1.4. Cocaine treatment alters DNA methylation in the *PP1c* and *fosB* promoters

To determine the role of DNA methylation on cocaine-induced behavioural sensitisation, cocaine-induced changes in DNA methylation patterns within the *PP1c* promoter region was evaluated. Using a MeDIP assay, we found that both AC and RC treatment resulted in *PP1c* promoter-associated CpG island hypermethylation at 24 h after treatment (Figure 11B). Methylation-specific qPCR (MSP qPCR) data confirmed DNA hypermethylation within the *PP1c* promoter region at 24 h after AC and RC treatments (Figures 11A,C; two-way ANOVA, treatment $F_{2,66}=2.77$, $p=0.0699$; methylation effect $F_{1,66}=31.24$, $p<0.0001$; interaction $F_{2,66}=8.34$, $p=0.0006$).

Figure 11. Cocaine treatment was associated with altered DNA methylation in the *PP1c* promoters in the NAc at 24 h after treatment. (**A**) The position of the *PP1c* promoter-associated CpG island. The target region indicates the locations of methylation-specific qPCR (MSP qPCR) primer pairs. (**B**) Using a methylated DNA immunoprecipitation (MeDIP) assay, we found that acute (AC) and repeated cocaine (RC) treatment elicited DNA hypermethylation associated with the *PP1c* promoter region. One-way ANOVA, Bonferroni post-hoc test, ***$p<0.001$ compared with saline (SAL) group, $n=6$. (**C**) Using MSP qPCR, we found that AC and RC treatment elicited hypermethylation associated with the *PP1c* promoter region. Two-way ANOVA, Bonferroni post-hoc test, *$p<0.05$, ***$p<0.001$ compared with methylated SAL group, $n=11$. Error bars indicate SEM. M, methylated; MeDNA, methylated DNA; U, unmethylated.

Consistent with the upregulated *fosB* mRNA levels, our MeDIP data demonstrated hypomethylation at the *fosB* promoter at 1.5 h after AC and RC treatments (Figures 12A,B).


Figure 12. Cocaine treatment was associated with altered DNA methylation in *fosB* promoters in the NAc at 1.5 h after treatment. (**A**) The position of the *fosB* promoter-associated CpG island. The target region indicates the locations of the qPCR primer pairs. (**B**) Acute (AC) and repeated cocaine (RC) treatments elicited DNA hypo-methylation associated with the *fosB* promoter region, determined using a methylated DNA immunoprecipitation (MeDIP) assay. One-way ANOVA, Bonferroni post-hoc test, ***$p<0.001$ compared with saline (SAL) group, $n=6$. Error bars indicate SEM. MeDNA, methylated DNA

To further confirm that AC and RC administration altered DNA methylation at the promoter regions of the *PP1c* and *fosB* genes, a ChIP assay was performed. Consistent with the MeDIP and MSP qPCR results, ChIP analysis demonstrated that AC and RC cocaine treatments increased the *PP1c* promoter-associated MeCP2 binding by 1.8- to 2-fold in the NAc at 24 h after treatments (Figure 13A). However, in the *fosB* promoter, AC and RC treatments were associated with a significant decrease in MeCP2 binding compared with saline control at 1.5 h after treatment (Figure 13B).

Figure 13. Altered patterns of MeCP2 binding at the *PP1c* and *fosB* promoters in the NAc, determined using a chromatin immunoprecipitation (ChIP) assay. (**A**) Acute (AC) and repeated cocaine (RC) treatments increased MeCP2 binding at the *PP1c* promoter at 24 h after treatment and (**B**) decreased MeCP2 binding at the *fosB* promoter region at 1.5 h after treatment. One-way ANOVA, Bonferroni post-hoc test, *p<0.01, ***p<0.001 relative to SAL group, *n*=6. Error bars indicate SEM.

1.5. The effect of the DNMT inhibitor zebularine on cocaine-induced DNA methylation and the development of behavioural sensitisation in mice

As we found that cocaine treatment increased *Dnmt3a* and *Dnmt3b* mRNA levels and caused *PP1c* promoter-region hypermethylation, the effect of the DNMT inhibitor zebularine was assessed on cocaine-induced molecular changes and the development of behavioural sensitisation. To correlate the molecular changes with cocaine-induced behavioural sensitisation, a dose of zebularine (300 ng per 0.5 µl, i.c.v.) that did not affect basal locomotor activity and that decreased DNA methylation at the *PP1c* promoter region at 1.5 h after acute treatment (Figure 14A) was selected from a pilot study.

For the co-treatment experiment, all mice received an i.c.v. infusion of saline or zebularine followed by i.p. injection of saline or cocaine (15 mg/kg) 20 min later. Locomotor activity was recorded for 60 min immediately after the last i.p. injection. Mice treated with repeated saline and cocaine (S+C) for 7 days displayed significantly enhanced locomotion on day 7 compared with day 1 (Figure 14B; two-way ANOVA with repeated measures, treatment $F_{3,39}$=15.98, *p*<0.0001; days effect $F_{1,39}$=10.26, *p*=0.0027; interaction $F_{3,39}$=5.69, *p*=0.0025). However, mice co-treated with zebularine and cocaine (Z+C) did not show any sensitisation on day 7 compared with day 1 (*p*<0.05). There was also no behavioural sensitisation after repeated zebularine and saline (Z+S) treatments. Thus, our results suggest that the inhibition of DNMTs by zebularine did not affect acute cocaine-induced locomotor activity but instead delayed cocaine-induced behavioural sensitisation in mice.

Figure 14. Inhibition of DNMT by zebularine prevented cocaine-induced behavioural sensitisation. (**A**) Acute zebularine (ZEB) treatment elicited DNA hypomethylation associated with the *PP1c* promoter region in the NAc at 1.5 h after treatment, determined using a methylated DNA immunoprecipitation (MeDIP) assay. T-test, *p=0.034, n=4. (**B**) Mice were treated with cocaine (15.0 mg/kg, i.p.) alone or co-treated with zebularine (300 ng per 0.5 µl, i.c.v.) daily for 7 days, and their ambulation was recorded for 1 h immediately after treatment. Mice were treated with saline (0.5 µl, i.c.v.) + saline (0.1 ml per 10 g body weight, i.p.; S+S); zebularine i.c.v. + saline i.p. (Z+S); saline i.c.v.+ cocaine i.p. (S+C); or zebularine i.c.v. + cocaine i.p. (Z+C). Two-way ANOVA with repeated measures, Bonferroni post-hoc test, ***p<0.001 S+C 1st vs. 7th day, n=7–12. Error bars indicate SEM. MeDNA, methylated DNA.

Finally, we searched for molecular evidence to confirm that zebularine infusions i.c.v. prior to cocaine treatment altered DNA methylation levels at the *PP1c* promoter region in the NAc. Using a MeDIP assay, we found that repeated cocaine treatment (S+C) induced DNA hypermethylation at the *PP1c* promoter region at 24 h after treatment compared with the saline control group (S+S), and repeated zebularine and cocaine (Z+C) co-treatment prevented this effect (Figure 15A; one-way ANOVA, p<0.001 S+S vs. S+C, p<0.001 S+C vs. Z+C, n=6). Similarly, MSP qPCR data demonstrated that there was a significant decrease in DNA methylation associated with the *PP1c* promoter region in the Z+C group compared with the S+C group (Figure 15B; two-way ANOVA, treatment $F_{3,45}$=39.0, p<0.0001, methylation effect $F_{1,45}$=42.8, p<0.0001; interaction $F_{3,45}$=80.8, p<0.0001). There were also significant changes between the zebularine- (Z+S) and the saline- (S+S) treated groups (p<0.05).

Consistent with the *PP1c* promoter-associated CpG-island methylation results, we observed that zebularine attenuated cocaine-induced downregulation of *PP1c* mRNA levels (Figure 15C; one-way ANOVA, p<0.001 S+S vs. S+C, p<0.05 S+C vs. Z+C, n=6). These data indicate that the inhibition of DNMTs by zebularine reverses cocaine-induced *PP1c* gene hypermethylation and mRNA downregulation in the NAc.

Figure 15. The DNMT inhibitor zebularine altered DNA methylation at the *PP1c* promoter region in the NAc at 24 h after treatment. Mice were treated with saline (0.5 µl, i.c.v.) + saline (0.1 ml per 10 g body weight, i.p.; S+S); zebularine i.c.v. + saline i.p. (Z+S); saline i.c.v. + cocaine i.p. (S+C); or zebularine i.c.v. + cocaine i.p. (Z+C). (**A**) Repeated Z+C co-treatment decreased DNA methylation levels associated with the *PP1c* promoter relative to the S+C group. (**B**) Repeated Z+C treatment decreased DNA methylation levels associated with the *PP1c* promoter relative to the S+C group. Two-way ANOVA, Bonferroni post-hoc test, ***$p<0.001$ methylated S+C vs. methylated Z+C, $n=5-7$. (**C**) The blockade of *PP1c* methylation by zebularine was associated with enhanced *PP1c* mRNA levels. One-way ANOVA, Bonferroni post-hoc test *$p<0.05$ S+C vs. Z+C, $n=5-7$. Error bars indicate SEM. M, methylated; MeDNA, methylated DNA; U, unmethylated.

2. The effect of treatment with **SAM** on cocaine-induced DNA methylation and behavioural sensitisation in mice (Paper II)

2.1. SAM pretreatment potentiates the development and expression of cocaine-induced behavioural sensitisation in mice

The effect of SAM (4520 mg/kg/day) on the behavioural sensitisation to cocaine (10 mg/kg/day) in adult mice was evaluated. Our data showed that repeated cocaine treatment (S+C) and repeated SAM and cocaine co-treatment (M+C) for 7 days caused significantly enhanced locomotion on day 7 compared with day 1 (Figure 16A) indicating the development of behavioural sensitisation. There were also significant differences ($p<0.001$) between S+C and M+C groups on day 7. However, we did not find any difference in locomotor activity between SAM (M+S) and saline control (S+S) groups.

In a cocaine (7 mg/kg i.p.) challenge study (on days 14 and 28), S+C and M+C groups demonstrated a robust sensitisation and exhibited more locomotor activity than the S+S group (Figure 16B). Importantly, the M+C group showed greater sensitisation compared with the S+C group. Cocaine challenge also increased locomotor activity in the M+S group compared with the S+S group but these changes were not substantial. These data demonstrated that exogenous SAM pretreatment did not affect the acute cocaine-induced locomotor response but instead potentiated the development and the expression of cocaine-induced behavioural sensitisation in mice.

Figure 16. (**A**) The effect of treatment with S-adenosylmethionine (SAM) on cocaine-induced behavioural sensitisation in mice. Two-way ANOVA repeated measurements, treatment $F_{3,198}=103.47$, $p<0.0001$; days effect $F_{3,198}=47.07$, $p<0.0001$; interaction $F_{9,198}=21.86$, $p<0.0001$; Bonferroni post-hoc test, *$p<0.05$, saline + saline (S+S) vs. S + cocaine (S+C); #$p<0.05$, S+S vs. S-adenosylmethionine + cocaine (M+C); ^$p<0.05$, Saline + S-adenosylmethionine (M+S) vs. S+C; +$p<0.05$, M+S vs. M+C; §$p<0.05$, S+C vs. M+C on the indicated days; $n=17$ (S+S and M+C), $n=18$ (M+S and S+C). (**B**) Cocaine challenge, two-way ANOVA repeated measurements, treatment $F_{3,23}=24.58$, $p<0.0001$; time $F_{1,23}=11.60$, $p=0.0024$; interaction $F_{3,23}=0.36$, $p=0.7831$; $n=8$. Error bars indicate SEM.

2.2. SAM modifies cocaine-induced gene expression

An Illumina microarray was used to study persistent changes in gene expression in the NAc following repeated SAM and cocaine treatment. The samples for gene expression profiling were collected 24 h after the final treatment. Four different treatment groups – S+S, M+S, S+C and M+C (4 samples per group) – were compared, and differentially expressed genes were identified by a combination of statistical significance ($p<0.05$) and fold change (FC; FC>1.5). In total, 482 separate transcripts were expressed differently between the M+S, S+C and M+C groups, representing 1.88 % of the total number of transcripts analysed whereas 98.12 % of the transcripts remained unaltered.

To assess the direction of gene expression changes induced by the treatments, the M+S, S+C and M+C treatment groups were compared with the S+S group. Our data showed that in the M+S group a total of 18 transcripts (36%) were up- and 32 transcripts (64%) were downregulated (see Supplementary Tables S1, S2 in Paper II), representing 0.19 % (n=50) of the total number of transcripts analysed. In the S+C group, 93 transcripts (38.6%) were up- and 148 transcripts (61.4%) were downregulated (see Tables 2, 3 in Paper II), representing 0.94% (n=241) of the total number of transcripts analysed. In the M+C group, 54 transcripts (42.5%) were up- and 73 transcripts (57.5%) downregulated (see Supplementary Tables S3, S4 in Paper II), representing 0.49% (n=127) of the total number of transcripts analysed.

Comparisons between M+S, S+C, and M+C groups were also performed. Our analysis showed that 28 of 32 (87.5%) SAM-responsive transcripts were down- and 9 of 18 (50%) were upregulated in the S+C group (see Supplementary Figures S1A, S2A in Paper II). Comparisons between the M+S and M+C groups demonstrated that 12 of 32 (37.5%) SAM-responsive transcripts were down- and 8 of 18 (44.4%) were upregulated in the M+C group (see Supplementary Figures S1B, S2B in Paper II). Interestingly, we found that 64 transcripts (43.2%) of the 148 cocaine-responsive genes were down- and 50 transcripts (53.8%) of the 93 cocaine-responsive genes were upregulated in the M+C group (see Supplementary Figures S1C, S2C in Paper II). These data suggest that SAM pretreatment reduced 56.8% and 46.2% (of genes down- and upregulated by cocaine, respectively) of cocaine-induced transcripts.

Gene ontology (GO) analysis was performed to group significantly regulated genes into similar biological or molecular functional categories. GO analysis showed an over-representation of downregulated genes in the M+S, S+C and M+C groups encoding proteins involved in: (i) cell cycle, differentiation and proliferation, (ii) developmental processes, and (iii) signal transduction (see Supplementary Table S5 in Paper II). The upregulated genes in all of those groups were primarily aggregated into categories of (i) multicellular organismal processes, (ii) cell cycle, differentiation and proliferation, (iii) signal transduction, (iv) developmental processes and/or ion transport (see Supplementary Table S6 in Paper II). Table S6 shows that genes involved in "cell-cell signaling" and "behaviour" were upregulated only in the S+C group.

2.3. SAM pretreatment alters cocaine-induced CpG-island methylation and transcriptional activity in the NAc

qPCR analysis was performed to validate the subset of gene expression changes observed in the microarray analyses. Genes chosen for qPCR validation were selected based on their potential roles in cocaine-induced neuronal plasticity and on *in silico* analysis that revealed CpG islands located within their promoter regions. From the microarray data conducted on samples from mice treated repeatedly with cocaine, 3 genes were selected for validation: a) the down-regulated genes *solute carrier family 17 member 7* or *vesicular glutamate transporter 1* (*Slc17a7*) and *cholecystokinin* (*Cck*); b) the upregulated gene *galanin* (*Gal*).

Using the same RNA samples as used for gene expression profiling, transcriptional analysis of *Slc17a7* and *Cck* revealed a significant decrease in mRNA levels in the NAc following repeated M+S, S+C or M+C treatments. There were significant differences ($p<0.001$) in both genes between the S+C and the M+C groups. Using mouse cerebellum as a reference brain region, we found that the selected genes mRNA were altered in the cerebellum also but these changes were not as marked as in the NAc. *Slc17a7* and *Cck* mRNA level comparisons between both brain tissues demonstrated that *Slc17a7* mRNA was significantly different ($p<0.001$) within the S+C group between the NAc and cerebellum and that *Cck* mRNA levels were also different within the S+C and M+C groups between the NAc and cerebellum (Figures 17A,B).

Gal mRNA data from the NAc showed that repeated M+S, S+C and M+C treatments increased ($p<0.001$) *Gal* expression significantly compared with the S+S group. Furthermore, *Gal* mRNA was significantly different ($p<0.001$) between the S+C and M+C groups. In the cerebellum, we found that M+S and S+C treatments ($p<0.001$) upregulated *Gal* expression significantly compared with the saline control group. There were also statistical differences ($p<0.001$) between S+C and M+C groups. *Gal* mRNA level comparisons between both brain regions demonstrated that there were significant differences ($p<0.001$) within the S+C and M+C groups between the NAc and cerebellum (Figure 17C).

Figure 17. The effect of repeated S-adenosylmethionine (SAM) and cocaine administration on selected gene mRNA levels in the mouse NAc ($n=8$) or cerebellum ($n=6$). (**A**) *Slc17a7* mRNA, two-way ANOVA, treatment $F_{3,44}=27.80$, $p<0.0001$; tissue effect $F_{1,44}=8.44$, $p=0.0057$; interaction $F_{3,44}=7.51$, $p=0.0004$; Bonferroni post-hoc test, ***$p<0.001$ Saline + Cocaine (S+C) NAc vs. S+C cerebellum; (**B**) *Cck* mRNA, treatment $F_{3,44}=27.67$, $p<0.0001$; tissue effect $F_{1,44}=36.35$, $p<0.0001$; interaction $F_{3,44}=7.66$, $p=0.0003$; Bonferroni post-hoc test, ***$p<0.001$ S+C and S-adenosyl-methionine + Cocaine (M+C) NAc vs. S+C and M+C cerebellum; and (**C**) *Gal* mRNA, treatment $F_{3,44}=2045.35$, $p<0.0001$; tissue effect $F_{1,44}=1269.06$, $p<0.0001$; interaction $F_{3,44}=885.82$, $p<0.0001$; Bonferroni post-hoc test, ***$p<0.001$ S+C and M+C NAc vs. S+C and M+C cerebellum. Error bars indicate SEM.

Using a MeDIP assay, *Slc17a7, Cck,* and *Gal* promoter-associated CpG-island methylation analysis was performed in the NAc tissue. For the *Slc17a7* promoter, MeDIP analysis revealed that both M+S and S+C treatment resulted in promoter hypermethylation compared with the S+S group (Figure 18A). We also found that repeated SAM pretreatment decreased *Slc17a7* promoter hypermethylation significantly ($p<0.001$) compared with the S+C group. With regard to *Cck* promoter methylation, M+S and S+C treatments resulted in promoter hypermethylation (Figure 18B). However, there was an additive increase in *Cck* promoter methylation levels in the M+C group compared with the S+C group ($p<0.001$). *Gal* MeDIP analysis demonstrated that M+S and S+C treatments induced promoter-associated CpG-island hypomethylation (Figure 18C). Remarkably, we found that repeated M+C treatment essentially reversed *Gal* promoter hypomethylation compared with the S+C treatment ($p<0.001$).

Figure 18. The effect of repeated S-adenosylmethionine (SAM) and cocaine treatment on selected gene promoter methylation levels in the mouse NAc. (**A**) *Slc17a7* promoter methylation, one-way ANOVA, $F_{3,28}=1583$, $p<0.0001$; Bonferroni post-hoc test; $^\$p<0.05$, Saline + Saline (S+S) vs. Saline + S-adenosylmethionine (M+S); $*p<0.05$, S+S vs. Saline + Cocaine (S+C); $^\#p<0.05$, S+S vs. S-adenosylmetionine + Cocaine (M+C); $^\wedge p<0.05$, M+S vs. S+C; $^+p<0.05$, M+S vs. M+C; $^\$p<0.05$, S+C vs. M+C, $n=8$; (**B**) *Cck* promoter methylation, $F_{3,28}=2587$, $p<0.0001$; Bonferroni post-hoc test; $^\$p<0.05$, S+S vs. M+S; $*p<0.05$, S+S vs. S+C; $^\#p<0.05$, S+S vs. M+C; $^\wedge p<0.05$, M+S vs. S+C; $^+p<0.05$, M+S vs. M+C; $^\$p<0.05$, S+C vs. M+C, $n=8$; and (**C**) *Gal* promoter methylation, $F_{3,28}=39.58$, $p<0.0001$; Bonferroni post-hoc test, $^\$p<0.05$, S+S vs. M+S; $*p<0.05$, S+S vs. S+C; $^\wedge p<0.05$, M+S vs. S+C; $^\$p<0.05$, S+C vs. M+C, $n=8$. Error bars indicate SEM. MeDNA, methylated DNA.

MeDIP data from the mouse cerebellum showed that repeated M+S and S+C treatments enhanced ($p<0.001$, *Slc17a7, Cck*) promoter-associated CpG island methylation significantly (see Supplementary Figures S3A,B in Paper II). Moreover, comparisons of *Slc17a7* and *Cck* promoter methylation from both brain tissues demonstrated that there were significant differences ($p<0.001$) within the S+C and M+C groups between the NAc and cerebellum. A comparison of *Gal* MeDIP data between both brain regions showed that there were significant changes ($p<0.001$) only within the S+C groups between the NAc and cerebellum (see Supplementary Figure S3C in Paper II).

58

2.4. The effect of SAM treatment on methyltransferase activity and DNMT-expression in PC12 cells

To evaluate the underlying mechanism of the SAM modifying effect at the gene and genome level, we studied the effects of a single and repeated doses (7 days) of 0.5 mM SAM on DNMT activity in PC12 cells. Time-course analyses showed that SAM altered methyltransferase activity in a biphasic manner: a single SAM treatment (SST) enhanced and a repeated SAM treatment (RST) decreased DNMT activity compared with vehicle controls (Figures 19A,B). To link methyltransferase activity with *Dnmt3a* and *Dnmt3b* mRNA levels, we measured the SAM-altered DNMT activity on 1st, 3rd, 5th and 7th treatment days. On the 1st day, DNMT activity was similar to vehicle control, on the 3rd day its activity was reduced by approximately 50%, on the 5th by 65% and on the 7th day by 82% compared with controls (Figure 19C).

Figure 19. S-adenosylmethionine (SAM) altered DNMT activity in PC12 cells in a biphasic manner: (**A**) a single SAM treatment (SST) enhanced [(two-way ANOVA, treatment $F_{1,30}=15.64$, $p=0.0004$; time $F_{4,30}=6.77$, $p=0.0005$; interaction $F_{4,30}=4.91$, $p=0.0037$; Bonferroni post-hoc test, $^\$p<0.001$ SST SAM 2 h vs. SST control 2 h; $n=4$) whereas (**B**) repeated SAM treatments (RST) decreased DNMT activity compared with controls (two-way ANOVA, treatment $F_{1,30}=206.74$, $p<0.0001$; time $F_{4,30}=0.18$, $p=0.9461$; interaction $F_{4,30}=0.13$, $p=0.9717$; $n=4$)]. (**C**) The effect of RST SAM treatment on DNMT activity in cells, two-way ANOVA, treatment $F_{1,12}=141.58$, $p<0.0001$; time $F_{3,12}=5.65$, $p=0.0447$; interaction $F_{3,12}=6.22$, $p=0.0086$; Bonferroni post-hoc test, $^{\$\$}p<0.001$ RST SAM vs. RST control on the indicated days; $n=4$. Error bars indicate SEM. OD, optical density.

We found that the decrease in DNMT activity in PC12 cells after repeated SAM treatment correlated with downregulation of *Dnmt3a* mRNA (Figure 20A) but not marked with *Dnmt3b* mRNA levels (Figure 20B). *In silico* analysis of *Dnmt3a* revealed that CpG islands located within the promoter region; thus, we assessed *Dnmt3a* promoter methylation following repeated SAM treatments. The MeDIP results showed that repeated SAM treatment resulted in a significant increase in methylation of the *Dnmt3a* promoter (Figure 20C), thereby decreasing *Dnmt3a* gene transcription in PC12 cells.

Figure 20. (**A**) Repeated S-adenosylmethione (RST SAM) treatments downregulated *Dnmt3a* mRNA levels compared with control groups; two-way ANOVA, treatment $F_{1,18}=47.49$, $p<0.0001$; time $F_{2,18}=1.15$, $p=0.3391$; interaction $F_{2,18}=1.15$, $p=0.3391$; $n=4$. (**B**) The effect of RST SAM treatments on *Dnmt3b* expression; in each group, $n=4$. (**C**) RST SAM treatment significantly hypermethylated the *Dnmt3a* promoter region in PC12 cells. T-test, ***$p=0.0003$, $n=4$. Error bars indicate SEM. MeDNA, methylated DNA.

2.5. SAM treatment hypermethylates the *Dnmt3a* promoter and downregulates mRNA levels in the NAc

To bridge the data from PC12 cell and mice, we assessed *Dnmt3a* and *Dnmt3b* promoter methylation patterns and transcriptional activity in the NAc. Using MeDIP, we discovered that M+S and M+C treatment increased *Dnmt3a* promoter methylation (Figure 21A) but there was no significant change in the *Dnmt3b* promoter (Figure 21B). Using qPCR, our data demonstrated that

Dnmt3a mRNA was significantly decreased following M+S and M+C treatments and increased following S+C treatment compared with the saline-treated group (Figure 21C). There were significant ($p<0.001$) differences in both *Dnmt3a* and *Dnmt3b* mRNA levels in the NAc after the S+C and M+C treatments (Figures 21C,D). These data indicate that repeated SAM treatments may decrease methyltransferase activity *in vitro* and that repeated SAM treatments are associated with hypermethylation of the *Dnmt3a* promoter region both *in vitro* and *in vivo*.

Figure 21. Repeated S-adenosylmethionine (SAM) and cocaine treatment altered DNA methylation (**A**) at the *Dnmt3a* promoter; one-way ANOVA, $F_{3,28}=80.83$, $p<0.0001$; Bonferroni post-hoc test, $^{\$}p<0.05$, Saline + Saline (S+S) vs. Saline + S-adeno-sylmethionine (M+S); $^{\#}p<0.05$, S+S vs. S-adenosylmethionine + Cocaine (M+C); $^{\wedge}p<0.05$, M+S vs. Saline + Cocaine (S+C); $^{+}p<0.05$, M+S vs. M+C; $^{\S}p<0.05$, S+C vs. M+C; $n=8$; and at the (**B**) *Dnmt3b* promoter in the NAc, $F_{3,28}=13.04$, $p<0.0001$; Bonferroni post-hoc test, $^{*}p<0.05$, S+S vs. S+C; $^{\wedge}p<0.05$, M+S vs. S+C; $^{+}p<0.05$, M+S vs. M+C; $n=8$. The effect of SAM and cocaine treatment on (**C**) *Dnmt3a* mRNA levels; one-way ANOVA, $F_{3,28}=40.83$, $p<0.0001$; Bonferroni post-hoc test, $^{\$}p<0.05$, S+S vs. M+S; $^{*}p<0.05$, S+S vs. S+C; $^{\#}p<0.05$, S+S vs. M+C; $^{\wedge}p<0.05$, M+S vs. S+C; $^{+}p<0.05$, M+S vs. M+C; $^{\S}p<0.05$, S+C vs. M+C; $n=8$; and (**D**) on *Dnmt3b* mRNA level, $F_{3,28}=35.27$, $p<0.0001$; Bonferroni post-hoc test, $^{*}p<0.05$, S+S vs. S+C; $^{\#}p<0.05$, S+S vs. M+C; $^{\wedge}p<0.05$, M+S vs. S+C; $^{+}p<0.05$, M+S vs. M+C; $^{\S}p<0.05$, S+C vs. M+C; $n=8$. Error bars indicate SEM. MeDNA, methylated DNA.

3. The role of MS on DNA methylation and behavioural changes in rats (Paper III)

3.1. The effect of MS on exploratory behaviour and cocaine-induced behaviour

Previous studies have demonstrated that MS alters exploratory behaviour in a novel environment (Kaneko et al., 1994; Marmendal et al., 2006). To validate our model of MS, we first used the exploratory box test to measure novelty-related behaviour in adult rats. The exploratory box test data demonstrated that MS for 180 min per day increased line crossing and the sum of exploratory activity in adult rats compared with rats from the AFR group (Figure 22). No differences were found between the MS15 and MS180 groups. Based on these data, we considered our MS model to be behaviourally valid.

Figure 22. The effect of maternal separation (MS) on exploratory behaviour in adult rats. One-way ANOVA followed by Bonferroni post-hoc tests, *$p < 0.05$ animal-facility reared (AFR) group vs. MS180 group, $n=8$. Error bars indicate SEM.

An acute cocaine (10 mg/kg, i.p.) treatment study was performed at PND120–140. Figure 23A shows that acute cocaine treatment increased locomotor activity considerably in both MS groups compared with the control group (two-way ANOVA repeated measures, MS effect $F_{2,64}=2.47$, $p=0.08$; days effect $F_{2,64}=48.87$, $p<0.0001$; interaction $F_{4,64}=4.40$, $p=0.0033$). There were also significant differences ($p<0.05$) between the MS15 and MS180 groups.

After a daily injection of cocaine over 5 consecutive days (repeated cocaine treatment), both MS15 and MS180 rats developed behavioural sensitisation; however, there were no significant differences between groups (Figure 23B; two-way ANOVA repeated measures, MS effect $F_{2,66}=2.23$, $p=0.124$; days effect $F_{2,66}=7.93$, $p=0.008$; interaction $F_{4,66}=0.17$, $p=0.953$). These data indicate that MS for 180 min increased the response to acute cocaine treatment and that MS enhanced the development of behavioural sensitisation in general when compared with AFR adult rats.

Figure 23. (**A**) Maternal separation (MS) was associated with an increased response to acute cocaine treatment. Two-way ANOVA repeated measures, Bonferroni post-hoc test, **$p<0.01$ animal-facility reared (AFR) group vs. MS15 or MS180 groups; #$p<0.05$ MS15 vs. MS180, $n=13$. (**B**) The effects of repeated cocaine treatments on the development of behavioural sensitisation. Two-way ANOVA repeated measures, Bonferroni post-hoc test, **$p<0.01$ MS15 1st day vs. MS15 5th day; *$p<0.05$ MS180 1st day vs. MS180 5th day, $n=13$. Error bars indicate SEM.

3.2. MS-induced DNMT upregulation is maintained into adulthood

To evaluate the role of DNA methylation on MS-induced changes in gene expression, we initially assessed the effect of MS on *Dnmt1, Dnmt3a* and *Dnmt3b* mRNA levels in the NAc of infant (PND15) rats. Using qPCR, we found that MS for 15 min per day during the first two weeks of life increased *Dnmt3b* mRNA levels significantly and that MS for 180 min enhanced expression levels of all DNMTs in the NAc of PND15 rats (see Supplementary Figures S1A-C in Paper III).

Next, expression levels of DNMTs in the NAc of adult rats (PND120) were assessed. We found that DNMTs were significantly upregulated both in the MS15 and MS180 groups compared with AFR animals (Figures 24A-C). We also found that *Dnmt3a* and *Dnmt3b* mRNA levels were significantly different ($p<0.001$) between the MS15 and MS180 groups. To confirm our *Dnmt3a* mRNA results, Western blotting was performed. We found that NAc DNMT3A protein levels were increased in MS15 and MS180 adult rats compared with the AFR group (Figure 24D) and that there was a significant difference ($p<0.01$) between the MS15 and MS180 groups. These findings indicate that early-life stress (MS180) during the first two weeks of life increased *Dnmts* mRNA levels significantly compared with MS15 and AFR groups and that these changes persist into adulthood.

Figure 24. The effect of maternal separation (MS) on the levels of (**A**) *Dnmt1,* (**B**) *Dnmt3a* and (**C**) *Dnmt3b* mRNA in the NAc of adult rats. One-way ANOVA, Bonferroni post-hoc test, ***$p<0.001$ compared with the animal-facility reared (AFR) group; #$p<0.001$ MS15 vs. MS180, n=6. (**D**) The effect of MS on the protein levels of DNMT3A in the NAc of adult rats. One-way ANOVA, Bonferroni post-hoc test, ***$p<0.001$ compared with the AFR group; #$p<0.01$ MS15 vs. MS180, n=6. Error bars indicate SEM. OD, optical density.

3.3. The effect of MS on global DNA methylation levels in the NAc and PFC

For this part of the study, we assessed whether MS could alter global DNA methylation levels in the NAc and in the PFC of adult rats. Global methylation analysis (methylated DNA as a percentage of total DNA) showed that DNA methylation was significantly decreased in the NAc of MS180 animals (Figure 25A). We also found that DNA methylation was decreased in the PFC of MS15 and MS180 animals but that these changes were not statistically significant (Figure 25B). These data suggest that MS may alter global DNA methylation levels in the NAc of adult rats.

64

Figure 25. (**A**) The levels of global DNA methylation, shown as percentage methylated DNA (5-mC) of total DNA, in the NAc and (**B**) in the PFC of adult rats. One-way ANOVA, Bonferroni post-hoc test, *$p<0.05$ animal-facility reared (AFR) group vs. MS180 group, $n=7$.

3.4. MS is associated with hypermethylation in the *PP1c* and *A$_{2A}$R* promoter regions in the NAc

To investigate the role of MS at a gene level, *PP1c* and *A$_{2A}$R* genes were chosen based on both their possible participation in cocaine-induced neuroplasticity mechanisms and on data from *in silico* analysis that revealed CpG islands within their promoter regions. We also examined the expression and promoter-region methylation levels of *Reelin (Reln)*, which is not associated with cocaine-induced neuronal plasticity although its promoter is epigenetically regulated. Using a MeDIP assay, we measured *PP1c* promoter-region methy-lation of PND15 rats. We found that MS15 and MS180 upregulated *PP1c* promoter-region methylation levels significantly (see Supplementary Figure S2A in Paper III). To validate the MeDIP results, we used a methylation-specific qPCR analysis (MSP qPCR). This analysis revealed that methylation of the *PP1c* promoter region was increased in both separated-animal groups at PND15 (see Supplementary Figure S2B in Paper III; two-way ANOVA repeated measures, treatment $F_{2,30}=6.64$, $p=0.0041$; methylation effect $F_{1,30}=96.78$, $p<0.0001$; interaction $F_{2,30}=26.11$, $p<0.0001$). The data from DNA methylation analysis correlated with qPCR results because we found that *PP1c* mRNA levels were decreased in the MS180 group compared with control animals (see Supplementary Figure S2C in Paper III).

To determine whether MS-induced *PP1c* gene promoter-region hypermethy-lation and transcriptional downregulation is persistent, we examined *PP1c* promoter methylation and transcriptional activity at PND120. Data generated using MeDIP and MSP qPCR assays demonstrated that both MS15 and MS180 elicited DNA hypermethylation at the promoter region of *PP1c* (Figure 26A MeDIP; and Figure 26B; MSP qPCR assay, two-way ANOVA repeated

measures, treatment $F_{2,26}=15.37$, $p<0.0001$; methylation effect $F_{1,26}=94.92$, $p<0.0001$; interaction $F_{2,26}=36.90$, $p<0.0001$). In correlation with this $PP1c$ promoter-region hypermethylation, we found that $PP1c$ mRNA was significantly decreased in the NAc of separated rats (Figure 26C).

Figure 26. (**A**) A methylated DNA immunoprecipitation (MeDIP) assay showed that maternal separation (MS) elicited DNA hypermethylation of the $PP1c$ promoter region; one-way ANOVA, Bonferroni post-hoc test, ***$p<0.001$ compared with the animal-facility reared (AFR) group; [#]$p<0.001$ MS15 vs. MS180, $n=6$. (**B**) Methylation-specific qPCR showed that MS elicited hypermethylation of the $PP1c$ promoter region. Two-way ANOVA, Bonferroni post-hoc test, *$p<0.05$, ***$p<0.001$ compared with methylated or unmethylated DNA of the AFR group, $n=6$. (**C**) The effect of MS on $PP1c$ mRNA levels, quantified using qPCR. One-way ANOVA, Bonferroni post-hoc test, ***$p<0.001$ compared with the AFR group, $n=6$. Error bars indicate SEM. M, methylated; MeDNA, methylated DNA; U, unmethylated.

The second gene of interest was $A_{2A}R$. We observed that methylation of $A_{2A}R$ at PND15 was enhanced in the NAc of separated animals (see Supplementary Figure S3A in Paper III). Quantification of $A_{2A}R$ mRNA by qPCR demonstrated that hypermethylation of the $A_{2A}R$ promoter was associated with reduced mRNA

levels in MS groups but these data did not achieve statistical significance (see Supplementary Figure S3B in Paper III).

To assess whether MS-induced $A_{2A}R$ hypermethylation was persistent, we evaluated promoter methylation and mRNA at PND120. MeDIP results showed that changes in DNA methylation at the $A_{2A}R$ promoter is maintained into adulthood (Figure 27A). Furthermore, we found that $A_{2A}R$ hypermethylation was statistically different ($p<0.001$) between MS15 and MS180 animals. We also found that hypermethylation of the $A_{2A}R$ promoter lead to reduced mRNA in the MS180 group (Figure 27B). There were also significant differences ($p<0.05$) between the MS15 and MS180 groups. Thus, these data suggest that MS during the first two weeks of life results in persistent $PP1c$ and $A_{2A}R$ promoter-region hypermethylation and transcriptional downregulation in the NAc. However, neither handling nor MS affected $Reln$ promoter-region methylation or mRNA in the NAc (data not shown).

Figure 27. Maternal separation (MS) was associated with $A_{2A}R$ promoter methylation and transcriptional downregulation in the NAc of adult rats. (**A**) A methylated DNA immunoprecipitation (MeDIP) assay showed that MS elicited DNA hypermethylation of the $A_{2A}R$ promoter region. One-way ANOVA, Bonferroni post-hoc test, ***$p<0.001$ animal-facility reared (AFR) group vs. MS15 or MS180 groups; #$p<0.001$ MS15 vs. MS180, $n=6$. (**B**) The effect of MS on mRNA levels of the $A_{2A}R$ gene. One-way ANOVA, Bonferroni post-hoc test, ***$p<0.001$ AFR vs. MS180, #$p<0.05$ MS15 vs. MS180, $n=6$. Error bars indicate SEM. MeDNA, methylated DNA.

To determine whether the $PP1c$ and $A_{2A}R$ promoter-region hypermethylation and transcriptional downregulation is NAc-specific, the PFC of adult rats was studied. Our data showed that neither handling nor MS affected $PP1c$ or $A_{2A}R$ mRNA or promoter methylation levels in the PFC (see Supplementary Figures S4A,B; S5A,B in Paper III). There were also no changes in $Reln$ mRNA or promoter-methylation levels in the PFC of MS15 and MS180 animals (Fig. S4C; S5C). These data indicate that $PP1c$ and $A_{2A}R$ mRNA and promoter methylation changes after MS are NAc-specific.

DISCUSSION

1. The role of DNA methylation on cocaine-induced behavioural sensitisation in mice (Paper I)

In study I, our aim was to investigate the role of cocaine treatment on the expression of DNMTs and selected genes (*PP1c, fosB*) in the NAc of adult mice; and to assess the effect of a DNMT inhibitor on cocaine-induced gene expression changes and the development of behavioural sensitisation in mice.

1.1. The role of DNMT on cocaine-induced behavioural sensitisation

Previous findings have implied that the function of DNMTs in the central nervous system (CNS) may include DNA repair and neurodegeneration (Brooks et al., 1996; Endres et al., 2000 and 2001; Fan et al., 2001) and that the mis-regulation of DNA methylation and DNMTs may be involved in cognitive disorders such as schizophrenia, Rett syndrome, and Fragile X mental retardation (Sutcliffe et al., 1992; Amir et al., 1999; Veldic et al., 2004).

Studies by Miller and Sweatt (2007) have demonstrated that DNA methylation levels were rapidly and dynamically regulated in the hippocampus following the associative training paradigm of contextual fear conditioning. They found that *Dnmt3a* and *Dnmt3b* mRNA levels were upregulated in the CA1 area of the hippocampus following fear conditioning (Miller and Sweatt, 2007). Our data showed that acute cocaine treatment upregulated *Dnmt3a* and *Dnmt3b* mRNA levels in the NAc and hippocampus (Figures 8B,C and 9B,C; respectively). In addition, we found that *Dnmt3a* expression achieved the highest level after acute cocaine treatment and that it diminished after repeated cocaine exposure. With respect to *Dnmt3a* and *Dnmt3b* expression levels in the NAc, cocaine-induced changes in the hippocampus were more dynamic as there were no significant changes at 24 h after treatment. However, neither acute nor repeated cocaine treatment altered *Dnmt1* mRNA levels in the NAc or hippocampus; thus, we hypothesize that cocaine induces *de novo* DNA methylation.

Currently, the signal transduction processes that control cocaine-induced DNMTs expression in the adult CNS are unknown. Although DNA methylation form part of the regulation of gene expression, it infers that there may be some overlap in intracellular signaling pathways with other chromatin modification mechanisms. In the adult CNS chromatin modification is governed by various intracellular signaling pathways, including the Ras-mitogen-activated protein kinase (MAPK/ERK) cascade (Renthal and Nestler, 2008; Brami-Cherrier et al., 2009). It has been found that targeting the Ras signaling pathway with drugs, such as methotrexate and inhibitors of MAPK/ERK, decreases DNA methylation in malignant hematological diseases and colon cancer cells, indicating a causal relationship between Ras signaling and DNA methylation

(MacLeod et al., 1995; Philips, 2004; Diaz-Flores and Shannon, 2007; Lu et al., 2007; Morgan et al., 2007).

In recent years, the MAPK/ERK signaling cascade has been implicated in responses to most drugs of abuse (Berke and Hyman, 2000; Nestler, 2001; Fasano and Brambilla, 2002; Girault et al., 2007). It has been found that in response to cocaine, MAPK/ERK and the downstream MSK1 controls an early phase of histone H3 phosphorylation at the *c-fos* promoter in striatal neurons (Brami-Cherrier et al., 2005). MSK1 action may be potentiated by the concomitant inhibition of PP1 by nuclear translocation of the dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32; Stipanovich et al., 2008; Brami-Cherrier et al., 2009). Cocaine also phosphorylates the transcription factor CREB via the MAPK/ERK–MSK1 cascade (Swank and Sweatt, 2001; Levine et al., 2005). As discussed above, phosphorylation and activation of CREB recruits CBP, which regulates chromatin structure as part of CREB-dependent activation of nuclear gene transcription (Sweatt, 2009). Therefore, we speculate that cocaine-induced activation of the Ras signaling pathway may trigger both DNA methylation and histone modifications.

1.2. DNA methylation regulates *PP1c* and *fosB* transcription in the NAc after acute and repeated cocaine treatment

As we found that cocaine treatment significantly upregulated *Dnmt3a* and *Dnmt3b* expression in the NAc and thereby may induce hypermethylation of certain genes promoters, we evaluated *PP1c* and *fosB* promoter-region methylation and mRNA levels in the NAc of mice. Our data demonstrated that DNMT activation results in hypermethylation of the *PP1c* promoter region after acute and repeated cocaine treatment (Figures 11B,C), increased MeCP2 binding in the *PP1c* promoter region (Figure 13A) and decreased *PP1c* expression at both the mRNA and protein level (Figures 10A,B). It has been shown that methylation of DNA brings about a general deacetylation of histones H3 and H4, prevents methylation at histone H3 lysine K4 and induces methylation of histone H3 lysine K9 (Kouzarides, 2007; Li et al., 2007; Shahbazian and Grunstein, 2007; Patra and Szyf, 2008). Based on these data, we speculate that MeCP2 can recruit co-repressor complexes to methylated *PP1c* promoter regions including histone-modifying enzymes, such as HDACs and HMTs. Repression of *PP1c* may result in several effects at the intracellular signal transduction level. For example, inhibition of *PP1* has been shown to increase phosphorylation of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunit GluR1 and Ca2+/calmodulin-dependent protein kinase II (Genoux et al., 2002). Reduced PP1 may have important effects for transcriptional regulation by CREB via the ability of PP1 to complex with HDAC. Canettieri and colleagues (2003) have demonstrated that a HDAC1-PP1 complex represses CREB activation under basal conditions and dephosphorylates CREB to return the system to baseline following stimulation (Canettieri et

al., 2003). These data suggest that repression of PP1 is crucial for providing phosphorylated CREB with the capacity to recruit CBP to the promoter, at which time histones are acetylated and help drive the transcription of particular genes. Thus, repression of the *PP1c* gene via methylation of its promoter regions should allow aberrant phosphorylation of crucial receptors, protein kinases and transcription factors during cocaine-induced neuroadaptation.

Previous studies have demonstrated that the expression of Fos-family proteins (c-fos, fosB, fra-1, and fra2) is induced rapidly in the NAc after acute exposure to drugs of abuse (Hope et al, 1994). This induction is transient, lasting only 4-12 h after drug exposure. In our study, we found that cocaine treatment hypomethylated the *fosB* promoter (Figure 12B), decreased MeCP2 binding in the *fosB* promoter region (Figure 13B) and increased *fosB* mRNA levels (Figure 10C). These data suggest that cocaine may also induce DNA demethylation, thereby increasing the transcription of particular genes. However, in contrast with the large amount of information that has accumulated on DNA methylation, DNA demethylation remains quite controversial and a largely unresolved area of research, and there is no consensus on DNA demethylases in mammalian cells although several potential canditates have been proposed (Métivier et al., 2008; Ooi and Bestor, 2008).

I.3. DNMT inhibition by zebularine delays the development of cocaine-induced behavioural sensitisation

The effect of the DNMT inhibitor zebularine on cocaine-induced molecular changes and the development of behavioural sensitisation were assessed. Our data showed that zebularine blocked hypermethylation in the *PP1c* promoter region and delayed the development of cocaine-induced behavioural sensitisation. The decrease in *PP1c* hypermethylation was triggered using an i.c.v. infusion of zebularine and it was sufficient to re-establish *PP1c* gene expression in the NAc. It has been found that zebularine is a potent inhibitor that affects all DNMT subtypes (Weisenberger et al., 2004; Marquez et al., 2005). However, we were unable to determine the DNMT subtype important for the development of behavioural sensitisation. It is possible that both DNMT3A and DNMT3B work together to hypermethylate the promoter-associated CpG islands and to then transcriptionally repress these genes, aiding in the development of behavioural sensitisation.

In Figure 14A we show that a single dose of zebularine caused hypomethylation in the promoter of *PP1c* at 1.5 h after treatment. However, the effect of repeated zebularine (Z+S) administrations resulted in *PP1c* promoter-region hypermethylation at 24 h after the last treatment (Figures 15A,B). Based on zebularine pharmacokinetics, the plasma zebularine concentration in mice declines with a terminal half-life ($t_{1/2}$) of 40 min after an intravenous (i.v.) injection of 100 mg/kg (Holleran et al., 2005). We speculate that at 24 h after the last administration of zebularine (Z+S), the DNMT inhibitory effect has

ended. Therefore, it is possible that the slight increase in methylation in the *PP1c* promoter-associated CpG islands in the Z+S groups (Figures 15A,B) is due to a compensatory increase in DNMT activity after zebularine inhibition. Despite this slight hypermethylation in the *PP1c* promoter region after Z+S treatment*,* we found that *PP1c* mRNA levels were increased approximately 1.5-fold in the Z+S group compared with the saline control (S+S, Figure 15C) suggesting that smaller changes in DNA methylation may not alter gene transcription. Repeated Z+C co-treatment data demonstrated that zebularine treatment blocked *PP1c* promoter-region hypermethylation (Figures 15A,B), which was associated with an enhanced *PP1c* mRNA level (Figure 15C). We speculate that in addition to *PP1c*, zebularine may also inhibit hypermethylation in promoter-associated CpG islands of other genes, re-establish the transcription of these genes and therefore inhibit cocaine-induced neuroplasticity in the brain.

At the behavioural level, we found that repeated Z+C co-treatment delayed the development of behavioural sensitisation although zebularine (Z+S) itself did not affect locomotor activity. Interestingly, zebularine did not modify the acute cocaine effect, suggesting that the promoter-region hypermethylation may be an important underlying mechanism of the altered gene expression during the development of behavioural sensitisation. Therefore, we hypothesize that zebularine, via normalization of gene transcription at the cellular level, stabilized neuronal network function and therefore delayed the development of psychostimulant-induced behavioural sensitisation. As DNA methylation plays an important role in learning and memory formation (Miller and Sweatt, 2007), zebularine may also delay cocaine-induced behavioural sensitisation by inhibiting DNA methylation in the hippocampus and altering cocaine-environment associated learning and memory formation.

2. The role of SAM in cocaine-induced DNA methylation and behavioural sensitisation in mice (Paper II)

In this study, we assessed the role of the methyl donor SAM on cocaine-induced gene expression changes and the development of behavioural sensitisation in mice.

2.1. The effect of SAM treatment on cocaine-induced gene expression and CpG-island methylation

Using whole-genome gene expression analysis, our data demonstrated that repeated SAM treatments altered 50 transcripts significantly. Of these transcripts, 36% were upregulated and 64% were downregulated suggesting that treatment with exogenous SAM primarily silences gene expression, as expected from the typical silencing effect of DNA hypermethylation. Compared with SAM, cocaine treatment has a broader impact upon gene expression. Repeated

cocaine treatments changed 241 transcripts and predominantly downregulated these transcripts. Thirty seven transcripts of the 50 SAM-responsive genes were also altered in the S+C group. Interestingly, the number of significantly affected genes in the M+C group was lower than in the S+C group. These data demonstrate that 46% and 57% (respectively up- and downregulated) SAM and cocaine treatment-group transcripts were no longer significantly different compared with the respective transcripts from the S+C group, suggesting that SAM pretreatment modified the cocaine-induced gene expression pattern in the NAc. GO analysis revealed that SAM pretreatment decreased the expression of several cocaine-induced genes in different functional groups, demonstrating that SAM's blunting effect is non-specific.

Other microarray studies have demonstrated that several genes are affected by cocaine (S+C) treatment (Freeman et al., 2010; Rodríguez-Borrero et al., 2010; Maze and Nestler, 2011). However, there have been only a few reports demonstrating an effect of SAM or MET (a precursor of SAM) at the genome level. In SK-N-BE neuroblastoma cells, SAM modulates 7 genes (of a total of 588 genes analysed), of which 3 were upregulated and 4 downregulated, showing low levels of modulation (Cavallaro et al., 2006). Weaver and colleagues (2006) demonstrated that repeated MET intraventricular treatments altered 337 transcripts, representing 1.08% of the population of genes on the DNA microarray, and of these altered transcripts, 217 (64%) were down-regulated and 120 (35.6%) were upregulated in the rat hippocampus (Weaver et al., 2006). It is difficult to compare our results with these data but nevertheless, the ratio of up- and downregulated genes is similar between all of the studies. Both SAM and MET affect the expression of a limited number of genes and do not affect the vast majority of the genome, suggesting that SAM or MET treatments, despite their global nature, do not result in a general silencing of gene expression. The basis for the specificity of SAM or MET gene expression effects remains unknown. Thus, treatment with exogenous SAM induces minor effects on whole-genome gene expression; however, SAM pretreatment significantly modified cocaine-induced gene expression by blunting non-specifically the cocaine response.

To determine the effect of SAM and cocaine at the gene level, we selected (from the gene expression profiling data) *Cck*, *Slc17a7*, and *Gal* genes for analysis based on their possible participation in cocaine-induced neuro-adaptations in the NAc (Hökfelt et al., 1980; Josselyn et al., 1997; Fremeau et al., 2001; Narasimhaiah et al., 2009). We found that repeated SAM treatments caused both hypermethylation and hypomethylation in the promoter regions of the selected genes, and these changes associated with down- and upregulated mRNA expression, respectively (Figures 17A-C; 18A-C; see supplementary Figures S3A-C in Paper II). These results are comparable in part with the studies that demonstrated that treatment with exogenous SAM elicits gene silencing via promoter hypermethylation (Watson et al., 1999; Fuso et al., 2001; Pulukuri et al., 2007). Similarly, repeated treatments with MET is also

associated with hypermethylation of the *Reln* and *glutamate decarboxylase 67* (*Gad67)* promoter regions in mouse frontal cortex and striatum (Tremolizzo et al., 2002; Dong et al., 2008). We also found that SAM pretreatment inhibited cocaine-induced hyper- and hypomethylation (*Slc17a7* and *Gal*, respectively) in the NAc. Interestingly, SAM additively enhanced cocaine-induced hyper-methylation at the *Cck* promoter, which was associated with *Cck* transcriptional downregulation in the NAc (Figures 17B and 18B). Thus, it appears that SAM pretreatment may both increase and decrease cocaine-induced DNA methylation at a gene level.

To evaluate whether the effects of SAM are NAc-specific or not, we assessed the expression of the selected genes and promoter-region methylation levels in the mouse cerebellum. Our data showed that repeated SAM treatment changed *Slc17a7* and *Cck* promoter methylation levels significantly in both brain regions (see supplementary Figures S3A,B in Paper II) indicating that SAM effects are rather non-specific. As expected, the cocaine effects on the gene expression were more prominent in the NAc than in the cerebellum. These data suggest that SAM treatment modifies cocaine- (another epigenetic factor) specific effects in the NAc.

2.2. The effect of SAM on DNMT expression and methyltransferase activity

In this part of the study, we analysed the consequences of acute and repeated SAM treatments on DNMTs expression and methyltransferase activity in PC12 cells. We found that treatment with exogenous SAM induced a biphasic effect on methyltransferase activity (Figures 19A,B) because a single SAM treatment enhanced whereas repeated daily treatments significantly reduced methyl-transferase activity. Both *in vitro* and *in vivo* data show that repeated SAM treatments increases *Dnmt3a* promoter-region hypermethylation, which is associated with downregulation of *Dnmt3a* mRNA (Figures 20A,C and 21A,C). SAM and cocaine co-treatment (M+C) also increased *Dnmt3a* promoter methylation compared with the S+C group. As we found significantly down-regulated *Dnmt3b* mRNA levels in the M+C group (Figure 21D), without methylation of the *Dnmt3b* promoter, we speculate that SAM-induced histone methylation may be involved in *Dnmt3b* expression. Moreover, based on accumulating data, we propose the following model for the regulation of DNA methylation/demethylation activities. A single dose of SAM stimulates methyl-transferase activity resulting in increased DNA methylation. It is possible that SAM increases DNA methylation by also decreasing demethylation via inhibition of MBD2 (Detich et al., 2003). Repeated administration of exogenous SAM decreases methyltransferase activity via decreased *Dnmt3a* and *Dnmt3b* expression and via increased levels of intracellular SAH, which inhibits DNMT activity and is the product of the transmethylation reactions (Chiang, 1998). Therefore, we propose that the modifing effect on cocaine-induced gene

expression in the NAc following repeated SAM treatment may result from an altered balance between methylation/demethylation activities. We also speculate that the decrease in SAM-induced methyltransferase activity is reversible after discontinuing treatment with exogenous SAM. Although we found that SAM and cocaine treatment may also cause promoter-associated CpG-island hyper-methylation (e.g., *Cck*), we speculate that other factor(s) may participate in fine-tuning the balance in DNA methylation/demethylation.

2.3. The effect of SAM treatment on cocaine-induced behavioural sensitisation

At the behavioural level, we found that repeated SAM treatment alone did not affect locomotor activity (Figure 16A); a related finding has been described following repeated MET treatment (Tremolizzo et al., 2002). Several recent studies indicate that injections of DNMT inhibitors into different brain regions may affect inversely the development of cocaine-induced behavioural sensitisation and CPP in mice. For example, continuous intra-NAc infusion of RG108 over the 7 days increased cocaine-induced CPP and enhanced the induction of behavioural sensitisation to chronic cocaine (LaPlant et al., 2010). Injections of the DNMT inhibitor 5-aza into hippocampus CA1 area prevented the acquisition of cocaine-induced CPP; however 5-aza had no effect on acquisition after injection into the prelimbic cortex (Han et al., 2010). We previously demonstrated that repeated zebularine i.c.v. injections decreased cocaine-induced behavioural sensitisation, suggesting that zebularine (due to diffusion into brain tissue) affected DNMT activity in the hippocampus to a greater extent than the NAc (Paper I). In this study, we found that SAM pretreatment significantly potentiated cocaine-induced ambulations during the development and expression of behavioural sensitisation in mice. Therefore, our behavioural data, coupled with the decreased *Dnmt3a* and *Dnmt3b* mRNA levels in the NAc, support the findings that decreased methyltransferase activity in the NAc positively regulates cocaine-induced behavioural sensitisation (LaPlant et al., 2010). Increased locomotor activity in the M+C group on treatment days 5–7 is also consistent with the decreased *Dnmt3a* mRNA level and methyltransferase activity in PC12 cells (Figures 19C and 20A). It is not known how treatment with exogenous SAM affects *Dnmt3*a and *Dnmt3b* expression in other brain regions; however, we speculate that reduced *Dnmt3a* and *Dnmt3b* expression in the NAc may have a greater impact on cocaine-induced locomotor activity compared with other brain regions (e.g., CA1 area).

The cocaine challenge study suggests that increased locomotor activity in the M+C group (compared with the S+C group) is persistent indicating that the effects of SAM on cocaine are long-lasting even after a period of cocaine withdrawal. Recently, it has been reported that chronic MET (0.78 g/kg, twice per day subcutaneously) diminished the rewarding effects of cocaine in the CPP procedure (LaPlant et al., 2010). There are a number of methodological

differences between the LaPlant study and our study that could account for these disparate findings including the drugs (MET vs. SAM), doses of MET and SAM, and the different pretreatment regimens. We think that an especially important factor is the pretreatment regimen as SAM or MET may affect different genes depending on the interval between pretreatment and cocaine administration. However, our data indicate that the methyl donor SAM modifies cocaine-induced gene expression in the NAc of mice and thereby contributes to the development of behavioural sensitisation.

3. The role of MS in DNA methylation and behavioural changes (Paper III)

Using MS as an early-life stress model, our aim was to investigate whether MS in rats could alter the expression of DNMTs and selected genes ($PP1c$, $A_{2A}R$) in the NAc of infant and adult rats and whether these changes were associated with the development of cocaine-induced behavioural sensitisation in adulthood.

3.1. The effect of MS on exploratory behaviour and cocaine-induced behaviour in adult rats

To validate our model of MS, we used the exploratory box test to measure novelty-related behaviour in adult rats subjected to MS manipulation. Exploratory behaviour in novel environments is influenced by the conflicting motivators fear and curiosity. Mällo and colleagues (2007) found that animals with a high motivation to explore displayed reduced anxiety-like behaviour (Mällo et al., 2007). It has also been reported that chronic variable stress increased exploratory activity in the exploratory box test and increased dopamine D_1 receptor-specific cAMP accumulation in the NAc of rats (Matrov et al., 2011). Our data demonstrated that in the adult MS180 group, rats showed increased exploratory activity compared with the AFR and MS15 groups. These data were consistent with the Marmendal et al. (2006) study, where early deprivation was found to increase exploratory behaviour in adult male Wistar offspring. The exploratory box test data are also consistent with our cocaine results, and several studies have demonstrated that there is a significant correlation between a subject's locomotor response to a novel environment and its locomotor response to cocaine (Hooks et al., 1991; Bardo et al., 1996). There is a report demonstrating that exposure to novelty activates, at least in part, the same neural substrate that mediates the rewarding effects of drugs of abuse (Bardo et al., 1996); however, the exact mechanism underlying the effects of MS on exploratory behaviour is unknown.

The acute cocaine treatment (10 mg/kg, i.p.) study demonstrated that adult rats from the MS180 group showed an increased response to acute cocaine treatment (Figure 23A), suggesting that the duration of MS affected this result.

The repeated cocaine treatment study indicates that the early-life stress (both handling and MS) increased susceptibility to cocaine-induced behavioural sensitisation in adult animals compared with the AFR group (Figure 23B). Few studies have investigated the influence of MS on the effects of cocaine. For example, Li and colleagues (2003) observed that in adulthood, AFR, MS15 and MS180 groups did not differ in their locomotor responses to an acute intravenous cocaine treatment and that MS15 and MS180 groups showed significantly less robust effects of cocaine challenge than rats from an AFR group; however, they used only female rats (Li et al., 2003). Kikusui and colleagues (2005) found that repeated MS increased the hyperlocomotor response to 10.0 mg/kg cocaine regardless of mouse gender (Kikusui et al., 2005). Marin and Planeta (2004) found that male adolescent rats exposed to MS exhibited an increased locomotor response to cocaine; however, this response was not observed in adult rats (Marin and Planeta, 2004). Brake and colleagues (2004) demonstrated that MS and non-handled animals displayed a dose-dependent increased sensitivity to cocaine-induced locomotor activity compared with a handled group (Brake et al., 2004). These data suggest that the outcome of the model of early-life stress may depend on various factors, such as environmental conditions, gender, specifics of the separation procedure and the duration of separation, among others.

3.2. The effect of MS on the expression of DNMT and selected genes

In this study, we showed that early-life stress upregulated DNMTs expression in the NAc of infant rats and that this upregulation persisted into adulthood. We found that MS increased expression levels of *Dnmt3a* primarily, suggesting that *de novo* methylation dominated. The signal transduction processes that control MS-induced DNMTs expression in the infant CNS are unknown. As we found upregulated *Dnmt3a* mRNA levels in the NAc, we hypothesized that increased GR stimulation by corticosterone during MS could trigger a cascade of molecular events, which continually increases DNMTs expression in the brain. These changes facilitate adaptation to acute environmental challenges but may lead to behavioural pathologies in chronic stress conditions.

On a global level, we found that MS significantly decreased DNA methylation in the NAc but not the PFC of adult rats (Figure 25). There is a limited number of studies that describe MS-induced DNA methylation on a global level in the rat brain. Using mild and high prenatal stress, Mychasiuk et al. (2011) found that mild prenatal stress increased and high prenatal stress decreased global DNA methylation levels in the frontal cortex and hippocampus of rat offspring.

Studies have demonstrated that stressful experiences during early life may cause both DNA hypo- and hypermethylation of specific gene promoters (Weaver et al., 2004; Fuchikami et al., 2009; Murgatroyd et al., 2009; Roth et

al. 2009; Franklin et al., 2010). We found that MS was associated with hyper-methylation and transcriptional downregulation of the *PP1c* and *A2AR* promoter regions in the NAc but not the PFC. Neither handling nor MS affected *Reln* promoter-region methylation or transcription levels in the NAc and PFC. These data suggest that MS effects may be gene- and brain-region specific. Moreover, because we found that on global level MS was associated with DNA hypomethylation and at gene level with DNA hypermethylation, our findings suggest that MS may regulate DNA methylation at different levels – on a global and a gene level. However, the exact mechanisms underlying these changes are unknown. A similar phenomenon – global DNA hypomethylation and gene-specific hypermethylation – has been observed in aging-related conditions (Wilson et al., 1987; Oakes et al., 2003; Calvanese et al., 2009). Furthermore, in many complex diseases including cancer, atherosclerosis and psychiatric disorders (Baylin and Herman, 2000; Pogribny and Beland, 2009), it is common to observe global DNA hypomethylation and gene-specific hypermethylation (Kile et al., 2010).

As mentioned above, gene expression analysis showed that MS induced persistent transcriptional downregulation of the neuronal plasticity-related genes *PP1c* and *A2AR* in the NAc. The PP1 enzyme contains both a catalytic subunit and a regulatory subunit (Goldberg et al., 1995). Protein kinase A and PP1 regulate the phosphorylation state and activity of many physiological effectors including neurotransmitter receptors, for example the AMPA receptor, that regulate the excitability of medium spiny neurons (Yan et al., 1999). Repression of the *PP1c* gene via hypermethylation of its promoter region could enable aberrant phosphorylation of crucial receptors and transcription factors during and after MS. Our data suggest that environmental factors, MS and cocaine treatment (cocaine resulted in *PP1c* promoter hypermethylation and transcriptional downregulation in the NAc of mice, Paper I) have a similar effects on *PP1c* promoter methylation and transcription activity in the NAc.

The activity of the $A_{2A}R$ determines the response to acute cocaine treatment. NAc contains a high density of $A_{2A}Rs$, which pre- and postsynaptically regulate glutamatergic and dopaminergic neurotransmission on GABAergic striatal efferent neurons, in part by acting on heteromers of adenosine receptors with dopamine and metabotropic glutamate receptors (Ferré et al., 2007). At the behavioural level, pharmacological blockade typically potentiates the acute behavioural effects of psychostimulants by acting on the NAc $A_{2A}Rs$ (Popoli et al., 1998; Filip et al., 2006). These finding are consistent with our results that demonstrate that reduced *A2AR* mRNA levels in the NAc of MS180 rats is associated with an enhanced response to acute cocaine treatment.

Thus, we conclude that stressful experiences in early life may create a background, via aberrant DNA methylation, that promotes the development of cocaine-induced behavioural sensitisation in adult rats.

CONCLUSIONS

1. Our data demonstrated that cocaine treatment caused a dynamic increase in *Dnmt3a* and *Dnmt3b* expression levels in the NAc and hippocampus suggesting that cocaine induces *de novo* DNA methylation. At the gene level, we determined that cocaine treatment induced both DNA methylation/ demethylation thereby affecting the transcription of particular genes. Intra-cerebroventricular treatment with the DNMT inhibitor zebularine normalised hypermethylated gene transcription and delayed the development of cocaine-induced behavioural sensitisation in adult mice indicating that DNA methylation/ demethylation activities may be important processes during the development of behavioural sensitisation in adult mice.

2. The methyl donor SAM modified cocaine-induced gene expression at the genome and gene level in the NAc and may thereby contribute to the development of cocaine-induced behavioural sensitisation in adult mice.

3. Maternal separation may cause, via aberrant DNA methylation, persistent changes in gene expression and create a background that promotes the development of cocaine-induced behavioural sensitisation in adult rats.

In summary, our results suggest that DNA methylation plays an important role in the development of cocaine-induced behavioural sensitisation. Furthermore, environmental factors, such as SAM and early-life stress, may promote, via DNA methylation, the development of psychostimulant-induced drug addiction in mice and rats.

REFERENCES

Akil H (2005) Stressed and depressed. *Nat Med* 11:116–118.

Allis CD, Berger SL, Cote J, Dent S, Jenuwien T, Kouzarides T, Pillus L, Reinberg D, Shi Y, Shiekhattar R, Shilatifard A, Workman J, Zhang Y (2007) New nomenclature for chromatin-modifying enzymes. *Cell* 131:633–636.

Allison DB, Cui X, Page GP, Sabripour M (2006) Microarray data analysis: from disarray to consolidation and consensus. *Nat Rev Genet* 7:55–65.

Ambroggi F, Turiault M, Milet A, Deroche-Gamonet V, Parnaudeau S, Balado E, Barik J, van der Veen R, Maroteaux G, Lemberger T, Schütz G, Lazar M, Marinelli M, Piazza PV, Tronche F (2009) Stress and addiction: glucocorticoid receptor in dopaminoceptive neurons facilitates cocaine seeking. *Nat Neurosci* 12:247–249.

Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY (1999) Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. *Nat Genet* 23:185–188.

Anier K, Kalda A (2012) Epigenetics in the Central Nervous System. *Curr Tran Geriatr Gerontol Rep* 1:190–198.

Banerjee T, Chakravarti D (2011) A peek into the complex realm of histone phosphorylation. *Mol Cell Biol* 31:4858–4873.

Bannister AJ, Kouzarides T (2005) Reversing histone methylation. *Nature* 436:1103–1106.

Bardo MT, Donohew RL, Harrington NG (1996) Psychobiology of novelty seeking and drug seeking behavior. *Behav Brain Res* 77:23–43.

Barrett RM, Wood MA (2008) Beyond transcription factors: the role of chromatin modifying enzymes in regulating transcription required for memory. *Learn Mem* 15:460–467.

Barrot M, Olivier JDA, Perrotti LI, DiLeone RJ, Berton O, Eisch AJ, Impey S, Storm DR, Neve RL, Yin JC, Zachariou V, Nestler EJ (2002) CREB activity in the nucleus accumbens shell controls gating of behavioral responses to emotional stimuli. *Proc Natl Acad Sci U S A* 99:11435–11440.

Baylin SB, Herman JG (2000) DNA hypermethylation in tumorigenesis – epigenetics joins genetics. *Trends Genet* 16:168–174.

Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society, Series B* 57:289–300.

Bennett MR (2011) The prefrontal–limbic network in depression: Modulation by hypothalamus, basal ganglia and midbrain. *Progress in Neurobiology* 93:468–487.

Berger SL (2007) The complex language of chromatin regulation during transcription. *Nature* 447:407–412.

Bergmann A, Lane ME (2003) Hidden targets of microRNAs for growth control. *Trends Biochem Sci* 28:461–463.

Berke JD, Hyman SE (2000) Addiction, dopamine, and the molecular mechanisms of memory. *Neuron* 25:515–532.

Bernstein BE, Meissner A, Lander ES (2007) The Mammalian Epigenome. *Cell* 128:669–681.

Bertran-Gonzalez J, Bosch C, Maroteaux M, Matamales M, Hervé D, Valjent E, Girault JA (2008) Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. *J Neurosci* 28:5671–5685.

Bestor TH (2000) The DNA methyltransferases of mammals. *Hum Mol Genet* 9:2395–2402.

Bird A (2002) DNA methylation patterns and epigenetic memory. *Genes Dev* 16:6–21.

Bottiglieri T (2002) S-Adenosyl-L-methionine (SAMe): from the bench to the bedside – molecular basis of a pleiotrophic molecule. *Am J Clin Nutr* 76:1151S–1157S.

Bourc'his D, Xu GL, Lin CS, Bollman B, Bestor TH (2001) Dnmt3L and the establishment of maternal genomic imprints. *Science* 294:2536–2539.

Bowers MS, McFarland K, Lake RW, Peterson YK, Lapish CC, Gregory ML, Lanier SM, Kalivas PW (2004) Activator of G protein signaling 3: a gatekeeper of cocaine sensitization and drug seeking. *Neuron* 42:269–281.

Brady KT, Sonne SC (1999) The role of stress in alcohol use, alcoholism treatment, and relapse. *Alcohol Res Health* 23:263–271.

Brake WG, Zhang TY, Diorio J, Meaney MJ, Gratton A (2004) Influence of early post-natal rearing conditions on mesocorticolimbic dopamine and behavioural responses to psychostimulants and stressors in adult rats. *Eur J Neurosci* 19:1863–1874.

Brami-Cherrier K, Valjent E, Hervé D, Darragh J, Corvol JC, Pages C, Arthur SJ, Girault JA, Caboche J (2005) Parsing molecular and behavioral effects of cocaine in mitogen- and stress-activated protein kinase-1-deficient mice. *J Neurosci* 25:11444–11454.

Brami-Cherrier K, Roze E, Girault JA, Betuing S, Caboche J (2009) Role of the ERK/MSK1 signalling pathway in chromatin remodelling and brain responses to drugs of abuse. *J Neurochem* 108:1323–1335.

Briand LA, Blendy JA (2010) Molecular and genetic substrates linking stress and addiction. *Brain Res* 1314:219–234.

Brooks PJ, Marietta C, Goldman D (1996) DNA mismatch repair and DNA methylation in adult brain neurons. *J Neurosci* 16:939–945.

Caldji C, Diorio J, Meaney MJ (2000) Variations in maternal care in infancy regulate the development of stress reactivity. *Biol Psychiatry* 48:1164–1174.

Calvanese V, Lara E, Kahn A, Fraga MF (2009) The role of epigenetics in aging and age-related diseases. *Ageing Research Reviews* 8:268–276.

Campbell J, Spear LP (1999) Effects of early handling on amphetamine-induced locomotor activation and conditioned place preference in the adult rat. *Psychopharmacology (Berl)* 143:183–189.

Canettieri G, Morantte I, Guzmán E, Asahara H, Herzig S, Anderson SD, Yates JR 3rd, Montminy M (2003) Attenuation of a phosphorylation-dependent activator by an HDAC-PP1 complex. *Nat Struct Biol* 10:175–181.

Carlezon WA Jr, Thome J, Olson VG, Lane-Ladd SB, Brodkin ES, Hiroi N, Duman RS, Neve RL, Nestler EJ (1998) Regulation of cocaine reward by CREB. *Science* 282:2272–2275.

Carlezon WA Jr, Duman RS, Nestler EJ (2005) The many faces of CREB. *Trends Neurosci* 28:436–445.

Caudill MA, Wang JC, Melnyk S, Pogribny IP, Jernigan S, Collins MD, Santos-Guzman J, Swendseid ME, Cogger EA, James SJ (2001) Intracellular S-adenosylhomocysteine concentrations predict global DNA hypomethylation in tissues of methyl-deficient cystathionine beta-synthase heterozygous mice. *J Nutr* 131:2811–2818.

Cavallaro RA, Fuso A, D'Anselmi F, Seminara L, Scarpa S (2006) The effect of S-adenosylmethionine on CNS gene expression studied by cDNA microarray analysis. *J Alzheimers Dis* 9:415–419.

Cervoni N, Szyf M (2001) Demethylase activity is directed by histone acetylation. *J Biol Chem* 276:40778–40787.

Cervoni N, Detich N, Seo SB, Chakravarti D, Szyf M (2002) The oncoprotein Set/TAF-1beta, an inhibitor of histone acetyltransferase, inhibits active demethylation of DNA, integrating DNA methylation and transcriptional silencing. *J Biol Chem* 277:25026–25031.

Chahrour M, Zoghbi HY (2007) The story of Rett syndrome: from clinic to neurobiology. *Neuron* 56:422–437.

Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, Zoghbi HY (2008) MeCP2, a key contributor to neurological disease, activates and represses transcription. *Science* 320:1224–1229.

Champagne FA, Francis DD, Mar A, Meaney MJ (2003) Variations in maternal care in the rat as a mediating influence for the effects of environment on development. *Physiol Behav* 79:359–371.

Chandrasekar V, Dreyer JL (2009) microRNAs miR-124, let-7d and miR-181a regulate cocaine-induced plasticity. *Mol Cell Neurosci* 42:350–362.

Chawla S, Vanhoutte P, Arnold FJ, Huang CL, Bading H (2003) Neuronal activity-dependent nucleocytoplasmic shuttling of HDAC4 and HDAC5. *J Neurochem* 85:151–159.

Chen JC, Chen PC, Chiang YC (2009) Molecular mechanisms of psychostimulant addiction. *Chang Gung Med J* 32:148–154.

Chen JF, Moratalla R, Yu L, Martín AB, Xu K, Bastia E, Hackett E, Alberti I, Schwarzschild MA (2003) Inactivation of adenosine A2A receptors selectively attenuates amphetamine-induced behavioral sensitization. *Neuropsychopharmacology* 28:1086–1095.

Cheng X, Roberts RJ (2001) AdoMet-dependent methylation, DNA methyltransferases and base flipping. *Nucleic Acids Res* 29:3784–3795.

Cheng X, Blumenthal RM (2008) Mammalian DNA methyltransferases: a structural perspective. *Structure* 16:341–350.

Cheung P, Allis CD, Sassone-Corsi P (2000) Signaling to chromatin through histone modifications. *Cell* 103:263–271.

Chiang PK, Gordon RK, Tal J, Zeng GC, Doctor BP, Pardhasaradhi K, McCann PP (1996) S-Adenosylmethionine and methylation. *FASEB J* 10:471–480.

Chiang PK (1998) Biological effects of inhibitors of S-adenosylhomocysteine hydrolase. *Pharmacol Ther* 77:115–134.

Colby CR, Whisler K, Steffen C, Nestler EJ, Self DW (2003) Striatal cell type-specific overexpression of DeltaFosB enhances incentive for cocaine. *J Neurosci* 23:2488–2493.

Curran T, Franza BR Jr (1988) Fos and Jun: the AP-1 connection. *Cell* 55:395–397.

Daniels WM, Pietersen CY, Carstens ME, Stein DJ (2004) Maternal separation in rats leads to anxiety-like behavior and a blunted ACTH response and altered neurotransmitter levels in response to a subsequent stressor. *Metab Brain Dis* 19:3–14.

Daniels WM, Fairbairn LR, van Tilburg G, McEvoy CR, Zigmond MJ, Russell VA, Stein DJ (2009) Maternal separation alters nerve growth factor and corticosterone levels but not the DNA methylation status of the exon 1(7) glucocorticoid receptor promoter region. *Metab Brain Dis* 24:615–627.

Day JJ, Sweatt JD (2010) DNA methylation and memory formation. *Nat Neurosci* 13:1319–1323.

Day JJ, Sweatt JD (2011) Epigenetic Mechanisms in Cognition. *Neuron* 70:813–829.

De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M (1998) Brain corticosteroid receptor balance in health and disease. *Endocr Rev* 19:269–301.

De Kloet ER, Sibug RM, Helmerhorst FM, Schmidt MV (2005) Stress, genes and the mechanism of programming the brain for later life. *Neurosci Biobehav Rev* 29:271–281.

Deroche-Gamonet V, Sillaber I, Aouizerate B, Izawa R, Jaber M, Ghozland S, Kellendonk C, Le Moal M, Spanagel R, Schütz G, Tronche F, Piazza PV (2003) The glucocorticoid receptor as a potential target to reduce cocaine abuse. *J Neurosci* 23:4785–4790.

Detich N, Hamm S, Just G, Knox JD, Szyf M (2003) The methyl donor S-Adeno-sylmethionine inhibits active demethylation of DNA: a candidate novel mechanism for the pharmacological effects of S-Adenosylmethionine. *J Biol Chem* 278:20812–20820.

Diaz-Flores E, Shannon K (2007) Targeting oncogenic Ras. *Gene Dev* 21:1989–1992.

Diorio D, Viau V, Meaney MJ (1993) The role of the medial prefrontal cortex (cingulate gyrus) in the regulation of hypothalamic-pituitary-adrenal responses to stress. *J Neurosci* 13:3839–3847.

Dong E, Nelson M, Grayson DR, Costa E, Guidotti A (2008) Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. *Proc Natl Acad Sci U S A* 105:13614–13619.

Du P, Kibbe WA, Lin SM (2008) Lumi: a pipeline for processing Illumina microarray. *Bioinformatics* 24:1547–1548.

Eden A, Gaudet F, Waghmare A, Jaenisch R (2003) Chromosomal instability and tumors promoted by DNA hypomethylation. *Science* 300:455.

Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Res* 30:207–210.

Edwards S, Graham DL, Bachtell RK, Self DW (2007) Region-specific tolerance to cocaine-regulated cAMP-dependent protein phosphorylation following chronic self-administration. *Eur J Neurosci* 25:2201–2213.

Endres M, Meisel A, Biniszkiewicz D, Namura S, Prass K, Ruscher K, Lipski A, Jaenisch R, Moskowitz MA, Dirnagl U (2000) DNA methyltransferase contributes to delayed ischemic brain injury. *J Neurosci* 20:3175–3181.

Endres M, Fan G, Meisel A, Dirnagl U, Jaenisch R (2001) Effects of cerebral ischemia in mice lacking DNA methyltransferase 1 in post-mitotic neurons. *NeuroReport* 12:3763–3766.

Enoch MA, Goldman D (1999) Genetics of alcoholism and substance abuse. *Psychiatr Clin North Am* 22:289–299.

Enoch MA (2011) The role of early life stress as a predictor for alcohol and drug dependence. *Psychopharmacology (Berl)* 214:17–31.

Fahlke C, Engel JA, Eriksson CJ, Hård E, Söderpalm B (1994) Involvement of cortico-sterone in the modulation of ethanol consumption in the rat. *Alcohol* 11:195–202.

Fan G, Beard C, Chen RZ, Csankovszki G, Sun Y, Siniaia M, Biniszkiewicz D, Bates B, Lee PP, Kuhn R, Trumpp A, Poon C, Wilson CB, Jaenisch R (2001) DNA hypomethylation perturbs the function and survival of CNS neurons in postnatal animals. *J Neurosci* 21:788–797.

Fasano S, Brambilla R (2002) Cellular mechanisms of striatum-dependent behavioral plasticity and drug addiction. *Curr Mol Med* 2:649–665.

Felsenfeld G, Groudine M (2003) Controlling the double helix. *Nature* 421:448–453.

Ferré S, Diamond I, Goldberg SR, Yao L, Hourani SMO, Huang ZL, Urade Y, Kitchen I (2007) Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry. Implications for drug addiction, sleep and pain. *Prog Neurobiol* 83:332–347.

Filip M, Frankowska M, Zaniewska M, Przegalinski E, Muller CE, Agnati L, Franco R, Roberts DC, Fuxe K (2006) Involvement of adenosine A2A and dopamine receptors in the locomotor and sensitizing effects of cocaine. *Brain Res* 1077:67–80.

Fischle W, Wang Y, Allis CD (2003) Histone and chromatin cross-talk. *Curr Opin Cell Biol* 15:172–183.

Flagel SB, Vázquez DM, Robinson TE (2003) Manipulations during the second, but not the first, week of life increase susceptibility to cocaine self-administration in female rats. *Neuropsychopharmacology* 28:1741–1751.

Francis D, Diorio J, Liu D, Meaney MJ (1999) Nongenomic transmission across generations of maternal behavior and stress responses in the rat. *Science* 286:1155–1158.

Franklin TB, Mansuy IM (2010) Epigenetic inheritance in mammals: Evidence for the impact of adverse environmental effects. *Neurobiology of Disease* 39:61–65.

Franklin TB, Russig H, Weiss IC, Gräff J, Linder N, Michalon A, Vizi S, Mansuy IM (2010) Epigenetic transmission of the impact of early stress across generations. *Biol Psychiatry* 68:408–415.

Freeman WM, Nader MA, Nader SH, Robertson DJ, Gioia L, Mitchell SM, Daunais JB, Porrino LJ, Friedman DP, Vrana KE (2001) Chronic cocaine-mediated changes in non-human primate nucleus accumbens gene expression. *J Neurochem* 77:542–549.

Freeman WM, Lull ME, Patel KM, Brucklacher RM, Morgan D, Roberts DC, Vrana, KE (2010) Gene expression changes in the medial prefrontal cortex and nucleus accumbens following abstinence from cocaine self-administration. *BMC Neurosci* 26:11–29.

Fremeau RT Jr, Troyer MD, Pahner I, Nygaard GO, Tran CH, Reimer RJ, Bellocchio EE, Fortin D, Storm-Mathisen J, Edwards RH (2001) The expression of vesicular glutamate transporters defines two classes of excitatory synapse. *Neuron* 31:247–260.

Fuchikami M, Morinobu S, Kurata A, Yamamoto S, Yamawaki S (2009) Single immobilization stress differentially alters the expression profile of transcripts of the brain-derived neurotrophic factor (BDNF) gene and histone acetylation at its promoters in the rat hippocampus. *Int J Neuropsychopharmacol* 12:73–82.

Fuso A, Cavallaro RA, Orru L, Buttarelli FR, Scarpa S (2001) Gene silencing by Sadenosylmethionine in muscle differentiation. *FEBS Lett* 508:337–340.

Garcea R, Daino L, Pascale R, Simile MM, Puddu M, Ruggiu ME, Seddaiu MA, Satta G, Sequenza MJ, Feo F (1989) Protooncogene methylation and expression in regenerating liver and preneoplastic liver nodules induced in the rat by diethylnitrosamine: effect of variations of S-adenosylmethionine:S-adenosylhomocysteine ratio. *Carcinogenesis* 10:1183–1192.

Genoux D, Haditsch U, Knobloch M, Michalon A, Storm D, Mansuy IM (2002) Protein phosphatase 1 is a molecular constraint on learning and memory. *Nature* 418:970–975.

Gibney ER, Nolan CM (2010) Epigenetics and gene expression. *Heredity (Edinb)* 105:4–13.

Girault JA, Valjent E, Caboche J, Hervé D (2007) ERK2: a logical and gate critical for drug-induced plasticity? *Curr Opin Pharmacol* 7:77–85.

Goeders NE (2002) The HPA axis and cocaine reinforcement. *Psychoneuroendocrinology* 27:13–33.

Goeders NE (2003) The impact of stress on addiction. *Eur Neuropsychopharmacol* 13:435–441.

Goldberg J, Huang HB, Kwon YG, Greengard P, Nairn AC, Kuriyan J (1995) Three-dimensional structure of the catalytic subunit of protein serine/threonine phosphatase-1. *Nature* 376:745–753.

Goldman D (1993) Recent developments in alcoholism: genetic transmission. *Recent Dev Alcohol* 11:231–248.

Goldman D, Oroszi G, Ducci F (2005) The genetics of addictions: uncovering the genes. *Nat Rev Genet* 6:521–532.

Goll MG, Bestor TH (2005) Eukaryotic cytosine methyltransferases. *Annu Rev Biochem* 74:481–514.

Gonzalo S (2010) Epigenetic alterations in aging. *J Appl Physiol* 109:586–597.

Grace L, Hescham S, Kellaway LA, Bugarith K, Russell VA (2009) Effect of exercise on learning and memory in a rat model of developmental stress. *Metab Brain Dis* 24:643–657.

Graham DL, Edwards S, Bachtell RK, DiLeone RJ, Rios M, Self DW (2007) Dynamic BDNF activity in nucleus accumbens with cocaine use increases self-administration and relapse. *Nat Neurosci* 10:1029–1037.

Grant PA (2001) A tale of histone modifications. *Gen Biol* 2(4):reviews0003.1-0003.6.

Grimm JW, Lu L, Hayashi T, Hope BT, Su TP, Shaham Y (2003) Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. *J Neurosci* 23:742–747.

Grunstein M (1997) Histone acetylation in chromatin structure and transcription. *Nature* 389:349–352.

Guo JU, Su Y, Zhong C, Ming GL, Song H (2011) Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. *Cell* 145:423–434.

Haig D (2004) The (dual) origin of epigenetics. *Cold Spring Harb Symp Quant Biol* 69:67–70.

Hake SB, Xiao A, Allis CD (2004) Linking the epigenetic 'language' of covalent histone modifications to cancer. *Br J Cancer* 90:761–769.

Han J, Li Y, Wang D, Wei C, Yang X, Sui N (2010) Effect of 5-aza-2-deoxycytidine microinjecting into hippocampus and prelimbic cortex on acquisition and retrieval of cocaine-induced place preference in C57BL/6 mice. *Eur J Pharmacol* 642:93–98.

Heim C, Nemeroff CB (2001) The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. *Biol Psychiatry* 49:1023–1039.

Hökfelt T, Rehfeld JF, Skirboll L, Ivemark B, Goldstein M, Markey K (1980) Evidence for coexistence of dopamine and CCK in mesolimbic neurones. *Nature* 285:476–478.

Hollander JA, Im HI, Amelio AL, Kocerha J, Bali P, Lu Q, Willoughby D, Wahlestedt C, Conkright MD, Kenny PJ (2010) Striatal microRNA controls cocaine intake through CREB signalling. *Nature* 466:197–202.

Holleran JL, Parise RA, Joseph E, Eiseman JL, Covey JM, Glaze ER, Lyubimov AV, Chen YF, D'Argenio DZ, Egorin MJ (2005) Plasma pharmacokinetics, oral bioavailability, an interspecies scaling of the DNA methyltransferase inhibitor, zebularine. *Clin Cancer Res* 11:3862–3868.

Holliday R, Pugh JE (1975) DNA modification mechanisms and gene activity during development. *Science* 187:226–232.

Hooks MS, Jones GH, Smith AD, Neill DB, Justice JB Jr (1991) Response to novelty predicts the locomotor and nucleus accumbens dopamine response to cocaine. *Synapse* 9:121–128.

Hope BT, Nye HE, Kelz MB, Self DW, Iadarola MJ, Nakabeppu Y, Duman RS, Nestler EJ (1994) Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. *Neuron* 13:1235–1244.

Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* 4:44–57.

Huot RL, Thrivikraman KV, Meaney MJ, Plotsky PM (2001) Development of adult ethanol preference and anxiety as a consequence of neonatal maternal separation in Long Evans rats and reversal with antidepressant treatment. *Psychopharmacology (Berl)* 158:366–373.

Huot RL, Plotsky PM, Lenox RH, McNamara RK (2002) Neonatal maternal separation reduces hippocampal mossy fiber density in adult Long Evans rats. *Brain Res* 950:52–63.

Hyman SE, Malenka RC, Nestler EJ (2006) Neural mechanisms of addiction: the role of reward- related learning and memory. *Annu Rev Neurosci* 29:565–598.

Im HI, Hollander JA, Bali P, Kenny PJ (2010) MeCP2 controls BDNF expression and cocaine intake through homeostatic interactions with microRNA-212. *Nat Neurosci* 13:1120–1127.

Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y (2010) Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. *Nature* 466:1129–1133.

Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, He C, Zhang Y (2011) Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. *Science* 333:1300–1303.

Jenuwein T, Allis CD (2001) Translating the histone code. *Science* 293:1074–1080.

Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. *Nat Rev Genet* 3: 415–428.

Jorissen HJ, Ulery PG, Henry L, Gourneni S, Nestler EJ, Rudenko G (2007) Dimerization and DNA-binding properties of the transcription factor DeltaFosB. *Biochemistry* 46:8360–8372.

Josselyn SA, De Cristofaro A, Vaccarino FJ (1997) Evidence for CCK(A) receptor involvement in the acquisition of conditioned activity produced by cocaine in rats. *Brain Res* 763:93–102.

Kalda A, Heidmets LT, Shen HY, Zharkovsky A, Chen JF (2007) Histone deacetylase inhibitors modulates the induction and expression of amphetamine-induced behavioral sensitization partially through an associated learning of the environment in mice. *Behav Brain Res* 181:76–84.

Kalivas PW, McFarland K, Bowers S, Szumlinski K, Xi ZX, Baker D (2003) Glutamate transmission and addiction to cocaine. *Ann N Y Acad Sci* 1003:169–175.

Kalivas PW, O'Brien C (2008) Drug addiction as a pathology of staged neuroplasticity. *Neuropsychopharmacology* 33:166–180.

Kalivas PW, Volkow ND (2005) The neural basis of addiction: A pathology of motivation and choice. *Am J Psychiatry* 162:1403–1413.

Kalivas PW, Volkow N, Seamans J (2005) Unmanageable motivation in addiction: a pathology in prefrontal-accumbens glutamate transmission. *Neuron* 45:647–650.

Kaneko WM, Riley AL, Ehlers CL (1994) Behavioral and electrophysiological effects of early repeated maternal separation. *Depression* 2:43–53.

Kapoor A, Agius F, Zhu JK (2005) Preventing transcriptional gene silencing by active DNA demethylation. *FEBS Lett* 579:5889–5898.

Kelz MB, Chen J, Carlezon WA Jr, Whisler K, Gilden L, Beckmann AM, Steffen C, Zhang YJ, Marotti L, Self DW, Tkatch T, Baranauskas G, Surmeier DJ, Neve RL, Duman RS, Picciotto MR, Nestler EJ (1999) Expression of the transcription factor deltaFosB in the brain controls sensitivity to cocaine. *Nature* 401:272–276.

Kikusui T, Faccidomo S, Miczek KA (2005) Repeated maternal separation: differences in cocaine-induced behavioral sensitization in adult male and female mice. *Psychopharmacology (Berl)* 178:202–210.

Kile ML, Baccarelli A, Tarantini L, Hoffman E, Wright RO, Christiani DC (2010) Correlation of global and gene-specific DNA methylation in maternal-infant pairs. *PLoS One* 29:5(10):e13730.

Kim JK, Samaranayake M, Pradhan S (2009) Epigenetic mechanisms in mammals. *Cell Mol Life Sci* 66:596–612.

Kim JS, Shukla SD (2006) Acute in vivo effect of ethanol (binge drinking) on histone H3 modifications in rat tissues. *Alcohol Alcohol* 41:126–132.

Klose RJ, Bird AP (2006) Genomic DNA methylation: the mark and its mediators. *Trends Biochem Sci* 31:89–97.

Koob GF, Bloom FE (1988) Cellular and molecular mechanisms of drug dependence. *Science* 242:715–723.

Koob G, Kreek MJ (2007) Stress, dysregulation of drug reward pathways, and the transition to drug dependence. *Am J Psychiatry* 164:1149–1159.

Koob GF, Le Moal M (2001) Drug addiction, dysregulation of reward, and allostasis. *Neuropsychopharmacology* 24:97–129.

Koob GF, Le Moal M (2005) Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. *Nat Neurosci* 8:1442–1444.

Koshibu K, Gräff J, Beullens M, Heitz FD, Berchtold D, Russig H, Farinelli M, Bollen M, Mansuy IM (2009) Protein phosphatase 1 regulates the histone code for long-term memory. *J Neurosci* 29:13079–13089.

Kosten TA, Miserendino MJ, Kehoe P (2000) Enhanced acquisition of cocaine self-administration in adult rats with neonatal isolation stress experience. *Brain Res* 875:44–50.

Kosten TA, Sanchez H, Zhang XY, Kehoe P (2004) Neonatal isolation enhances acquisition of cocaine self-administration and food responding in female rats. *Behav Brain Res* 151:137–149.

Kosten TA, Zhang XY, Kehoe P (2005) Neurochemical and behavioral responses to cocaine in adult male rats with neonatal isolation experience. *J Pharmacol Exp Ther* 314:661–667.

Kouzarides T (2007) Chromatin modifications and their function. *Cell* 128:693–705.

Kumar A, Choi KH, Renthal W, Tsankova NM, Theobald DE, Truong HT, Russo SJ, Laplant Q, Sasaki TS, Whistler KN, Neve RL, Self DW, Nestler EJ (2005) Chromatin remodeling is a key mechanism underlying cocaine-induced plasticity in striatum. *Neuron* 48:303–314.

Kuo MH, Allis CD (1998) Roles of histone acetyltransferases and deacetylases in gene regulation. *Bioessays* 20:615–626.

LaPlant Q, Vialou V, Covington HE 3rd, Dumitriu D, Feng J, Warren BL, Maze I, Dietz DM, Watts EL, Iñiguez SD, Koo JW, Mouzon E, Renthal W, Hollis F, Wang

H, Noonan MA, Ren Y, Eisch AJ, Bolaños CA, Kabbaj M, Xiao G, Neve RL, Hurd YL, Oosting RS, Fan G, Morrison JH, Nestler EJ (2010) Dnmt3a regulates emotional behavior and spine plasticity in the nucleus accumbens. *Nat Neurosci* 13:1137–1143.

LaPlant Q, Nestler EJ (2011) CRACKing the histone code: Cocaine's effects on chromatin structure and function. *Horm Behav* 59:321–330.

LaSalle JM, Powell WT, Yasui DH (2013) Epigenetic layers and players underlying neurodevelopment. *Trends Neurosci* 36:460–470.

Levine AA, Guan Z, Barco A, Xu S, Kandel ER, Schwartz JH (2005) CREB-binding protein controls response to cocaine by acetylating histones at the fosB promoter in the mouse striatum. *Proc Natl Acad Sci U S A* 102:19186–19191.

Levine S (2005) Developmental determinants of sensitivity and resistance to stress. *Psychoneuroendocrinology* 30:939–946.

Li B, Carey M, Workman JL (2007) The role of chromatin during transcription. *Cell* 128:707–719.

Li MD, van der Vaart AD (2011) MicroRNAs in addiction: adaptation's middlemen? *Mol Psychiatry* 16:1159–1168.

Li Y, Robinson TE, Bhatnagar S (2003) Effects of maternal separation on behavioural sensitization produced by repeated cocaine administration in adulthood. *Brain Res* 960:42–47.

Liu D, Diorio J, Tannenbaum B, Caldji C, Francis D, Freedman A, Sharma S, Pearson D, Plotsky PM, Meaney MJ (1997) Maternal care, hippocampal glucocorticoid receptors, and hypothalamic-pituitary-adrenal responses to stress. *Science* 277:1659–1662.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25:402–408.

Lu L, Dempsey J, Liu SY, Bossert JM, Shaham Y (2004) A single infusion of brain-derived neurotrophic factor into the ventral tegmental area induces long-lasting potentiation of cocaine seeking after withdrawal. *J Neurosci* 24:1604–1611.

Lu R, Wang X, Chen ZF, Sun DF, Tian XQ, Fang JY (2007) Inhibition of extracellular signal regulated kinase mitogen-activated protein kinase pathway decrease DNA-methylation in colon cancer cells. *J Biol Chem* 282:12249–12259.

Lu SC (2000) S-Adenosylmethionine. *Int J Biochem Cell Biol* 32:391–395.

Ma DK, Guo JU, Ming GL, Song H (2009a) DNA excision repair proteins and Gadd45 as molecular players for active DNA demethylation. *Cell Cycle* 8:1526–1531.

Ma DK, Jang MH, Guo JU, Kitabatake Y, Chang ML, Pow-Anpongkul N, Flavell RA, Lu B, Ming GL, Song H (2009b) Neuronal activity-induced Gadd45b promotes epigenetic DNA demethylation and adult neurogenesis. *Science* 323:1074–1077.

MacLeod AR, Rouleau J, Szyf M (1995) Regulation of DNA methylation by the Ras signaling pathway. *J Biol Chem* 270:11327–11337.

Mällo T, Alttoa A, Kõiv K, Tõnissaar M, Eller M, Harro J (2007) Rats with persistently low or high exploratory activity: behaviour in tests of anxiety and depression, and extracellular levels of dopamine. *Behav Brain Res* 177:269–281.

Mantsch JR, Saphier D, Goeders NE (1998) Corticosterone facilitates the acquisition of cocaine self-administration in rats: opposite effects of the type II glucocorticoid receptor agonist dexamethasone. *J Pharmacol Exp Ther* 287:72–80.

Marin MT, Planeta CS (2004) Maternal separation affects cocaine-induced locomotion and response to novelty in adolescent, but not in adult rats. *Brain Res* 1013:83–90.

Marinelli M, Rougé-Pont F, De Jesus-Oliveira C, Le Moal M, Piazza PV (1997) Acute blockade of corticosterone secretion decreases the psychomotor stimulant effects of cocaine. *Neuropsychopharmacology* 16:156–161.

Marinelli M, Piazza PV (2002) Interaction between glucocorticoid hormones, stress and psychostimulant drugs. *Eur J Neurosci* 16:387–394.

Marmendal M, Eriksson CJ, Fahlke C (2006) Early deprivation increases exploration and locomotion in adult male Wistar offspring. *Pharmacol Biochem Behav* 85:535–544.

Marquez VE, Kelley JA, Agbaria R, Ben-Kasus T, Cheng JC, Yoo CB, Jones PA (2005) Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. *Ann NY Acad Sci* 1058:246–254.

Matrov D, Vonk A, Herm L, Rinken A, Harro J (2011) Activating effects of chronic variable stress in rats with different exploratory activity: association with dopamine d(1) receptor function in nucleus accumbens. *Neuropsychobiology* 64:110–122.

Matthews K, Halls FS, Wilkinson LS, Robbins TW (1996) Retarded acquisition and reduced expression of conditioned locomotor activity in adult rats following repeated early maternal separation: effects of prefeeding, d-amphetamine, dopamine antagonists and clonidine. *Psychopharmacology (Berl)* 126:75–84.

Matto V, Harro J, Allikmets L (1996) The effects of cholecystokinin A and B receptor antagonists, devazepide and L 365260, on citalopram-induced decrease of exploratory behaviour in rat. *J Physiol Pharmacol* 47:661–669.

Maze I, Covington HE 3rd, Dietz DM, LaPlant Q, Renthal W, Russo SJ, Mechanic M, Mouzon E, Neve RL, Haggarty SJ, Ren Y, Sampath SC, Hurd YL, Greengard P, Tarakhovsky A, Schaefer A, Nestler EJ (2010) Essential role of the histone methyl-transferase G9a in cocaine-induced plasticity. *Science* 327:213–216.

Maze I, Nestler EJ (2011) The epigenetic landscape of addiction. *Ann NY Acad Sci* 1216:99–113.

McClung CA, Nestler EJ (2003) Regulation of gene expression and cocaine reward by CREB and DeltaFosB. *Nat Neurosci* 6:1208–1215.

McClung CA, Ulery PG, Perrotti LI, Zachariou V, Berton O, Nestler EJ (2004) DeltaFosB: a molecular switch for long-term adaptation in the brain. *Brain Res Mol Brain Res* 132:146–154.

McClung CA, Nestler EJ, Zachariou V (2005) Regulation of gene expression by chronic morphine and morphine withdrawal in the locus coeruleus and ventral tegmental area. *J Neurosci* 25:6005–6015.

McEwen BS, Sapolsky RM (1995) Stress and cognitive function. *Curr Opin Neurobiol* 5:205–216.

McEwen BS (1998) Stress, adaptation, and disease. Allostasis and allostatic load. *Ann N Y Acad Sci* 840:33–44.

McEwen BS (2000) The neurobiology of stress: from serendipity to clinical relevance. *Brain Res* 886:172–189.

McGowan PO, Meaney MJ, Szyf M (2008) Diet and the epigenetic (re)programming of phenotypic differences in behavior. *Brain Res* 1237:12–24.

McGowan PO, Sasaki A, D'Alessio AC, Dymov S, Labonté B, Szyf M, Turecki G, Meaney MJ (2009) Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. *Nat Neurosci* 12:342–348.

McQuown SC, Wood MA (2010) Epigenetic regulation in substance use disorders. *Curr Psychiatry Rep* 12:145–153.

Meaney MJ, Aitken DH, van Berkel C, Bhatnagar S, Sapolsky RM (1988) Effect of neonatal handling on age-related impairments associated with the hippocampus. *Science* 239:766–768.

Meaney MJ, Brake W, Gratton A (2002) Environmental regulation of the development of mesolimbic dopamine systems: a neurobiological mechanism for vulnerability to drug abuse? *Psychoneuroendocrinology* 27:127–138.

Meaney MJ, Szyf M (2005) Environmental programming of stress responses through DNA methylation: life at the interface between a dynamic environment and a fixed genome. *Dialogues Clin Neurosci* 7:103–123.

Métivier R, Huet G, Gallais R, Finot L, Petit F, Tiffoche C, Mérot Y, LePéron C, Reid G, Penot G, Demay F, Gannon F, Flouriot G, Salbert G (2008) Dynamics of estrogen receptor-mediated transcriptional activation of responsive genes in vivo: apprehending transcription in four dimensions. *Adv Exp Med Biol* 617:129–138.

Miller CA, Sweatt JD (2007) Covalent modification of DNA regulates memory formation. *Neuron* 53:857–869.

Moffett MC, Vicentic A, Kozel M, Plotsky P, Francis DD, Kuhar MJ (2007) Maternal separation alters drug intake patterns in adulthood in rats. *Biochem Pharmacol* 73:321–330.

Moore LD, Le T, Fan G (2013) DNA Methylation and Its Basic Function. *Neuropsychopharmacology* 38:23–38.

Morgan MA, Ganser A, Reuter CW (2007) Targeting the RAS signaling pathway in malignant hematologic diseases. *Curr Drug Target* 8:217–235.

Murgatroyd C, Patchev AV, Wu Y, Micale V, Bockmühl Y, Fischer D, Holsboer F, Wotjak CT, Almeida OF, Spengler D (2009) Dynamic DNA methylation programs persistent adverse effects of early-life stress. *Nat Neurosci* 12:1559–1566.

Mychasiuk R, Ilnytskyy S, Kovalchuk O, Kolb B, Gibb R (2011) Intensity mattes: brain, behaviour and the epigenome of prenatally stressed rats. *Neuroscience* 180:105–110.

Narasimhaiah R, Kamens HM, Picciotto MR (2009) Effects of galanin on cocaine-mediated conditioned place preference and ERK signaling in mice. *Psycho-pharmacology (Berl)* 204:95–102.

Narlikar GJ, Fan HY, Kingston RE (2002) Cooperation between complexes that regulate chromatin structure and transcription. *Cell* 108:475–487.

Nestler EJ, Aghajanian GK (1997) Molecular and cellular basis of addiction. *Science* 278:58–63.

Nestler EJ (2001) Molecular basis of long-term plasticity underlying addiction. *Nat Rev Neurosci* 2:119–128.

Nestler EJ, Barrot M, Self DW (2001) DeltaFosB: a sustained molecular switch for addiction. *Proc Natl Acad Sci U S A* 98:11042–11046.

Nestler EJ (2008) Transcriptional mechanisms of addiction: role of DeltaFosB. *Phil Trans R Soc Lond B* 363:3245–3255.

Norton VG, Imai BS, Yau P, Bradbury EM (1989) Histone acetylation reduces nucleosome core particle linking number change. *Cell* 57:449–457.

Oakes CC, Smiraglia DJ, Plass C, Trasler JM, Robaire B (2003) Aging results in hypermethylation of ribosomal DNA in sperm and liver of male rats. *Proc Natl Acad Sci U S A* 100:1775–1780.

Okano M, Xie S, Li E (1998) Dnmt2 is not required for de novo and maintenance methylation of viral DNA in embryonic stem cells. *Nucleic Acids Res* 26:2536–2540.

Okano M, Bell DW, Haber DA, Li E (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. *Cell* 99:247–257.

Ooi SK, Bestor TH (2008) The colorful history of active DNA demethylation. *Cell* 133:1145–1148.

Pascale RM, Simile MM, De Miglio MR, Feo F (2002) Chemoprevention of hepatocarcinogenesis: S-adenosyl-L-methionine. *Alcohol* 27:193–198.

Patra SK, Szyf M (2008) DNA methylation-mediated nucleosome dynamics and oncogenic Ras signaling. Insights from FAS, FAS ligand and RASSF1A. *FEBS J* 275:5217–5235.

Paulson PE, Camp DM, Robinson TE (1991) Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats. *Psychopharmacology* 103:480–492.

Paxinos G, Franklin KBJ (2001) The Mouse Brain in Stereotaxic Coordinates. Second Edition, *Academic Press, San Diego, CA.*

Peakman MC, Colby C, Perrotti LI, Tekumalla P, Carle T, Ulery P, Chao J, Duman C, Steffen C, Monteggia L, Allen MR, Stock JL, Duman RS, McNeish JD, Barrot M, Self DW, Nestler EJ, Schaeffer E (2003) Inducible, brain region-specific expression of a dominant negative mutant of c-Jun in transgenic mice decreases sensitivity to cocaine. *Brain Res* 970:73–86.

Philips MR (2004) Methotrexate and Ras methylation: a new trick for an old drug? *Sci STKE* 225:pe13.

Piazza PV, Rougé-Pont F, Deminière JM, Kharoubi M, Le Moal M, Simon H (1991) Dopaminergic activity is reduced in the prefrontal cortex and increased in the nucleus accumbens of rats predisposed to develop amphetamine self-administration. *Brain Res* 567:169–174.

Piazza PV, Le Moal ML (1996) Pathophysiological basis of vulnerability to drug abuse: role of an interaction between stress, glucocorticoids, and dopaminergic neurons. *Annu Rev Pharmacol Toxicol* 36:359–378.

Pierce RC, Kalivas PW (1997) A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. *Brain Res Rev* 25:192–216.

Plotsky PM, Meaney MJ (1993) Early, postnatal experience alters hypothalamic corticotropin-releasing factor (CRF) mRNA, median eminence CRF content and stress-induced release in adult rats. *Brain Res Mol Brain Res* 18:195–200.

Pogribny IP, Poirier LA, James SJ (1995) Differential sensitivity to loss of cytosine methyl groups within the hepatic p53 gene of folate/methyl deficient rats. *Carcinogenesis* 16:2863–2867.

Pogribny IP, Beland FA (2009) DNA hypomethylation in the origin and pathogenesis of human diseases. *Cell Mol Life Sci* 66:2249–2261.

Poirier LA (2002) The effects of diet, genetics and chemicals on toxicity and aberrant DNA methylation: an introduction. *J Nutr* 132:2336S–2339S.

Popoli P, Reggio R, Pezzola A, Fuxe K, Ferré S (1998) Adenosine A1 and A2A re-ceptor antagonists stimulate motor activity: evidence for an increased effectiveness in aged rats. *Neurosci Lett* 251:201–204.

Pryce CR, Feldon J (2003) Long-term neurobehavioural impact of the postnatal environment in rats: manipulations, effects and mediating mechanisms. *Neurosci Biobehav Rev* 27:57–71.

Pryce CR, Rüedi-Bettschen D, Dettling AC, Weston A, Russig H, Ferger B, Feldon J (2005) Long-term effects of early-life environmental manipulations in rodents and primates: Potential animal models in depression research. *Neurosci Biobehav Rev* 29:649–674.

Pulukuri SM, Estes N, Patel J, Rao JS (2007) Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. *Cancer Res* 67:930–939.

Renthal W, Maze I, Krishnan V, Covington HE, 3rd, Xiao G, Kumar A, Russo SJ, Graham A, Tsankova N, Kippin TE, Kerstetter KA, Neve RL, Haggarty SJ, McKinsey TA, Bassel-Duby R, Olson EN, Nestler EJ (2007) Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. *Neuron* 56:517–529.

Renthal W, Nestler EJ (2008) Epigenetic mechanisms in drug addiction. *Trends Mol Med* 14:341–350.

Renthal W, Kumar A, Xiao G, Wilkinson M, Covington HE 3rd, Maze I, Sikder D, Robison AJ, LaPlant Q, Dietz DM, Russo SJ, Vialou V, Chakravarty S, Kodadek TJ, Stack A, Kabbaj M, Nestler EJ (2009) Genome-wide analysis of chromatin regulation by cocaine reveals a role for sirtuins. *Neuron* 62:335–348.

Rice JC, Allis CD (2001) Histone methylation versus histone acetylation: new insights into epigenetic regulation. *Curr Opin Cell Biol* 13:263–273.

Robertson KD, Wolffe AP (2000) DNA methylation in health and disease. *Nat Rev Genet* 1:11–19.

Robinson AJ, Nestler EJ (2011) Transcriptional and Epigenetic Mechanisms of Addiction. *Nat Rev Neurosci* 12:623–637.

Robinson TE, Becker JB (1986) Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. *Brain Res Rev* 11:157–198.

Robinson TE, Berridge KC (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. *Brain Res Rev* 18:247–291.

Rodríguez-Borrero E, Rivera-Escalera F, Candelas F, Montalvo J, Muñoz-Miranda WJ, Walker JR, Maldonado-Vlaar CS (2010) Arginine vasopressin gene expression changes within the nucleus accumbens during environment elicited cocaine-conditioned response in rats. *Neuropharmacology* 58:88–101.

Ross SA (2003) Diet and DNA methylation interactions in cancer prevention. *Ann N Y Acad Sci* 983:197–207.

Roth TL, Lubin FD, Funk AJ, Sweatt JD (2009) Lasting epigenetic influence of early-life adversity on the BDNF gene. *Biol Psychiatry* 65:760–769.

Sanchis-Segura C, Lopez-Atalaya JP, Barco A (2009) Selective boosting of transcriptional and behavioral responses to drugs of abuse by histone deacetylase inhibition. *Neuropsychopharmacology* 34:2642–2654.

Sapolsky RM (1996) Stress, Glucocorticoids, and Damage to the Nervous System: The Current State of Confusion. *Stress* 1:1–19.

Sapolsky RM, Romero LM, Munck AU (2000) How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. *Endocr Rev* 21:55–89.

Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. *Nat Protoc* 3:1101–1108.

Seckl JR, Meaney MJ (2004) Glucocorticoid programming. *Ann N Y Acad Sci* 1032:63–84.

Shahbazian MD, Grunstein M (2007) Functions of site-specific histone acetylation and deacetylation. *Annu Rev Biochem* 76:75–100.

Shea A, Walsh C, Macmillan H, Steiner M (2004) Child maltreatment and HPA axis dysregulation: relationship to major depressive disorder and post traumatic stress disorder in females. *Psychoneuroendocrinology* 30:162–178.

Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. *Cell* 119:941–953.

Shi Y, Whetstine JR (2007) Dynamic regulation of histone lysine methylation by demethylases. *Mol Cell* 25:1–14.

Siedlecki P, Zielenkiewicz P (2006) Mammalian DNA methyltransferases. *Acta Biochim Pol* 53:245–256.

Sinha R (2008) Chronic Stress, Drug Use, and Vulnerability to Addiction. *Ann N Y Acad Sci* 1141:105–130.

Smith R, Mill J (2011) Epigenetics and Chronic Diseases: An Overview. In: Roach HI, Bronner F, Oreffo ROC (Eds.), Epigenetic Aspects of Chronic Diseases. *Springer, Springer-Verlag London Ltd.,* pp.1–20.

Smith SM, Vale WW (2006) The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. *Dialogues Clin Neurosci* 8:383–395.

Smyth GK (2005) Limma: linear models for microarray data. In: Bioinformatics and Computational Biology Solutions using R and Bioconductor. *Springer, New York,* pp.397–420.

Steinmetz KL, Pogribny IP, James SJ, Pitot HC (1998) Hypomethylation of the rat glutathione S-transferase pi (GSTP) promoter region isolated from methyl-deficient livers and GSTP-positive liver neoplasms. *Carcinogenesis* 19:1487–1494.

Stipanovich A, Valjent E, Matamales M, Nishi A, Ahn JH, Maroteaux M, Bertran-Gonzalez J, Brami-Cherrier K, Enslen H, Corbillé AG, Filhol O, Nairn AC, Greengard P, Hervé D, Girault JA (2008) A phosphatase cascade by which rewarding stimuli control nucleosomal response. *Nature* 453:879–884.

Strahl BD, Allis CD (2000) The language of covalent histone modifications. *Nature* 403:41–45.

Su IH, Tarakhovsky A (2006) Lysine methylation and 'signaling memory'. *Curr Opin Immunol* 18:152–157.

Sutcliffe JS, Nelson DL, Zhang F, Pieretti M, Caskey CT, Saxe D, Warren ST (1992) DNA methylation represses FMR-1 transcription in fragile X syndrome. *Hum Mol Genet* 1: 397–400.

Swank MW, Sweatt JD (2001) Increased histone acetyltransferase and lysine acetyltransferase activity and biphasic activation of the ERK/RSK cascade in insular cortex during novel taste learning. *J Neurosci* 21:3383–3391.

Sweatt JD (2009) Experience-dependent Epigenetic Modifications in the CNS. *Biol Psychiatry* 65:191–197.

Szyf M, McGowan P, Meaney MJ (2008) The social environment and the epigenome. *Environ Mol Mutagen* 49:46–60.

Szyf M (2009) The early life environment and the epigenome. *Biochim Biophys Acta* 1790:878–885.

Szyf M (2011) DNA methylation, the early-life social environment and behavioral disorders. *J Neurodevelop Disord* 3:238–249.

Tachibana M, Sugimoto K, Fukushima T, Shinkai Y (2001) Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with

hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. *J Biol Chem* 276:25309–25317.

Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS (2010) Non-coding RNAs: regulators of disease. *J Pathol* 220:126–139.

Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, Rao A (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. *Science* 324:930–935.

Tambaro FP, Dell'aversana C, Carafa V, Nebbioso A, Radic B, Ferrara F, Altucci L (2010) Histone deacetylase inhibitors: clinical implications for hematological malignancies. *Clin Epigenetics* 1:25–44.

Telese F, Gamliel A, Skowronska-Krawczyk D, Garcia-Bassets I, Rosenfeld MG (2013) "Seq-ing" insights into the epigenetics of neuronal gene regulation. *Neuron* 77:606–623.

Tremolizzo L, Carboni G, Ruzicka WB, Mitchell CP, Sugaya I, Tueting P, Sharma R, Grayson DR, Costa E, Guidotti A (2002) An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. *Proc Natl Acad Sci U S A* 99:17095–17100.

Veldic M, Caruncho HJ, Liu WS, Davis J, Satta R, Grayson DR, Guidotti A, Costa E (2004) DNA-methyltransferase 1 mRNA is selectively over-expressed in telencephalic GABAergic interneurons of schizophrenia brains. *Proc Natl Acad Sci USA* 101:348–353.

Villar-Garea A, Fraga MF, Espada J, Esteller M (2003) Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. *Cancer Res* 63:4984–4989.

Walters CL, Blendy JA (2001) Different requirements for cAMP response element binding protein in positive and negative reinforcing properties of drugs of abuse. *J Neurosci* 21:9438–9444.

Wang JC, Kapoor M, Goate AM (2012) The genetics of substance dependence. *Annu Rev Genomics Hum Genet* 13:241–261.

Wang L, Lv Z, Hu Z, Sheng J, Hui B, Sun J, Ma L (2010) Chronic cocaine-induced H3 acetylation and transcriptional activation of CaMKIIalpha in the nucleus accumbens is critical for motivation for drug reinforcement. *Neuropsychopharmacology* 35:913–928.

Waterland RA (2006) Assessing the effects of high methionine intake on DNA methylation. *J Nutr* 136:1706S–1710S.

Waterland RA, Dolinoy DC, Lin JR, Smith CA, Shi X, Tahiliani KG (2006) Maternal methyl supplements increase offspring DNA methylation at Axin Fused. *Genesis* 44:401–406.

Watson WH, Zhao Y, Chawala RK (1999) S-adenosylmethionine attenuates the lipopolysaccharide-induced expression of the gene for tumour necrosis factor alpha. *Biochem J* 342:21–25.

Weaver IC, La Plante P, Weaver S, Parent A, Sharma S, Diorio J, Chapman KE, Seckl JR, Szyf M, Meaney MJ (2001) Early environmental regulation of hippocampal glucocorticoid receptor gene expression: characterization of intracellular mediators and potential genomic target sites. *Mol Cell Endocrinol* 185:205–218.

Weaver IC, Diorio J, Seckl JR, Szyf M, Meaney MJ (2004) Early environmental regulation of hippocampal glucocorticoid receptor gene expression: characterization

of intracellular mediators and potential genomic target sites. *Ann N Y Acad Sci* 1024:182–212.

Weaver IC, Champagne FA, Brown SE, Dymov S, Sharma S, Meaney MJ, Szyf M (2005) Reversal of maternal programming of stress responses in adult offspring through methyl supplementation: altering epigenetic marking later in life. *J Neurosci* 25:11045–11054.

Weaver IC, Meaney MJ, Szyf M (2006) Maternal care effects on the hippocampal transcriptome and anxiety-mediated behaviors in the offspring that are reversible in adulthood. *Proc Natl Acad Sci U S A* 103:3480–3485.

Weaver IC (2007) Epigenetic Programming by Maternal Behavior and Pharmacological Intervention. *Epigenetics* 2:22–28.

Weaver IC (2009) Epigenetic effects of glucocorticoids. *Semin Fetal Neonatal Med* 14:143–150.

Weisenberger DJ, Velicescu M, Cheng JC, Gonzales FA, Liang G, Jones PA (2004) Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation. *Mol Cancer Res* 2:62–72.

Wilson VL, Smith RA, Ma S, Cutler RG (1987) Genomic 5-methyldeoxycytidine decreases with age. *J Biol Chem* 262:9948–9951.

Winstanley CA, LaPlant Q, Theobald DE, Green TA, Bachtell RK, Perrotti LI, DiLeone RJ, Russo SJ, Garth WJ, Self DW, Nestler EJ (2007) DeltaFosB induction in orbitofrontal cortex mediates tolerance to cocaine-induced cognitive dysfunction. *J Neurosci* 27:10497–10507.

Wong CC, Mill J, Fernandes C (2011) Drugs and addiction: an introduction to epigenetics. *Addiction* 106:480–489.

Wu H, Coskun V, Tao J, Xie W, Ge W, Yoshikawa K, Li E, Zhang Y, Sun YE (2010) Dnmt3a-dependent nonpromoter DNA methylation facilitates transcription of neurogenic genes. *Science* 329:444–448.

Yan Z, Hsieh-Wilson L, Feng J, Tomizawa K, Allen PB, Fienberg AA, Nairn AC, Greengard P (1999) Protein phosphatase 1 modulation of neostriatalAMPA channels: regulation by DARPP-32 and spinophilin. *Nat Neurosci* 2:13–17.

Yang XJ, Seto E (2008) The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. *Nat Rev Mol Cell Biol* 9:206–218.

Yao WD, Gainetdinov RR, Arbuckle MI, Sotnikova TD, Cyr M, Beaulieu JM, Torres GE, Grant SG, Caron MG (2004) Identification of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity. *Neuron* 41:625–638.

Yoder JA, Bestor TH (1998) A candidate mammalian DNA methyltransferase related to pmt1p of fission yeast. *Hum Mol Genet* 7:279–284.

Yuferov V, Kroslak T, Laforge KS, Zhou Y, Ho A, Kreek MJ (2003) Differential gene expression in the rat caudate putamen after "binge" cocaine administration: advantage of triplicate microarray analysis. *Synapse* 48:157–169.

Zhang XY, Sanchez H, Kehoe P, Kosten TA (2005) Neonatal isolation enhances maintenance but not reinstatement of cocaine self-administration in adult male rats. *Psychopharmacology (Berl)* 177:391–399.

SUMMARY IN ESTONIAN

DNA metüülimise roll kokaiini poolt põhjustatud käitumusliku sensitisatsiooni kujunemises

Ravimsõltuvust defineeritakse kui kroonilist psüühika- ja käitumishäiret, mille peamiseks iseloomustajaks on vastupandamatu tung tarbida psühhotroopseid aineid hoolimata sellega kaasuvatest tõsistest kõrvaltoimetest (Kalivas et al., 2005; Hyman et al., 2006; Koob and Kreek, 2007). Eksperimentaalsed uuringud on näidanud, et ravimsõltuvus kujuneb välja järk-järgult ja sõltuvusega seotud neurobioloogilised muutused võivad jääda püsima ka pärast psühhotroopsete ainete tarvitamise lõppu. Ulatuslikud epidemioloogilised uuringud on näidanud, et ravimsõltuvuse kujunemisel on oluline roll nii geneetilisel eelsoodumusel kui ka keskkonnateguritel (Nestler, 2001; Goldman et al., 2005; Hyman et al., 2006).

Geenid, mis võivad suurendada riski ravimsõltuvuse tekkeks, on käesoleval ajal teadmata. Uuringud on näidanud, et ravimsõltuvuse teket saab mõjutada erinevate keskkonnateguritega nagu stress, psühhotroopsete ainete kättesaadavus, varajase eluea keskkond (Nestler, 2001; Weaver et al., 2004; Goldman et al., 2005; Waterland et al., 2006; Szyf, 2009). Hüpoteesi kohaselt peavad püsivate käitumuslike muutuste aluseks olema püsivad muutused geeniekspressioonis. Seetõttu on viimasel ajal üha enam hakatud tähelepanu pöörama epigeneetikale, mis kirjeldab geeniekspressiooni regulatsioonis osalevaid molekulaarseid mehhanisme ning keskkonna ja geenide vahelisi seoseid.

Geeniekspressiooni reguleerimiseks on vajalik, et vastav geen oleks transkriptsiooni läbiviivatele valkudele kättesaadav. Rakutuumas olev DNA on kokkupakitud kromatiiniks, mis on DNA, histoonide ja teiste valkude kompleks. Kromatiini piirkonnas, kus ei toimu transkriptsiooni (heterokromatiin) on DNA tihedalt seotud histoonidega pärssides transkriptsiooni läbiviivate valkude (nt. RNA polümeraas II) seostumist DNA-ga (Fischle et al. 2003). Kromatiini osa, mis on vähem kokkupakitud ning kus toimub geenide transkriptsioon, nimetatakse eukromatiiniks. Epigeneetilised mehhanismid nagu histoonide modifitseerimine, DNA metüülimine ja mikroRNA-d, on olulised mehhanismid geeniekspressiooni regulatsioonis. Häired epigeneetilistes mehhanismides võivad põhjustada tõsiseid patoloogiaid nagu näiteks kasvajate teket, arengu- ja psühhiaatrilisi häireid (Rett sündroom, Fragiilse X-i sündroom, autism, depressioon, ärevus) jne.

Korduv psühhostimulaatori (nt. kokaiini või amfetamiini) manustamine põhjustab katseloomadel suurenenud käitumusliku vastuse. Sellist fenomeni nimetatakse psühhomotoorseks ehk käitumuslikuks sensitisatsiooniks ning see modelleerib adiktiivset käitumist ja psühhostimulaatorite psühhootilisi komplikatsioone inimesel (Robinson and Berridge, 1993; Pierce and Kalivas, 1997). Käitumusliku sensitisatsiooni tekke ja avaldumisega on seotud aju sarrustuse piirkonnad nagu naalduv tuum *(nucleus accumbens)* ja prefrontaalne korteks.

Kuna käitumuslikule sensitisatsioonile on iseloomulikud püsivad muutused katseloomade käitumises, siis arvatakse, et osaliselt on selle põhjuseks lühi- ja pikaajalised geeniekspressiooni muutused, mis omakorda mõjutavad närvi-impulsi ülekannet, sünapsite moodustamist ja närviringide funktsioneerimist.

Mitmed uuringud viitavad, et epigeneetilised mehhanismid (eriti geeni promootori piirkonna DNA metüülimine) on seotud pikaajaliste geeniekspressiooni muutustega. DNA metüülimise korral liidetakse DNA metüültransferaasi (DNMT) vahendusel metüülrühm DNA tsütosiin-guanosiin (CpG) dinukleotiidsele järjestusele (Holliday and Pugh, 1975; Klose and Bird, 2006). CpG järjestust esineb kogu genoomi ulatuses ja valdavalt on need metüülitud. CpG järjestused, mis asuvad geeni promootoris on metüülitud väiksemas ulatuses ja nende metüülimise aste korreleerub geeni repressiooniga ehk siis DNA hüper-metüülimine pärsib transkriptsiooni reguleerivate valkude seostumist DNA-ga. Muutused DNA metüülimise/demetüülimise protsesside tasakaalus võivad luua olukorra, kus ekspresseeruvad need geenid, mis peaksid olema vaigistatud või vastupidi ning seeläbi võivadki tekkida püsivad geeniekspressiooni muutused, mis omakorda soodustavad erinevate haiguste, sealhulgas ravimsõltuvuse, teket.

Töö eesmärgid

Antud töö peaeesmärgiks oli hinnata DNA metüülimise rolli kokaiini poolt põhjustatud käitumusliku sensitisatsiooni kujunemises hiirtel ja rottidel.

Täpsemad töö eesmärgid olid järgmised:

1. Uurida: a) kokaiini manustamise mõju DNMT-de ja valitud markergeenide ekspressioonile hiirte naalduvas tuumas; ja b) hinnata DNMT inhibiitori, zebulariini, toimet kokaiini poolt esilekutsutud geeniekspressiooni muutustes ning käitumusliku sensitisatsiooni kujunemises täiskasvanud hiirtel.
2. Hinnata metüülrühma doonor S-adenosüülmetioniini (SAM) mõju kokaiini poolt esilekutsutud geeniekspressiooni muutustes ja käitumusliku sensitisatsiooni kujunemises täiskasvanud hiirtel.
3. Selgitada, kas varajases elueas kogetud stress (maternaalse separatsiooni mudel, MS) võib mõjutada DNMT-de ja valitud markergeenide ekspressiooni noorte ja täiskasvanud rottide naalduvas tuumas ning kas need muutused on seotud kokaiini poolt põhjustatud käitumusliku sensitisatsiooni tekkega täiskasvanueas.

Töö tulemused ja järeldused

1. Käesoleva töö tulemused näitavad, et kokaiini manustamine suurendas dünaamiliselt *Dnmt3a* ja *Dnmt3b* ekspressiooni hiirte naalduvas tuumas ja hipokampuses, kuid ei mõjutanud oluliselt *Dnmt1* ekspressiooni. Kuna on

leitud, et DNMT3 perekonda kuuluvad ensüümid DNMT3A ja DNMT3B vastutavad uute (*de novo)* metüülimismustrite loomise eest (Okano et al., 1999) ja DNMT1 olemasolevate metüülimismustrite säilitamise eest (Bestor, 2000; Goll and Bestor, 2005), siis võib järeldada, et kokaiini manustamine mõjutab pigem *de novo* DNA metüülimist. Kasutades metüülitud DNA immunosadestamist ja metüülspetsiifilist kvantitatiivset reaalaja PCR, leidsime, et nii akuutne kui ka korduv kokaiini manustamine suurendasid ravimsõltuvusega seotud markergeeni proteiin fosfataas 1 katalüütilise ala-ühiku (*PP1c*) promootori piirkonna hüpermetüülimist hiirte naalduvas tuumas. *PP1c* promootori hüpermetüülimise tulemusena oli oluliselt vähe-nenud *PP1c* ekspressioon nii mRNA kui valgu tasemel. *PP1c* ekspressiooni langus võib omakorda põhjustada häireid rakusisestes signaaliülekande protsessides, kuna on leitud et *PP1c* osaleb transkriptsioonifaktorite (nt. CREB), kinaaside (nt. Ca^{2+}/kalmoduliin-sõltuv proteiin kinaas II) ja retsep-torite (nt. AMPA retseptori alaühik GluR1) fosforüleerimise inhibeerimises (Genoux et al., 2002; Canettieri et al., 2003). Teiseks uuritavaks marker-geeniks oli antud töös *fosB*. Erinevalt *PP1c,* oli *fosB* promootor kokaiini manustamise järgselt hüpometüülitud ning transkriptsioon suurenenud. Siit järeldub, et kokaiini manustamine võib põhjustada nii DNA metüülimist kui ka demetüülimist (metüülmärgiste eemaldamist geeni promootori piir-konnast).

DNMT inhibiitori, zebulariini, intraventrikulaarne manustamine enne kokaiini manustamist kõrvaldas *PP1c* promootori hüpermetüülimise hiirte naalduvas tuumas ja normaliseeris *PP1c* ekspressiooni. Käitumiskatsete tule-musena leidsime, et zebulariini manustamine pidurdas kokaiini poolt põhjus-tatud käitumusliku sensitisatsiooni väljakujunemist täiskasvanud hiirtel. Seega, kokaiini poolt põhjustatud muutused DNA metüülimise/ demetüülimise protsessides võivad olla olulised mehhanismid käitumusliku sensitisatsiooni kujunemises ning DNMT inhibiitori manustamine võib normaliseerida hüpermetüülitud geenide transkriptsiooni.

2. Kasutades Illumina platvormil põhinevat, kogu genoomi katvat geeni-ekspressiooni analüüsi, leidsime, et kuigi genoomi tasemel mõjutab SAM vaid väheste geenide ekspressiooni, avaldab ta modifitseerivat toimet kokaiini poolt esilekutsutud geeniekspressiooni muutustele täiskasvanud hiirte naalduvas tuumas. SAM-i modifitseeriv toime avaldus ka geeni tase-mel, kuna avastasime, et korduv SAM-i manustamine põhjustas nii hüpo-kui ka hüpermetüülimist Illumina ekspressioonikiibi analüüsi andmete põhjal valitud markergeenide promootori piirkonnas. Lisaks leidsime, et korduv SAM-i manustamine vähendas metüültransferaasi aktiivsust ja langetas *Dnmt3a* ja *Dnmt3b* ekspressiooni nii *in vivo* kui ka *in vitro*. Siit järeldub, et SAM-i modifitseeriv toime kokaiini poolt esilekutsutud geeniekspressiooni muutustele võib olla seotud DNA metüülimise/demetüülimise protsesside tasakaalu muutustega hiirte naalduvas tuumas. Käitumiskatsete tulemused

näitasid, et SAM ise ei suurenda hiirte lokomotoorset aktiivsust. SAM + kokaiini koosmanustamise katsetes (SAM-i manustati hiirtele 20 minutit enne kokaiini süstimist) aga leidsime, et SAM suurendab kokaiini poolt põhjustatud lokomotoorse aktiivsuse tõusu nii käitumusliku sensitisatisooni induktsiooni- kui ka ekspressioonifaasis. Seega, metüülrühma doonor SAM avaldab modifitseerivat toimet kokaiini poolt esilekutsutud geeniekspressiooni muutustele naalduvas tuumas ning soodustab käitumusliku sensitisatsiooni teket täiskasvanud hiirtel.

3. Varajases elueas kogetud stressi modelleerimiseks kasutasime MS mudelit, mille korral rotipojad eraldati emast esimesel kahel elunädalal (postnataalsed päevad PND1-14) iga päev 180-ks minutiks. Töö tulemused näitasid, et MS põhjustas püsivaid muutuseid DNMT-de ja valitud markergeenide (*PP1c* ja *A2AR*) ekspressioonis rottide naalduvas tuumas. Kuna leidsime, et MS põhjustas globaalselt DNA hüpometüülimist ning *PP1c* ja *A2AR* promootorite hüpermetüülimist, siis oletame, et MS võib reguleerida DNA metüülimist nii globaalselt kui ka geeni spetsiifiliselt. Käitumiskatsete tulemused näitasid, et MS suurendas nii täiskasvanud rottide uudistamis- kui ka lokomotoorset aktiivsust. Antud töö tulemuste põhjal saab järeldada, et MS võib DNA metüülimise kaudu põhjustada püsivaid muutuseid geeniekspressioonis ning luua tausta, mis soodustab kokaiini poolt põhjustatud käitumusliku sensitisatsiooni teket täiskasvanueas.

Seega, käesoleva töö tulemused näitavad, et DNA metüülimine mängib olulist rolli kokaiini poolt põhjustatud käitumusliku sensitisatsiooni kujunemises. Veelgi enam, keskkonnategurid nagu SAM ja varajases elueas kogetud stress, võivad DNA metüülimise kaudu soodustada psühhostimulaatoritest tingitud ravimsõltuvuse teket nii hiirtel kui ka rottidel.

ACKNOWLEDGEMENTS

PUBLICATIONS

CURRICULUM VITAE

Name: Kaili Anier
Date of birth: 17.05.1980, Helme, Estonia
Citizenship: Estonian
Address: University of Tartu, Institute of Bio- and Translational Medicine, Department of Pharmacology, Ravila 19, Tartu, 50411, Estonia
Phone: +372 5690 1054
E-mail: kaili.anier@ut.ee

Education:

2008–...	University of Tartu, Faculty of Medicine, PhD studies in neurosciences
2003–2006	University of Tartu, Faculty of Physics and Chemistry, Department of Chemistry, Chair of Organic Cemistry, MSc
1999–2003	University of Tartu, Faculty of Physics and Chemistry, Department of Chemistry, BSc
1987–1999	Tõrva Secondary School

Professional employment:

2011–...	University of Tartu, Faculty of Medicine, Institute of Bio- and Translational Medicine, Department of Pharmacology, researcher
2008–2011	University of Tartu, Faculty of Medicine, Department of Pharmacology, researcher
2004–2008	University of Tartu, Faculty of Medicine, Department of Pharmacology, specialist

Special courses:

2011	Medical bioinformatics; Tartu, Estonia
2009	Laboratory animal science: C-category competence course; Tartu, Estonia

Professional organizations:

2005–...	Estonian Society of Pharmacology

Scientific work:

The scientific work has focused on the role of DNA methylation in the development of cocaine-induced behavioural sensitisation and on the role of epigenetic modifiers to reverse cocaine-induced behavioural sensitisation.

List of publications:

1. **Anier K**, Malinovskaja K, Pruus K, Aonurm-Helm A, Zharkovsky A, Kalda A (2013) Maternal separation is associated with DNA methylation and behavioural changes in adult rats. *European Neuropsychopharmacology* [Epub ahead of print].

2. **Anier K**, Zharkovsky A, Kalda A (2013) S-adenosylmethionine modifies cocaine-induced DNA methylation and increases locomotor sensitization in mice. *The International Journal of Neuropsychopharmacology* 16:2053–2066.

3. **Anier K**, Kalda A (2012) Epigenetics in the Central Nervous System. *Current Translational Geriatrics and Gerontology Reports* 1:190–198.

4. Jaako K, Aonurm-Helm A, Kalda A, **Anier K**, Zharkovsky T, Shastin A, Zharkovsky A (2011) Repeated citalopram administration counteracts kainic acid-induced spreading of PSA-NCAM-immunoreactive cells and loss of reelin in the adult mouse hippocampus. *European Journal of Pharmacology* 666:61–71.

5. **Anier K**, Malinovskaja K, Aonurm-Helm A, Zharkovsky A, Kalda A (2010) DNA methylation regulates cocaine-induced behavioral sensitization in mice. *Neuropsychopharmacology* 35:2450–2461.

6. Kipper K, **Anier K**, Leito I, Karjagin J, Oselin K, Herodes K (2009) Rapid Determination of Meropenem in Biological Fluids by LC: Comparison of Various Methods for Sample Preparation and Investigation of Meropenem Stability. *Chromatographia* 70:1423–1427.

7. Tamm R, Oselin K, Kallassalu K, Magi R, **Anier K**, Remm M, Metspalu A (2008) Thiopurine S-methyltransferase (TPMT) pharmacogenetics: three new mutations and haplotype analysis in the Estonian population. *Clinical Chemistry and Laboratory Medicine* 46:974–979.

8. Oselin K, **Anier K** (2007) Inhibition of human thiopurine S-methyltransferase by various nonsteroidal anti-inflammatory drugs in vitro: a mechanism for possible drug interactions. *Drug Metabolism and Disposition* 35:1452–1454.

9. Metsvaht T, Oselin K, Ilmoja M, **Anier K**, Lutsar I (2007) Pharmacokinetics of penicillin G in very-low-birth-weight neonates. *Antimicrobial Agents and Chemotherapy* 51:1995–2000.

10. Oselin K, **Anier K**, Tamm R, Kallassalu K, Mäeorg U (2006) Determination of thiopurine S-methyltransferase (TPMT) activity by comparing various normalization factors: Reference values for Estonian population using HPLC-UV assay. *Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences*, 834:77–83.

ELULOOKIRJELDUS

Nimi: Kaili Anier
Sünniaeg: 17.05.1980, Helme, Eesti
Kodakondsus: Eesti
Aadress: Tartu Ülikool, Bio- ja siirdemeditsiini instituut, Farmakoloogia osakond, Ravila 19, Tartu, 50411, Eesti
Telefon: +372 5690 1054
E-post: kaili.anier@ut.ee

Haridus:
2008–... Tartu Ülikool, Arstiteaduskond, Neuroteaduste doktoriõpe, doktorant
2003–2006 Tartu Ülikool, Füüsika-keemiateaduskond, orgaanilise keemia õppetool, MSc
1999–2003 Tartu Ülikool, Füüsika-keemiateaduskond, keemia eriala, BSc
1987–1999 Tõrva Gümnaasium

Teenistuskäik:
2011–... Tartu Ülikool, Arstiteaduskond, Bio- ja siiremeditsiini instituut, Farmakoloogia osakond, teadur
2008–2011 Tartu Ülikool, Arstiteaduskond, Farmakoloogia instituut, teadur
2004–2008 Tartu Ülikool, Arstiteaduskond, Farmakoloogia instituut, spetsialist

Erialane enesetäiendus:
2011 Meditsiiniline bioinformaatika; Tartu, Eesti
2009 Katseloomateadus: C-kategooria kursus; Tartu, Eesti

Erialaorganisatsioonid:
2005–... Eesti Farmakoloogia Selts

Teadustöö:
Teadustöö põhisuunaks on uurida DNA metüülimise rolli kokaiini poolt põhjustatud käitumusliku sensitisatsiooni kujunemises ning hinnata epigeneetiliste modifitseerijate toimet kokaiini poolt esilekutsutud käitumusliku sensitisatsiooni pööratavusele.

Publikatsioonide loetelu:

1. **Anier K**, Malinovskaja K, Pruus K, Aonurm-Helm A, Zharkovsky A, Kalda A (2013) Maternal separation is associated with DNA methylation and behavioural changes in adult rats. *European Neuropsychopharmacology* [Ilmumas].

2. **Anier K**, Zharkovsky A, Kalda A (2013) S-adenosylmethionine modifies cocaine-induced DNA methylation and increases locomotor sensitization in mice. *The International Journal of Neuropsychopharmacology* 16:2053–2066.

3. **Anier K**, Kalda A (2012) Epigenetics in the Central Nervous System. *Current Translational Geriatrics and Gerontology Reports* 1:190–198.

4. Jaako K, Aonurm-Helm A, Kalda A, **Anier K**, Zharkovsky T, Shastin A, Zharkovsky A (2011) Repeated citalopram administration counteracts kainic acid-induced spreading of PSA-NCAM-immunoreactive cells and loss of reelin in the adult mouse hippocampus. *European Journal of Pharmacology* 666:61–71.

5. **Anier K**, Malinovskaja K, Aonurm-Helm A, Zharkovsky A, Kalda A (2010) DNA methylation regulates cocaine-induced behavioral sensitization in mice. *Neuropsychopharmacology* 35:2450–2461.

6. Kipper K, **Anier K**, Leito I, Karjagin J, Oselin K, Herodes K (2009) Rapid Determination of Meropenem in Biological Fluids by LC: Comparison of Various Methods for Sample Preparation and Investigation of Meropenem Stability. *Chromatographia* 70:1423–1427.

7. Tamm R, Oselin K, Kallassalu K, Magi R, **Anier K**, Remm M, Metspalu A (2008) Thiopurine S-methyltransferase (TPMT) pharmacogenetics: three new mutations and haplotype analysis in the Estonian population. *Clinical Chemistry and Laboratory Medicine* 46:974–979.

8. Oselin K, **Anier K** (2007) Inhibition of human thiopurine S-methyltransferase by various nonsteroidal anti-inflammatory drugs in vitro: a mechanism for possible drug interactions. *Drug Metabolism and Disposition* 35:1452–1454.

9. Metsvaht T, Oselin K, Ilmoja M, **Anier K**, Lutsar I (2007) Pharmacokinetics of penicillin G in very-low-birth-weight neonates. *Antimicrobial Agents and Chemotherapy* 51:1995–2000.

10. Oselin K, **Anier K**, Tamm R, Kallassalu K, Mäeorg U (2006) Determination of thiopurine S-methyltransferase (TPMT) activity by comparing various normalization factors: Reference values for Estonian population using HPLC-UV assay. *Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences*, 834:77–83.

DISSERTATIONES NEUROSCIENTIAE
UNIVERSITATIS TARTUENSIS

1. **Sirli Raud.** Cholecystokinin$_2$ receptor deficient mice: changes in function of GABA-ergic system. Tartu, 2005.
2. **Kati Koido.** Single-nucleotide polymorphism profiling of 22 candidate genes in mood and anxiety disorders. Tartu, 2005.
3. **Dzhamilja Safiulina.** The studies of mitochondria in cultured cerebellar granule neurons: characterization of mitochondrial function, volume homeostasis and interaction with neurosteroids. Tartu, 2006.
4. **Tarmo Areda.** Behavioural and neurogenetic study of mechanisms related to cat odour induced anxiety in rodents. Tartu, 2006.
5. **Aleksei Nelovkov.** Behavioural and neurogenetic study of molecular mechanisms involved in regulation of exploratory behaviour in rodents. Tartu, 2006.
6. **Annika Vaarmann.** The studies on cystatin B deficient mice: neuro-chemical and behavioural alterations in animal model of progressive myo-clonus epilepsy of Unverricht-Lundborg type. Tartu, 2007.
7. **Urho Abramov.** Sex and environmental factors determine the behavioural phenotype of mice lacking CCK$_2$ receptors: implications for the beha-vioural studies in transgenic lines. Tartu, 2008.
8. **Hendrik Luuk.** Distribution and behavioral effects of WFS1 protein in the central nervous system. Tartu, 2009.
9. **Anne Must.** Studies on molecular genetics of male completed suicide in Estonian population. Tartu, 2009.
10. **Kaido Kurrikoff**. Involvement of cholecystokinin in chronic pain mecha-nisms and endogenous antinociception. Tartu, 2009.
11. **Anu Aonurm-Helm.** Depression-like phenotype and altered intracellular signalling in neural cell adhesion molecule (NCAM)-deficient mice. Tartu, 2010.
12. **Silva Sütt.** Role of endocannabinoid system and *Wfs1* in regulation of emotional behaviour: behavioural, pharmacological and genetic studies. Tartu, 2010.
13. **Mari-Anne Philips.** Characterization of *Myg1* gene and protein: expres-sion patterns, subcellular localization, gene deficient mouse and functional polymorphisms in human. Tartu, 2010.
14. **Ranno Rätsep.** Genetics of psoriasis and vitiligo, focus on IL10 family cytokines. Tartu, 2010.
15. **Kairit Joost.** Selective screening of metabolic diseases in Estonia: the application of new diagnostic methods. Tartu, 2012, 143 p.
16. **Monika Jürgenson.** A complex phenotype in mice with partial or complete deficiency of the NCAM protein. Tartu, 2012, 117 p.

17. **Ene Reimann.** Description of the cytokines and cutaneous neuroendocrine system in the development of vitiligo. Tartu, 2012, 117 p.
18. **Jürgen Innos.** Behavioural, pharmacological and neurochemical characterisation of limbic system-associated membrane protein (LSAMP) deficient mice. Tartu, 2013, 113 p.